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ABSTRACT 
Articular cartilage is a load-bearing tissue covering the ends of long bones. It has a zonal 
structure, with variations in cellular and extracellular matrix properties, that helps it to 
function as a low-friction bearing surface through millions of cycles of loading. 
Unfortunately, cartilage has only a minimal capacity for healing after damage. Therefore, 
even small cartilage defects commonly progress to widespread degeneration in a condition 
called osteoarthritis (OA), which is one of the primary causes of pain and disability in the 
elderly. OA increases the financial burden on both the individual and society. Many surgical 
strategies have been used for cartilage defect treatments, but they typically result in 
mechanically and biologically inferior repair tissue and lack the zonal structure of healthy 
articular cartilage. Cartilage tissue engineering is an alternative approach for cartilage defect 
treatment in which cells, biomaterials, and environmental factors are combined to grow new 
cartilage tissue. While this approach is promising, the lack of optimal cell sources and 
optimal culture conditions have  limited the success of cartilage tissue engineering for clinical 
application. Articular cartilage is a highly organized tissue with cellular and matrix properties 
that vary with depth zones. Recapitulation of the zonal organization remains an elusive goal 
in cartilage tissue engineering. We are interested in developing zonal cartilage tissue 
engineering approaches to improve the properties of the tissue-engineered cartilage. In this 
thesis, we aim to evaluate the effects of culture environments that mimic aspects of the native 
cartilage environment on chondrocyte subpopulations for zonal cartilage tissue engineering. 
Chondrocytes are the most commonly used cells for clinical cartilage tissue engineering, but 
have limitations based on changes in cell phenotype, donor-site morbidity, difficulties 
accessing the tissue and number of cells that can be isolated. Therefore, alternative cell 
sources are being investigated. Human umbilical cord perivascular cells (HUCPVCs), which 
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are non-invasively isolated from discarded umbilical cords, have been shown to have 
multilineage differentiation capacity and therefore may be a useful source for cartilage tissue 
engineering. In the first study of this thesis, we investigated the potential of HUCPVCs as a 
novel cell source for cartilage tissue engineering. HUCPVCs maintained their capacity to 
proliferate in culture at least 56 days. However, the capacity for multilineage differentiation 
was not demonstrated by HUCPVCs from passage 5 and passage 10 using several protocols 
for adipogenic, osteogenic and chondrogenic differentiation. Due to the limitations of these 
cells, further experiments focused on optimizing the culture environment for zonal cartilage 
tissue engineering using human chondrocytes.  
Mimicking the natural cellular environment is one approach to find the optimal culture 
environment. This approach has been successful, for example, in promoting chondrocyte 
bioactivity in low oxygen and dynamic compression environments. Applying this approach 
for zonal cartilage tissue engineering is more complex, as chondrocytes from different zones 
of cartilage are subjected to different stimuli and also display a zone-specific phenotype. For 
example, superficial zone chondrocytes, which synthesize less glycosaminoglycans (GAG) 
and more lubricating molecules such as proteoglycan 4 (PRG4), are subjected to higher shear 
stress than chondrocytes from deeper zones. The aim of the second study was to evaluate the 
effect of fluid induced shear stress created by rocker plate bioreactor on chondrocyte 
subpopulations. Fluid induced shear stresses did not have a significant effect on the 
chondrogenic gene expression of superficial zone chondrocytes or middle deep zone 
chondrocytes high density monolayer. The high density monolayer culture system lacks the 
3-dimensional extracellular matrix surrounding the chondrocytes, and may not be the optimal 
environment for in vitro chondrogenesis of chondrocytes. 
A wide variety of scaffolds have been used to provide a 3-dimensional environment and 
structural support in cartilage tissue engineering. However, there are no existing scaffolds 
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that truly mimic the cartilage ECM environment. We hypothesized that zone-specific 
decellularized cartilage ECM would provide the optimal environment to the sub-population 
chondrocytes of their zone and promote their activity. Superficial chondrocyte mixed with 
decellularized ECM of its own zone showed up-regulation of chondrogenesis markers (ACAN, 
PRG4) compared to the gold-standard chondrocyte pellet control, suggesting the potential use 
of decellularized ECM to improve in vitro zonal cartilage tissue engineering, especially in the 
superficial zone. 
While the in vitro results with decellularized ECM were promising, cartilage is not an isolated 
tissue in the joint. Rather, it is in close contact with bone and synovial fluid. To further 
evaluate the effects of decellularized ECM on zonal chondrocytes in a more realistic 
environment, constructs were tested in an in vitro full-thickness defect model. Cartilage 
constructs composed of decellularized ECM in alginate with and without zonal structure were 
made and cultured in free-swelling and inside a full-thickness defect model. The results 
showed the increased GAG production and accumulation in the full-thickness defect model 
compared to free-swelling culture. However, the results cannot rule out the effect of GAG 
absorbed from degraded bovine cartilage construct. 
We continued to evaluate the effect of full-thickness defect model in a subcutaneous SCID 
mouse model. We hypothesized that the full-thickness defect model provides the optimal 
cartilage environment to the cartilage construct in the SCID mice. The chondrocytes were 
embedded in alginate with and without the zonal structure and implanted in the subcutaneous 
of SCID mice for 42 days. The chondrogenic gene expression and protein production were 
evaluated from the SCID mice constructs compared to the in vitro control. The results were 
not significantly different for ACAN and PRG4 gene expression between in vitro and in vivo. 
However, there was high COL1A1 and low COL2A1 gene expression in the mouse model. 
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The results suggest that the full-thickness defect model may be used to provide the cartilage 
environment in SCID mice. However, modification is needed. 
In the previous studies, we evaluated the effect of the healthy joint environment from bovine 
cartilage ECM or bovine explants on the chondrocytes biosynthesis of cartilage construct to 
improve cartilage tissue engineering culture conditions in vitro and in an animal model. The 
results showed the positive effect of the healthy cartilage or cartilage and bone environment 
on the chondrocytes biosynthesis in cartilage construct. However, the cartilage tissue 
constructs need to survive in the OA joint environment for clinical application in OA. It is 
important to know how the OA environment affects the chondrocytes in tissue engineered 
constructs and how cyclic compression affects the chondrocyte biosynthesis in the OA 
condition. The final experiment aimed to evaluate the effect of soluble factors from sclerotic 
OA osteoblasts and normal osteoblasts on the chondrocytes biosynthesis in cartilage 
constructs and the effects of cyclic compressive stimuli, which have been proven to stimulate 
OA chondrocyte biosynthesis, on the chondrocytes after co-cultures in both conditions. Our 
data suggest that there is a clear zonal difference in how chondrocytes respond to OA 
osteoblast-conditioned medium and compressive stimulation. OA osteoblast condition media 
decreased the regulatory cytokine (IL-6), PRG4 gene expression and IL-6 secreted to the 
medium only in the S chondrocytes. Compression led to an increasing PRG4 and IL-6 gene 
expression in the MD chondrocytes and reduced the MMP13 and IL-6 gene expression in the 
S chondrocytes. The results highlight the importance of mechanical stimulation, and their role 
in decreasing the gene expression levels of catabolic enzymes such as MMP-13, and how 
soluble factors from the OA osteoblasts can mediate the decrease in gene expression levels of 
lubricating molecules such as PRG4, which is necessary in preventing mechanically-induced 
surface fibrillation.   
vi 
 
TABLE OF CONTENTS 
KEYWORDS .............................................................................................................................. i 
ABSTRACT ...............................................................................................................................ii 
TABLE OF CONTENTS .......................................................................................................... vi 
LIST OF TABLES AND FIGURES....................................................................................... xiv 
LIST OF ABBREVIATIONS .............................................................................................. xviii 
STATEMENT OF ORIGINAL AUTHORSHIP .................................................................... xxi 
LIST OF PUBLICATIONS AND PRESENTATIONS ........................................................xxii 
ACKNOWLEDGEMENTS ................................................................................................. xxiii 
CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW ...................................... 1 
1.1 Introduction  ..................................................................................................................... 1 
1.2 Composition, structure and function of normal articular cartilage ................................... 2 
1.2.1 ...... Chondrocytes the cartilage cells ............................................................................. 2 
1.2.2 ...... Cartilage extracellular matrix (ECM) ..................................................................... 4 
1.2.3 ...... The zones of articular cartilage ............................................................................... 6 
1.2.4 ...... Cartilage mechanical properties .............................................................................. 9 
1.3 Chondrogenesis cartilage development .......................................................................... 10 
1.4 Articular cartilage damage and disease .......................................................................... 11 
1.4.1 ...... Biomolecular environment .................................................................................... 13 
1.4.2 ...... Mechanical environment ....................................................................................... 18 
1.5 Articular cartilage repair and current treatments ............................................................ 19 
vii 
 
1.5.1 ...... Non-surgical methods ........................................................................................... 20 
1.5.2 ...... Surgical methods ................................................................................................... 20 
1.6 Cartilage tissue engineering ........................................................................................... 22 
1.6.1 ...... Traditional approaches .......................................................................................... 23 
1.6.2 ...... Zonal approaches .................................................................................................. 52 
1.7 Hypotheses and aims ...................................................................................................... 54 
CHAPTER 2 : MATERIALS AND METHODS ................................................................. 56 
2.1 Introduction  ................................................................................................................... 56 
2.2 Chondrocytes cells isolation and expansions ................................................................. 56 
2.3 Chondrogenic differentiation in pellets .......................................................................... 58 
2.4 Alginate-based hydrogel (alginate-gel) preparation ....................................................... 58 
2.5 Alginate-based hydrogel (alginate-gel) chondrogenic differentiation ........................... 59 
2.6 Pulverization and decellularization of bovine cartilage ................................................. 59 
2.7 Preparation of full-thickness defected in osteochondral discs ....................................... 60 
2.8 PI staining  .................................................................................................................... 60 
2.9 Sample processing for pellet histological samples ......................................................... 61 
2.10 Sample processing for alginate construct histological samples ..................................... 61 
2.11 Sample processing for alginate construct in osteochondral histological samples .......... 61 
2.12 Histology and immunofluorescence staining ................................................................. 62 
2.12.1 ... Tissue sectioning ................................................................................................... 62 
2.12.2 ... Alcian blue staining from the section ................................................................... 62 
viii 
 
2.12.3 ... Alcian blue staining for high cell density seeding ................................................ 63 
2.12.4 ... Immunofluorescence staining ............................................................................... 63 
2.13 Cell viability ................................................................................................................... 65 
2.14 DNA content ................................................................................................................... 65 
2.15 GAG content ................................................................................................................... 66 
2.16 Gene expression.............................................................................................................. 66 
2.16.1 ... RNA extraction ..................................................................................................... 66 
2.16.2 ... DNase treatment and reverse transcription for qRT-PCR .................................... 67 
2.16.3 ... Real-time PCR and data processing ...................................................................... 68 
2.17 Statistical analysis .......................................................................................................... 69 
CHAPTER 3 : HUMAN UMBILICAL CORD PERIVASCULAR CELLS AS A 
POTENTIAL ALLOGENEIC CELL SOURCE FOR ARTICULAR CARTILAGE TISSUE 
ENGINEERING   .................................................................................................................... 70 
3.1 Introduction .................................................................................................................... 70 
3.2 Materials and methods .................................................................................................... 72 
3.2.1 ...... Proliferation assay ................................................................................................. 72 
3.2.2 ...... Phenotypic characterization .................................................................................. 72 
3.2.3 ...... Multilineage differentiation assays ....................................................................... 73 
3.2.4 ...... Osteogenic differentiation ..................................................................................... 74 
3.2.5 ...... Adipogenic differentiation .................................................................................... 74 
3.2.6 ...... Chondrogenic differentiation in pellets ................................................................. 75 
3.2.7 ...... Hypoxia protocol................................................................................................... 75 
ix 
 
3.2.8 ...... Wet weight ............................................................................................................ 76 
3.2.9 ...... Statistical analysis ................................................................................................. 76 
3.3 Results  ................................................................................................................... 76 
3.3.1 ...... Proliferation .......................................................................................................... 76 
3.3.2 ...... Phenotypic characterization .................................................................................. 79 
3.3.3 ...... Multilineage differentiation assays ....................................................................... 80 
3.4 Discussion  ................................................................................................................... 84 
CHAPTER 4 : THE EFFECT OF ROCKER PLATE SHEAR STRESS ON 
CHONDROCYTES CHONDROGENESIS ............................................................................ 88 
4.1 Introduction .................................................................................................................... 88 
4.2 Materials and methods .................................................................................................... 90 
4.2.1 ...... Chondrocyte isolation and cultivation and analysis .............................................. 90 
4.2.2 ...... Statistics ................................................................................................................ 91 
4.3 Results  .................................................................................................................... 91 
4.3.1 ...... Chondrocytes morphology and cell viability ........................................................ 91 
4.3.2 ...... Gene expression .................................................................................................... 93 
4.3.3 ...... GAG and DNA content ......................................................................................... 94 
4.3.4 ...... Histology ............................................................................................................... 95 
4.4 Discussion  .................................................................................................................... 96 
CHAPTER 5 : THE POTENTIAL OF DECELLULARIZEDBOVINE CARTILAGE 
POWDER FOR CARTILAGE TISSUE ENGINEERING ................................................... 101 
5.1 Introduction .................................................................................................................. 101 
x 
 
5.2 Materials and methods .................................................................................................. 104 
5.2.1 ...... Decellularization of bovine cartilage .................................................................. 105 
5.2.2 ...... Chondrogenic differentiation for the first experiment ........................................ 105 
5.2.3 ...... Chondrogenic differentiation for the second experiments .................................. 106 
5.2.4 ...... Histology and gene expression ........................................................................... 107 
5.2.5 ...... Statistics .............................................................................................................. 108 
5.3 Results  .................................................................................................................. 108 
5.3.1 ...... Characterization of decellularization process ..................................................... 108 
5.3.2 ...... Cell viability for the first experiment .................................................................. 109 
5.3.3 ...... Histology for the first experiment ....................................................................... 110 
5.3.4 ...... Gene expression for the first experiment ............................................................ 111 
5.3.5 ...... Pellet morphology and cell viability ................................................................... 112 
5.3.6 ...... Gene expression .................................................................................................. 114 
5.3.7 ...... GAG and DNA content ....................................................................................... 116 
5.3.8 ...... Histology and immunofluorescence .................................................................... 117 
5.4 Discussion  .................................................................................................................. 120 
CHAPTER 6 : THE POTENTIAL OF DECELLULARIZED BOVINE CARTILAGE 
POWDER AND ALGINATE IN A FULL-THICKNESS DEFECT MODEL FOR IN VITRO 
ZONAL CARTILAGE TISSUE ENGINEERING ................................................................ 124 
6.1 Introduction .................................................................................................................. 124 
6.2 Material and methods ................................................................................................... 127 
6.2.1 ...... Human cartilage isolation ................................................................................... 127 
xi 
 
6.2.2 ...... Pulverization and decellularization of bovine cartilage ...................................... 128 
6.2.3 ...... Preparation of osteochondral discs with full-thickness defected ........................ 128 
6.2.4 ...... Chondrogenic differentiation .............................................................................. 128 
6.2.5 ...... Histology ............................................................................................................. 129 
6.2.6 ...... Gene expression .................................................................................................. 130 
6.2.7 ...... Statistics .............................................................................................................. 130 
6.3 Results  .................................................................................................................. 131 
6.3.1 ...... Cell viability ........................................................................................................ 131 
6.3.2 ...... Gene expression .................................................................................................. 132 
6.3.3 ...... GAG and DNA content ....................................................................................... 133 
6.3.4 ...... Histology and immunofluorescence .................................................................... 135 
6.4 Discussion  .................................................................................................................. 137 
CHAPTER 7 : ZONAL CHONDROGENESIS IN A SUBCUTANEOUS FULL-
THICKNESS DEFECT MODEL IN MOUSE ...................................................................... 141 
7.1 Introduction .................................................................................................................. 141 
7.2 Materials and methods .................................................................................................. 143 
7.2.1 ...... Chondrocyte isolation and alginate discs preparation ......................................... 144 
7.2.2 ...... Preparation of full-thickness defected in osteochondral discs and construct 
assembly ............................................................................................................................ 145 
7.2.3 ...... Animals and surgery ........................................................................................... 145 
7.2.4 ...... In vitro chondrogenic differentiation .................................................................. 146 
7.2.5 ...... Histology ............................................................................................................. 146 
xii 
 
7.2.6 ...... Gene expression .................................................................................................. 146 
7.2.7 ...... Statistics .............................................................................................................. 147 
7.3 Results  .................................................................................................................. 147 
7.3.1 ...... Macroscopic view and histology......................................................................... 147 
7.3.2 ...... Cell viability ........................................................................................................ 149 
7.3.3 ...... Gene expression .................................................................................................. 150 
7.3.4 ...... GAG and DNA content ....................................................................................... 153 
7.3.5 ...... Immunofluorescence ........................................................................................... 154 
7.4 Discussion  .................................................................................................................. 156 
CHAPTER 8 : EFFECT OF SOLUBLE FACTORS SECRETED FROM 
OSTEOBLASTS ON CHONDROCYTES SUBPOPULATIONS UNDER COMPRESSION .. 
  .................................................................................................................. 160 
8.1 Introduction .................................................................................................................. 160 
8.2 Materials and methods .................................................................................................. 162 
8.2.1 ...... Preparation of subchondral bone osteoblasts (SOBs) conditioned medium (CM) ... 
 .............  ............................................................................................................................. 162 
8.2.2 ...... Chondrocyte cultures .......................................................................................... 162 
8.2.3 ...... Cyclic compression application .......................................................................... 163 
8.2.4 ...... Multiplex immunoassay ...................................................................................... 164 
8.2.5 ...... GAG content ....................................................................................................... 164 
8.2.6 ...... Gene expression .................................................................................................. 164 
8.2.7 ...... Statistics .............................................................................................................. 165 
xiii 
 
8.3 Results  .................................................................................................................. 166 
8.3.1 ...... Gene expression .................................................................................................. 166 
8.3.2 ...... Cytokines in media.............................................................................................. 168 
8.3.3 ...... GAG content ....................................................................................................... 171 
8.4 Discussion  .................................................................................................................. 171 
CHAPTER 9 : SUMMARY OF FINDINGS AND FUTURE DIRECTIONS .................. 178 
9.1 Overview of thesis ........................................................................................................ 178 
9.2 Finding potential cell sources for (zonal) cartilage tissue engineering ........................ 178 
9.3 Importance of the microenvironment ........................................................................... 182 
9.3.1 ...... Mechanical stimulation ....................................................................................... 182 
9.3.2 ...... Extracellular matrix ............................................................................................. 184 
9.3.3 ...... Cartilage-bone interactions ................................................................................. 189 
9.4 Final conclusion............................................................................................................ 191 
CHAPTER 10 : REFERENCES ....................................................................................... 193 
 
 
 
 
  
xiv 
 
LIST OF TABLES AND FIGURES 
LIST OF TABLES 
Table 1.1: Decellularization techniques and scaffold preparation for cartilage tissue 
engineering. .............................................................................................................................. 35 
Table 2.1: List of primer sequences commonly used in the experiments for qRT-PCR. ........ 69 
Table 8.1: List of primer sequences used in the experiments for qRT-PCR. ........................ 165 
 
LIST OF FIGURES 
Figure 1.1: Schematic of cartilage extracellular matrix regions: pericellular, territorial and 
interterritorial. ............................................................................................................................ 4 
Figure 1.2: The zonal function and zonal properties and composition of articular cartilage. ... 9 
Figure 1.3: Schematic of (a) a normal healthy joint compared to (b) an osteoarthritis joint (61).
.................................................................................................................................................. 13 
Figure 1.4: Schematic of cellular roles and interactions in an OA joint (69). ......................... 17 
Figure 1.5: Overview of the tissue engineering approach for cartilage repair. ........................ 24 
Figure 1.6: Bioreactors in cartilage and bone tissue. ............................................................... 45 
Figure 1.7: Cartilage defect classification. .............................................................................. 50 
Figure 3.1: Phase-contrast images of HUCPVCs expanded in different media. ..................... 78 
Figure 3.2: Population doublings from 7 patients ranging from passage 3 to passage 10. ...... 79 
Figure 3.3: The histogram of HUCPVCs for CD31, CD45, CD90, CD105 and CD 146 from 
passage 3 and histogram of HUCPVCs for CD146 from passage 4 and passage 8. ................ 80 
Figure 3.4: Adipogenic differentiations of HUCPVCs expanded in MesenPRO plus 5 ng/mL 
of FGF2. ................................................................................................................................... 81 
xv 
 
Figure 3.5: Osteogenic differentiations of HUCPVCs expanded in MesenPRO plus 5 ng/mL 
of FGF2. ................................................................................................................................... 82 
Figure 3.6: Safranin O/Fast Green staining of pellets cultured for 28 days in chondrogenic 
medium. ................................................................................................................................... 82 
Figure 3.7: Effects of culture conditions on pellets wet weight following 3 weeks of 
chondrogenic cultures. ............................................................................................................. 84 
Figure 4.1: Chondrocyte morphology as observed under the phase contrast microscope 
(magnification 10 X). ............................................................................................................... 92 
Figure 4.2: Cell viability of high density seeded zonal chondrocytes (S and MD) after 14 days 
of culture. ................................................................................................................................. 93 
Figure 4.3: Effect of fluid shear stress on gene expression levels. .......................................... 94 
Figure 4.4: Effect of fluid shear stress on GAG and DNA content. ........................................ 95 
Figure 4.5: Alcian blue staining of subpopulation chondrocytes. ........................................... 96 
Figure 5.1: Overview of the experimental design for the first chondrogenic differentiation 
experiment.............................................................................................................................. 104 
Figure 5.2: Overview of the experimental design for the second chondrogenic differentiation 
experiment.............................................................................................................................. 107 
Figure 5.3: Propidium Iodide (PI) staining of cartilage powder to show DNA content after a 
range of times in decellularization solution. .......................................................................... 109 
Figure 5.4: Cell viability with Fluorescein diacetate (A-C)/Propidium iodide (D-F) (FDA/PI).
................................................................................................................................................ 110 
Figure 5.5: Alcian blue staining showing GAG distribution. ................................................ 111 
Figure 5.6: Effect of bovine ECM on full-thickness chondrocytes gene expression levels of 
ACAN, COL2A1, and COL1A1. ............................................................................................. 112 
Figure 5.7: Chondrocyte pellets at day 28 under the phase contrast microscope (4X). ........ 113 
xvi 
 
Figure 5.8: Cell viability with fluorescein diacetate (A-E)/propidium iodide (F-J) (FDA/PI).
................................................................................................................................................ 114 
Figure 5.9: Effect of bovine zonal ECM on subpopulation chondrocytes gene expression 
levels. ..................................................................................................................................... 115 
Figure 5.10: Effect of bovine zonal ECM on subpopulation chondrocyte GAG and DNA 
content. ................................................................................................................................... 117 
Figure 6.1: Overview of the experimental design for zonal chondrogenesis in free-swelling 
and full-thickness defect models. ........................................................................................... 127 
Figure 6.2: Cell viability of chondrocytes in alginate constructs with and without ECM 
additive in a free-swelling or in an osteochondral disc. ......................................................... 131 
Figure 6.3: Effect of bovine zonal ECM and/or osteochondral environment on alginate 
encapsulated chondrocytes gene expression levels. ............................................................... 133 
Figure 6.4: Effect of bovine zonal ECM and the osteochondral environment on alginate 
encapsulated chondrocytes GAG synthesis and retention. .................................................... 134 
Figure 6.5: Alcian blue and immunofluorescence images of various collagenous proteins of 
alginate encapsulated chondrocytes with ECM additive in free-swelling and in a full-
thickness defect model compared to non ECM additive and cartilage. ................................. 136 
Figure 7.1: Overview of the experimental design for zonal chondrogenesis in a full-thickness 
defect of osteochondral disc placed subcutaneously in a NOD-SCID mouse and in vitro.... 144 
Figure 7.2: Osteochondral constructs following 42 days in vitro and subcutaneous in NOD-
SCID mice. ............................................................................................................................. 148 
Figure 7.3: Histology of osteochondral discs after 42 days subcutaneous in NOD-SCID mice.
................................................................................................................................................ 149 
Figure 7.4: Cell viability of chondrocytes in alginate constructs in an osteochondral disc 
retrieved from in vitro culture and SCID mice. ..................................................................... 150 
xvii 
 
Figure 7.5: Gene expression levels of chondrocytes in alginate constructs in an osteochondral 
disc retrieved from in vitro culture and SCID mice. .............................................................. 152 
Figure 7.6: GAG and DNA content of chondrocytes in alginate constructs in an osteochondral 
disc retrieved from in vitro culture and SCID mice. .............................................................. 154 
Figure 7.7: Immunofluorescence images of various collagenous proteins of chondrocytes in 
alginate constructs in an osteochondral disc retrieved from in vitro culture and SCID mice.
................................................................................................................................................ 156 
Figure 8.1: Overview of the experimental design for effect of soluble factors secreted from 
osteoblasts on chondrocytes subpopulations under compression. ......................................... 163 
Figure 8.2: The gene expression of anabolic and catabolic factors by subpopulation 
chondrocytes encapsulated in alginate hydrogels in response to medium conditions with and 
without cyclic compression.................................................................................................... 167 
Figure 8.3: Cytokine IL-6 gene expression factors by subpopulation chondrocytes 
encapsulated in alginate hydrogels in response to medium conditions with and without cyclic 
compression. .......................................................................................................................... 168 
Figure 8.4: Multiplex ELISA analysis of various cytokines in conditioned media. .............. 171 
Figure 9.1: Freeze-dried zonal cartilage ECM constructs. .................................................... 189 
 
 
xviii 
 
LIST OF ABBREVIATIONS 
 Ø 
2D 
diameter 
two-dimensional 
3D 
ACAN 
three-dimensional 
aggrecan (gene) 
ADAMTS a disintegrin and metalloproteinase with thrombospondin motif 
ANOVA analysis of variance 
BMP bone morphogenetic protein 
BSA bovine serum albumin 
cDNA complementary deoxyribonucleic acid 
COL1A1 
COL2A1 
COL10A1 
Col I 
Col II 
CO2 
DAPI 
ddH2O 
collagen type I (gene) 
collagen type II (gene) 
collagen type X (gene) 
collagen type I (protein) 
collagen type II (protein) 
carbon dioxide 
4′,6-diamidino-2-phenylindole, dihydrochloride 
double distilled water 
DMMB 1,9-dimethylmethylene blue dye 
DMEM Dulbecco’s Modified Eagle Medium 
DNA deoxyribonucleic acid 
xix 
 
DNase deoxyribonuclease 
dNTP deoxynucleoside 5’-triphosphate 
ECM extracellular matrix  
EDTA  ethylenediamine tetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
FBS 
FDA 
foetal bovine serum 
fluorescein diacetate 
FGF fibroblast growth factor 
GAG glycosaminoglycan 
HEPES N-(2-hydroxyethyl) piperazine-N′-(2-ethanesulfonic acid) 
IGF 
IL-1β 
IL-4 
IL-6 
IL-10 
ITS+1 
insulin-like growth factor 
interleukin-1 beta 
interleukin-4 
interleukin-6 
interleukin-10 
insulin, transferrin, selenium, (+ BSA, linoleic acid) 
MSC mesenchymal stem cell 
MMP matrix metalloproteinase 
MgCl2 magnesium chloride 
mRNA messenger ribonucleic acid  
NaCl sodium chloride 
PBS phosphate-buffered saline 
xx 
 
 
 
 
 
 
 
 
 
 
 
PBE 
PI 
phosphate buffer containing EDTA 
propidium iodide 
PRG4 proteoglycan 4 
qRT-PCR quantitative real-time reverse transcriptase-polymerase chain 
reaction 
QUT Queensland University of Technology 
RNA ribonucleic acid  
RNase ribonuclease 
RT room temperature 
rpm 
SCID 
revolutions per minute 
severe combined immunodeficiency 
SD standard deviation 
TGF-β transforming growth factor type β  
TIMP tissue inhibitor of matrix metalloproteinase 
TnBP tri-n-butyl phosphate 
TNF-α tumor necrosis factor- alpha 
VEGF vascular endothelial growth factor 
  
 
 
  
  
  
xxi 
 
STATEMENT OF ORIGINAL AUTHORSHIP 
The work contained in this thesis has not been previously submitted to meet requirements for 
an award at this or any other higher education institution. To the best of my knowledge and 
belief, the thesis contains no material previously published or written by another person 
except where due reference is made. 
Kunnika Kuaha  M.Sc. 
14/2/2015 
 
 
 
 
 
 
 
 
 
 
QUT Verified Signature
xxii 
 
LIST OF PUBLICATIONS AND PRESENTATIONS 
1. Kuaha K, Rijckaert B, Klein T, Hutmacher D: Proliferation capacity of human umbilical 
cord perivascular cells in standard and reduced serum media. The 3rd Indo-Australian 
Conference on Biomaterials, Implants, Tissue Engineering & Regenerative Medicine 
(BITE, RM) and 19th Annual Conference of the Australasian Society for Biomaterials and 
Tissue Engineering (ASBTE), NSW, Australia (2009) (Poster Presentation) 
2. Kuaha K, Rijckaert B, Klein T, Hutmacher D: Human umbilical cord perivascular cells 
as a potential allergenic cell source for articular cartilage tissue engineering. 20th Annual 
Conference of the Australasian Society for Biomaterials and Tissue Engineering 
(ASBTE), Brisbane, Australia (2010) (Poster Presentation) 
3. Kuaha K, Schrobback K, Doran M, Hutmacher D, Klein T: Effect of hypoxia and high 
concentration of ascorbic acid on human Bone Marrow Stem Cells (hBMSCs) 
chondrogenesis. IHBI Postgraduate Student Research Conference, Gold Coast, Australia 
(2010) (Poster Presentation) 
4. Kuaha K, Schrobback K, Malda J, Hutmacher D, Klein T::Human Bone Marrow Stem 
Cells (BMSCs) chondrogenesis in spinner flask and rocker plate. 21st Annual Conference 
of the Australasian Society for Biomaterials and Tissue Engineering (ASBTE), 
Queenstown, New Zealand (2011) (Poster Presentation) 
5. Kuaha K, Jeon J, Schrobback K, Hutmacher D, Klein T: Chondrogenesis of human bone 
marrow stromal cells (BMSCs) in high-density monolayers with rocker plate stimulation. 
ASMR Postgraduate Student Conference, Brisbane, Australia (2011) (Poster 
Presentation) 
6. Kuaha K, Kabirirenani M, Hesami P, Schrobback K, Doran M, Hutmacher D, Klein T: 
The potential of decellularized bovine cartilage powder for cartilage tissue engineering. 
IHBI Postgraduate Student Research Conference, Brisbane, Australia (2011) (Poster 
Presentation) 
7. Reichert J, Klein T, Kuaha K, Rijckaert B, Noth U, Hutmacher D. 2011, Bone Tissue 
Engineering in Umbilical Cord Blood: A Future for Regenerative Medicine. Eds. 
Kadereit S. and Udolf G., World Scientific Publishing Co., Singapore; 105-143. 
 
xxiii 
 
ACKNOWLEDGEMENTS 
For my PhD journey, I would like to express my sincere gratitude to all those who 
made it possible for me to complete my study. I would like to express my appreciation and 
sincere thanks to the Science and Engineering Faculty, Queensland University of Technology 
for the scholarship they awarded to me in the PhD program. Also, I would like to express my 
gratitude to my colleagues at the Faculty of Associated Medical sciences, KhonKaen 
University for their support. 
I am deeply indebted to my advisor, Associate Professor Travis J. Klein, for all of his 
kindness, guidance and great encouragement throughout my study. I must equally express 
grateful to my co-advisor Professor Dietmar Hutmacher for his guidance, support, 
encouragements, and especially for providing me the opportunity to be a part of his team. 
Without their support, I cannot go to the end of my Ph.D. journey. I am also grateful to 
Professor Temduang Limpaiboon for her support and encouragements when I worked in 
Thailand. Besides my advisors, my sincere gratefulness is extended to my other committee 
members Professor Kunle Oloyede and Professor Louise Hafner and also to Associate 
Professor Jos Malda, Dr. Michael Doran and Professor Yin Xiao for their valuable 
suggestion, encouragement and insightful comments. I would like to thank Professor Ross 
Crowford for providing the osteoarthritic cartilage. My gratefulness is also to Associate 
Professor Dr. Pual Dalton and Mr. Kristofor Bogoevski for their proof reading of my thesis. 
My grateful appreciation is extended to my colleagues Dr. June Jeon, Dr. Karsten 
Schrobback, Mr. Christoph Meinert, and Mr. Peter Levett for their valuable suggestion, help 
and constructive criticisms and especially to June and Christoph for proof reading my thesis. 
My great appreciation is also to Mr. Bart Rijckaert who is my first friend in IHBI and shared 
half of the HUCPVCs works with me. Thanks also to all the members, past and present, of 
the CRL, regenerative medicine and bone group for their helpful suggestions, friendship and 
xxiv 
 
support extended during my time in IHBI. I am also grateful to Dr. Indira Prasadam and Dr. 
Mahboubeh Kabiri for technical advice, Dr. Parisa Hesami for animal work and to Mr. 
Samuel Perry for helping me on the qRT-PCR laboratory work. My thankfulness is also to all 
of my friends in IHBI for their kind and friendly. I would like to express my greatest 
appreciation to IHBI support staffs, SEF HDR Student Support staffs and the Research 
Students Centre staffs for their kind help, support and assistance during my study. 
I would like to express my deepest gratitude to Dr. Kanokpron Ithiwisawakul for 
providing medical support to my mother and grandmother. Because of your help, my study 
can continue to the end of processes. Thanks to Mrs. Warangnuch, Dr. Worrawan, Dr. 
Sawitre, Dr. Prontip and Miss Kesorn for their encouragements and the timely support to look 
after my mother when I could not do that. Thanks also to Dr. Adchara, Mr. Panya, Mrs 
Ganlaya, Mrs. Chitralada and Mr. Utai who made my life in Brisbane filled with happiness 
like home. Thankfulness is extended to all my friends, both in Thailand and Australia. There 
is a long list of friends that I may not say the name on here but all of your help and support is 
always in my thoughts. 
Finally, I want to thank to my lovely sister, Jongkolnee Kuaha. I owe her beyond 
words for taking all of the family responsibility and making it possible for me to study Ph.D. 
outside my home country. Last but not least, I dedicate this thesis to my beloved, 
grandmother, uncle and my parents for their love, continuous support, and encouragement all 
of their life. I wish you can accompany me in my success and happy with me somewhere. 
Love and miss you so much. 
1 
 
CHAPTER 1 : INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Introduction 
Articular cartilage functions as a low-friction, wear-resistant, load-bearing tissue in joints. It 
has an intricate structure that provides the mechanical properties to perform these functions. 
However, it lacks blood vessels and nerves, and has a poor intrinsic capacity to repair itself. 
Thus, once cartilage is damaged joints often progress to a condition termed osteoarthritis 
(OA), where cartilage is lost along with joint function. OA is a chronic disease defined by 
gradual loss of cartilage accompanied by abnormal changes to subchondral bone and 
synovium (1). The main symptoms of OA are joint pain and limited of joint movement which 
cause disability and poor quality of life in OA patients. Several methods have been developed 
for cartilage repair however joint replacement is the most common treatment for severe OA. 
In Australia, approximately 1.3 million people (~7% of the population) suffer from OA (2). 
The impact of the OA disease is to both individual and society. The direct medical cost of OA 
estimated by the Australian Institute of Health and Welfare (2) increased from AU$ 1.18 
billion in 2000-2001 (3) to AU$ 2.3 billion in 2007 and a main component of the hospital 
costs for OA is joint replacement surgery (2). Unfortunately, despite its prevalence and 
impact, we do not have a good understanding of OA nor an adequate method for cartilage 
regeneration. Cartilage tissue engineering aims to develop regenerative therapies for cartilage 
defects and OA through appropriate use of cells, biomaterials, and environments. This thesis 
focuses on advancing cartilage tissue engineering by determining the effects of specific 
environments on cartilage cells. 
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1.2 Composition, structure and function of normal articular cartilage 
There are three types of cartilage; hyaline cartilage, elastic cartilage, and fibrocartilage, 
which all differ with respect to function and extracellular composition. Articular cartilage is a 
hyaline cartilage which covers the ends of long bones such as the femur and tibia. The 
average thickness of articular cartilage including the calcified cartilage layer is approximately 
2.5 mm (4). However, there are differences in thickness between high- and low-load bearing 
areas of articular cartilage (5). Articular cartilage is an avascular tissue in which oxygen and 
nutrients are supplied by diffusion from synovial fluid, which itself has low oxygen (6). 
Therefore, the natural environment of articular cartilage is low in oxygen which varies from 
7% oxygen saturation at the articular surface to 1% at the interface between cartilage and 
bone (7). There is a report shows that oxygen tensions within cartilage are potently 
influenced by various factors such as oxygen levels in synovial fluid, cartilage thickness, cell 
density, and cell oxygen utilization rates. The oxygen supply from the subchondral bone may 
also affect oxygen tensions within cartilage (8). Chondrocytes consume considerably less 
oxygen compared to most other cell types, as the major energy supply derived by the specific 
glycolysis pathway that does not require oxygen (9). This unique environment should be 
considered when engineering cartilage tissues. 
1.2.1 Chondrocytes the cartilage cells 
Articular cartilage contains only one cell type, namely chondrocytes, although the 
chondrocyte density and phenotype varies with depth from the articular surface. The average 
density of chondrocytes in adult articular cartilage is approximately 10,000 per mm3 (4). 
Articular cartilage chondrocytes in the different zone of cartilage have some common 
properties however there are some difference in morphology, gene expression profile, matrix 
production and mechanical properties specific to their zone (10-12). The example of 
difference is shown in Fig 1.2. Chondrocytes in the superficial zone are flat, low matrix 
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synthesis (10) and secretion of proteoglycan 4 (PRG4) (13). while chondrocytes in middle 
zone are round and secretion of cartilage intermediate layer protein (CILP) (14). 
Chondrocytes in the deep zone are big oval and show the highest matrix synthesis and 
secretion of collagen type X at the deepest zone. Also, chondrocyte in superficial zone is 
expresses a glycoprotein that regulates complement activation called clusterin (15). 
Chondrocytes are surrounded by a hydrated extracellular matrix of collagen fibers and 
proteoglycans and are responsible for maintenance of the tissue (4). In addition, chondrocytes 
and other cells in the joint seem to have a role in maintain the balances of catabolic and 
anabolic activities within the cartilage response to the OA condition (16). To maintain 
cartilage homeostasis chondrocytes need to be sensible to the changed of ECM composition. 
Chondrocytes behavior is in influences by the signal from ECM. There are many integrin 
which is ECM receptor molecule have been found in the chondrocytes cell membrane such as 
type I collagen receptor, type VI collagen receptor and fibronectin receptor (Reviewed in 
(17)). Not only integrins, but also the other type of membrane receptors were found on 
chondrocytes membrane such as CD44, annexin V and annexin V was mainly expressed by 
chondrocytes at the superficial zone (18). Chondrocytes are embedded in 3 compartments of 
ECM which different in molecular compositions respected to a distance from the 
chondrocytes going from near to far. The pericellular matrix is the first region surrounding 
the chondrocytes which presence of fibronectin (19) and collagen type VI (20). However, the 
region also contains the other types of collagen and have high concentration of proteoglycan 
(21). Chondrocytes located in the superficial zone produce little pericellular matrix (4), 
whereas chondrocytes located in the deep zone produce large PCM (22). The territorial 
matrix is the second region wrap around the pericellular matrix. This region is an 
intermediate region. The main matrix composition is similar to the interterritorial matrix but 
still has a higher concentration of proteoglycan than the outer ECM (23). Collagen type VI is 
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also found in this region (23). The interterritorial matrix is the major area of ECM in the 
cartilage which has collagen type II and presence of collagen type IV fiber in the region. The 
proteoglycan concentration in the interterritorial matrix is various along the depth from the 
superficial zone to deep zone (24). A schematic of the extracellular matrix, with three 
different regions (pericellular, territorial and interterritorial) surrounding the chondrocytes is 
shown in Fig 1.1. 
 
Figure 1.1: Schematic of cartilage extracellular matrix regions: pericellular, territorial and 
interterritorial. 
1.2.2 Cartilage extracellular matrix (ECM) 
The vast majority of articular cartilage consists of a hydrated ECM, with the remaining ~10% 
of the volume consisting of chondrocytes. At a basic level, the main constituents of the ECM 
are collagens and proteoglycans. There are also glycoproteins and other molecules, such as 
growth factors: transforming growth factor β (TGF-β) (25), insulin-like growth factors (IGF) 
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(26), bone morphogenetic proteins (BMP) (27) and fibroblast growth factors (FGF) (28), 
which bind to the ECM. The ECM and other soluble mediators accompany with chondrocytes 
regulate cartilage homeostasis (17, 29).  
1.2.2.1 Collagens 
Collagens are the major insoluble fibrous proteins of the extracellular matrix of most tissues. 
The structure of collagen basically consists of 3 polypeptide chains which are held together 
by hydrogen bond in triple helix structure (30). Amino acid sequence of collagen chain has a 
unique pattern which consists of a repeating of glycine in every third unit (Gly-X-Y)n. 
Approximately 20 % of the amino acids in collagen are imino acids, proline and 
hydroxyproline (30). There are at least 20 different types of collagen in the ECM, with the 
predominant type varying depending on the tissue. Articular cartilage, collagen comprises 
approximately 12% to 24% of the wet weight (~150 µg/mg of wet weight) and collagen type 
II is the main type (31). Other types of collagen, including collagen I, VI, IX, X and XI are 
also found in various amounts according to the cartilage type (32). By the cross-linking of 
collagen fibril, collagen fibers are primarily responsible for the tensile strength of the tissue.  
1.2.2.2 Proteoglycans  
Proteoglycans consist of multiples of polysaccharide chains (glycosaminoglycans) linked to 
the core protein. The majority of the proteoglycan component is the polysaccharide chain. 
There are many types of proteoglycan in ECM. The diversity of proteoglycan caused by the 
different types of core protein, different types of polysaccharide chain and different in length. 
Glycosaminoglycans (GAGs) are the polysaccharide chains composed of repeating 
disaccharide units. There are 5 main groups of GAGs are distinguished according to their 
sugars: hyaluronan, chondroitin sulfate, dermatan sulfate, heparan sulfate, and keratan 
sulfate. GAGs are highly negatively charged because of sulfate or carboxyl groups on most of 
their sugars and it promotes water retention contribute to compressive strength of the tissue. 
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Aggrecan is the major type of proteoglycan in articular cartilage, which comprises around 3-
6% of the wet weight (~50 µg/mg wet weight) (31). Aggrecan is composed of core protein 
decorated with highly-charged GAG chains (chondroitin sulfate and keratan sulfate), and it 
forms massive proteoglycan aggregates by binding through link protein to a backbone of 
hyaluronic acid.  
1.2.2.3 Glycoproteins 
Glycoprotein consists of polysaccharide and protein the same as proteoglycan but the 
majority component is protein. Fibronectin and laminin are glycoproteins commonly found in 
the ECM of a variety of tissues, and are present in the pericellular matrix of cartilage. 
Fibronectin which is rich in the Arg-Gly-Asp (RGD) subunit play a role as a cell attachment 
molecule via the α5β1 integrin (33). Also, fibronectin can bind to many substances such as 
heparan sulfate, collagen and fibrin. Laminin is an important glycoprotein which is critical 
for organizing tissue development in early embryonic development.  
1.2.3 The zones of articular cartilage 
Articular cartilage can be divided into 4 zones from the surface to bone contact area which 
are different in the composition and functions; the superficial zone, the transitional or middle 
zone, the radial or deep zone and the calcified zone. Each zone has unique composition and 
arrangement of chondrocytes and extracellular matrix component (4). The structure and 
composition of each cartilage zone is shown in Fig 1.2. 
1.2.3.1 The superficial zone 
The superficial zone constitutes ~10% of the thickness of the articular cartilage, and contains 
flat and ellipsoidal chondrocytes. The average density of chondrocytes in different areas of 
the superficial zone is approximately 14,000-24,000 cells per mm3 (34). Chondrocytes from 
superficial zone synthesized less proteoglycans than the one in other zones (10). The 
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arrangement of the cells and collagen fibrils is parallel to the articular cartilage surface. The 
specific zonal marker expressed in this zone is PRG4 (35). Current report shows several 
potential gene markers for superficial chondrocytes were identified such as gene encoding for 
insulin-like growth factor-binding protein 5 (IGFBP5), EGF-containing fibulin-like 
extracellular matrix protein 1 (EFEMP1) and fibroblast growth factor receptor 2 (FGFR2) 
(36). The compressive aggregate modulus in the superficial zone is 1.16 ± 0.20 MPa (37). 
The tensile modulus of normal human cartilage at the superficial zone is 8.3 + 3.7 MPa (38). 
The shear modulus is low in the superficial zone compares to the deeper zone (39). 
1.2.3.2 The middle zone 
The middle zone comprises ~20% of the height of the tissue. Chondrocytes in the middle 
zone are more rounded and form single-cell chondrons. The average density of chondrocytes 
in different areas of the middle zone is approximately 9,000-18,000 cells per mm3 (34). This 
zone has high amount of proteoglycans (10). The arrangement of the cells and collagen fibril 
is random and the potential zonal marker for the middle zone is cartilage intermediate layer 
protein (CILP) (14). However, current report on zone-specific gene expression in normal 
human cartilage show that chondrocytes in the middle zone shared some of the gene 
expression patterns with chondrocytes from adjacent zones, while the most considerable 
different of gene expression patterns were found between superficial zone and deep zone. The 
only one gene was found unique expression pattern in middle deep chondrocytes is small 
nucleolar RNA, C/D box13 pseudogene 1 (SNORD13P1) which show up regulated in middle 
deep chondrocytes compared to superficial and deep zone chondrocytes (36). 
1.2.3.3 The deep zone 
The deep zone comprises ~60% of the height of the tissue. The average density of 
chondrocytes in different areas of the deep zone is approximately 7,000-9,000 cells per mm3 
(34). The deep zone has the highest compressive aggregate modulus, at 7.75 ± 1.45 MPa (37) 
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and the lowest tensile modulus is found (4.1 + 1.9 MPa) in the deep zone (38). The shear 
modulus is higher in deep zones than in superficial zone (39). The arrangement of cells and 
collagen fibrils in this zone is in vertical to the articular cartilage surface and the 
chondrocytes look more ellipsoid and form multiple-cell chondrons. The interface between 
the deep zone and calcified zone is termed the tidemark, which consists of multilayer of 
collagen fibrils formed as a thick bundle (40). Collagen type X, a marker for chondrocyte 
hypertrophy, is expressed in the deepest area of above the tidemark (41). 
1.2.3.4 The calcified zone 
The calcified zone, which forms the boundary between cartilage and bone, is composed of 
hypertrophic chondrocytes surrounded by partially mineralized matrix (calcified matrix). The 
calcified zone is the last layer of cartilage that transition into subchondral bone. The mainly  
of collagen found in the calcified zone of cartilage is collagen type X (41). Chondrocytes in 
this zone share many similarities with chondrocytes in hypertrophic zone of growth plate 
(42).  
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Figure 1.2: The zonal function and zonal properties and composition of articular cartilage. 
(A) Superficial zone, (B) Middle zone and (C) Deep zone The arrows indicate level change 
from high to low (adapted from (43)). 
1.2.4 Cartilage mechanical properties 
The biomechanical properties of articular cartilage are a result of its composition and 
arrangement of the ECM (44). For example, Treppo, et al, reported that the majority of the 
variation in the equilibrium modulus of each joint surface could be accounted for variation of 
its composition such as water content, percent GAG per wet weight and percent collagen per 
wet weight (45). Under normal physiological conditions, articular cartilage experiences 
several mechanical stimuli such as compressive stress, shear stress and hydrostatic pressure. 
The mechanical stimuli affect the biochemical composition of articular cartilage; for 
example, cartilage in high-loading areas has more proteoglycan than cartilage in low-loading 
areas (46). Estimated by the confined compression test, the aggregate modulus, or stiffness, 
of normal human cartilage is in the range of 0.5 to 0.9 MPa (47). The tensile modulus of 
healthy human cartilage is 5-25 MPa and the equilibrium shear modulus is 0.05-0.25 
MPa.(48). 
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1.3 Chondrogenesis cartilage development 
Cartilage tissue engineering requires the formation of new cartilage matrix by combining 
cells, scaffolds and signals. To achieve this, it is important to understand the natural in vivo 
process of chondrogenesis (49). Cartilage is the first skeletal tissue that is developed during 
embryogenesis. Endochondral ossification is the step following chondrogenesis for long bone 
formation. Several growth factors and transcription factors are involved in the cartilage 
development process. Chondrogenesis begins with mesenchymal cell condensation mediated 
by paracrine factors such as fibroblast growth factor (FGF) and transforming growth factor- 
(TGF-), and then the aggregated cells start to produce ECM, including collagen type I, 
fibronectin and proteoglycans. After strong interaction with the ECM, mesenchymal cells 
differentiate to be chondroblasts, secrete cartilage-specific ECM molecules and become 
chondrocytes. A transcription factor, Sox 9, is expressed by condensed mesenchymal cells 
and plays an important role in regulating chondrogenesis. During late maturation, 
chondrocytes increase in size, forming hypertrophic chondrocytes, secrete collagen type X 
and begin to mineralize calcium into the tissue. However, the normal adult chondrocytes does 
not go through the late maturation as in the osteochondral ossification of growth plate 
cartilage (50). The hypertrophic changes are found only in pathological conditions such as in 
OA (51). After that, hypertrophic chondrocytes die by apoptosis and the ECM are degraded, 
creating the space for vasculature. Osteoblasts enter the free space via the blood stream and 
proliferate, synthesize collagen type I and create bone-specific ECM by mineralization, 
resulting in bone formation. Matrix metalloproteinases (MMPs) has been suggested to play a 
role in cartilage matrix degradation in the late state of osteochondral ossification (52). In vitro 
chondrogenesis of adult mesenchymal stem cells (MSCs) seems to recapitulate in vivo 
endochondral ossification process as shown by hypertrophic chondrocyte marker gene 
(Collagen type X, matrix metalloproteinase 13) are up regulated within one week after 
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chondrogenic induction (53). To achieve a stable articular cartilage for tissue engineering 
application, induction of hypertrophy during in vitro chondrogenesis of MSCs must be 
prevented.  
Mechanical forces play a role in the natural chondrogenesis and endochondral ossification 
during skeletal development. Forces generated by muscle contraction and associated skeletal 
movement are important for joint development and guiding endochondral ossification process 
during embryonic, fetal and postnatal stages (54-56). However, mechanical forces seem to 
have minimal role in embryonic joint development when compared to their role in postnatal 
joint development (57). As reviewed by Walker, the movement may be less vital for the 
initial stage of human joint formation but it is crucial in maintenance of human joint and 
molding of the articular during fetus and postnatal joint development (57). In more detail, 
Carter et al, suggest that sporadically applied shear stress promotes cartilage degeneration 
and endochondral ossification, while sporadically applied hydrostatic compression retards 
these processes (55). This hypothesis is supported by a finite element computer model that 
can predict the key features of skeletal morphogenesis based on specific stresses (55). 
1.4 Articular cartilage damage and disease 
There are many conditions and diseases that can cause articular cartilage damage such as 
traumatic injury, rheumatoid arthritis (inflammatory disease), infections and osteoarthritis 
(OA). Among these conditions, osteoarthritis, which is a degenerative disease, is the most 
common cause of articular cartilage damage, especially in elderly (58). Because of the low 
cellularity and avascular nature, the tissue has minimal intrinsic repair capacity. Thus, even 
minor damage to articular cartilage can lead to large-scale degeneration. OA is a major cause 
of pain and disability to the global population (59). 
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OA is now considered as a whole joint failure, which includes degradation of articular 
cartilage, stiffening of the subchondral bone, and pathological changes of the synovial tissue 
(1). The weakening and contracture of ligaments and muscles are also observed in OA (60). 
The changes of synovial joint from normal to osteoarthritis are shown in Fig 1.3 (61). 
However, the mechanism of change in healthy to OA is still poorly understood. In a healthy 
joint, there is a balance between anabolic and catabolic factors to maintain the cartilage 
structure and function. When the balance shifts to the catabolic side by abnormal stimuli, 
cartilage starts to degrade. Continued cartilage degradation will lead to joint dysfunction and 
pain. In the early stages of articular cartilage degeneration, changes in the molecular structure 
and composition of the matrix are observed. These include the loss of proteoglycans and 
leads to an increase in water concentration (62, 63). With the progression of OA, chondrocyte 
phenotype also changes from the state of maturation arrest to hypertrophy (51, 64). Multiple 
factors are involved in OA pathogenesis. Biomolecular and mechanical environments, both 
play a role in the initiation and progression of disease. 
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Figure 1.3: Schematic of (a) a normal healthy joint compared to (b) an osteoarthritis joint 
(61). 
1.4.1 Biomolecular environment 
There are indications that multiple biomolecular factors are involved in OA pathogenesis. 
Reports show that the level of both catabolic signals (i.e. pro-inflammatory cytokines 
interleukin-1 beta (IL-1β) and tumor necrosis factor- alpha (TNF-α) as well as anabolic 
signals (i.e., growth factors including transforming growth factor type β (TGF β), bone 
morphogenetic proteins (BMPs), insulin-like growth factor-1 (IGF-1), and fibroblast growth 
factor-2 (FGF-2)) are altered, exerting their influence on an OA cartilage. Chondrocytes, 
bone cells and synovial cells all produce several cytokines, inflammatory mediators and 
catalytic enzymes which are found in OA joints and contribute to the onset and progression 
of OA (1, 65, 66).  
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1.4.1.1 Cytokines and growth factors 
Cytokines play an important role in OA (67). Cytokines inside the joints include pro-
inflammatory (e.g., IL-1β, TNF α), anti-inflammatory (e.g., interleukin-4 (IL-4), interleukin-
10 (IL-10)), and regulatory cytokines (e.g., interleukin-6 (IL-6)). Pro-inflammatory cytokines 
are often up-regulated in OA (68). IL-1β and TNF α have been shown to decrease the matrix 
synthesis (aggrecan, collagen type II) and increase cartilage matrix degradation (69). OA 
chondrocytes not only increase expression of IL-1β, TNF α, they also increase expression of 
IL-1 receptors (IL-1 receptor type I and IL-1 receptors type II) and TNF α receptors (TNF 
receptor I and TNF receptor II) (70, 71). These cytokine receptors are also expressed by OA 
synovial fibroblasts (71, 72). Acting through their receptors, IL-1β and TNF α stimulate the 
production of additional cytokines, such as IL-6, IL-8, and several substances which 
contribute to cartilage inflammation and degradation such as nitric oxide (NO) and 
prostaglandin E2 (PGE2). NO and PGE2 are the inflammation mediators which increase the 
production of MMPs and inhibit matrix synthesis in cartilage (69). IL-6 production is low in 
normal chondrocytes and it is increased by pro-inflammatory cytokines produced in OA 
conditions (73). Level of IL-6 is elevated in OA synovial fluid (74). Although, IL-6 is known 
as a pro-inflammatory cytokine, some evidence suggests that IL-6 has a protective role in 
inflammation (75). IL-10 is also reported to be significantly higher in OA cartilage (66). 
The articular cartilage metabolism is also regulated by several growth factors that are 
produced by chondrocytes itself or by the surrounding tissues such as synovium cells and 
bone cells. Insulin-like growth factor-1 (IGF-1) is a factors control the balances of anabolic 
activity and catabolic activity in normal cartilage. There is a report show that OA 
chondrocytes produces excessive levels of IGF type 1 receptor but lower binding affinity than 
normal chondrocytes this may leads to IGF non-responsiveness in OA (76). TGF–β and basic 
fibroblast growth factor (FGF) which were reported to play important roles in the 
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chondrogenesis and osteogenesis were expressed in the osteophytes of the human femoral 
heads in osteoarthritis but there was a difference in the localization (77). TGF–β was found in 
the superficial chondrocytes of osteophyte cartilage, but it was rarely found in superficial 
chondrocytes of degraded cartilage. However, FGF was found in whole osteophyte cartilage. 
These indicated the different role of these two growth factors in the osteophyte formation in 
OA (77). Also, bone morphogenetic protein -2 (BMP-2) and bone morphogenetic protein-4 
(BMP-4) are strongly expressed in OA chondrocytes (78, 79). 
1.4.1.2 Matrix metalloproteinases (MMPs), aggrecanase and tissue inhibitors of 
MMPs (TIMPs) 
Several enzymes related to cartilage degradation are found in the OA joint. Different types of 
matrix metalloproteinases (MMPs) are up regulated in injury and in OA cartilage. MMP-1,-
2,-3,-8,-9,-13 is all actively involved and up-regulated in OA cartilage compared to normal 
cartilage (80, 81). MMP-1, MMP-3, and MMP-13 are suggested to be a key regulator of 
cartilage degradation in OA (69). In some studies, MMPs expression is varies with zones. 
MMP-3 is up regulated in superficial layers but not deeper layer of bovine explants after 
being exposed to mechanical compression (1-5 MPa) (82). In addition, MMP-1, -3, -9 
expression seems to vary in different zones and stages of OA (80). 
A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) are the other 
important enzymes in OA cartilage destruction. While MMP-1, -2, -8, -13 are responsible for 
collage II degradation (83), both MMPs (MMP-2, -9) and aggrecanase (ADAMTS-1, -4, -5) 
are responsible for aggrecan degradation (84). The previous report shows that ADAMTS-4 is 
dominantly increased in expression in OA cartilage when compared to ADAMTS-5 which is 
constantly expressed in osteoarthritic and normal cartilage (85). However, there is a report 
showing that suppression of ADAMTS-4 or/and ADAMTS-5 reduce aggrecan degradation in 
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OA cartilage (86). ADAMTS-4 and ADAMTS-5 are suggested to be the key enzymes 
responsible for aggrecan destruction in human osteoarthritis (87) 
Tissue inhibitor of metalloproteinases (TIMPs), which inhibits of MMPs, have been showed 
to be up regulated in early OA (88). TIMPs (TIMP-1,-2,-3,-4) play a role as MMP inhibitors 
to regulate the MMPs activity for control the matrix degradation in the tissue. The balance 
between MMPs and TIMPs is important for joint cartilage homeostasis (89). In addition to 
inhibiting MMP activity, TIMP-3 inhibits aggrecanase activity in vitro (90). In OA 
chondrocytes, the gene expression of MMP is usually higher than the TIMPs although the 
expression of TIMPs in OA cartilage is higher than in normal chondrocytes (91). 
1.4.1.3 Contribution from other joint tissues 
To further complicate the process, growth factor, enzyme and cytokine levels in the joints can 
be regulated by many different cell types that reside within the joint and have an effect on 
chondrocyte behavior (92). The biomolecular factors which promote the catalytic activities of 
chondrocytes are increased in many cell types in the OA joint. These seem to be related to the 
degradation of cartilage matrix and OA progression. However, it is still unclear whether there 
exists a defined biological and environmental cause for cartilage degradation and progression 
of OA. The contribution of each cell type of cartilage, bone and synovial tissue on multiple 
biomolecular factors (not include inhibitors) in joint which involved in OA pathogenesis is 
shown in Fig 1.4. 
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Figure 1.4: Schematic of cellular roles and interactions in an OA joint (69). 
Initiated by intrinsic or external stimuli (abnormal mechanical loading, aging, cartilage 
injury), proinflammatory cytokines in the OA joint (IL-1 β, TNF-α, and IL-6 produced by 
synovial fibroblasts, T helper cells, chondrocytes and osteoblasts activate chondrocytes to 
increase catabolic activities and decrease anabolic activity via production of proteinases and 
other inflammatory mediators lead to cartilage destruction and abnormal changes of related 
tissue in OA joint.  
Bone osteophytes formation and subchondral bone change are the other characteristic of OA. 
Increased cytokines and growth factors released from bone cells seem to have influence on 
bone and cartilage changes. Reports show that cells in the subchondral bone in OA patients 
secrete high levels of TGF β1, ALP, IL-6, urokinase plasminogen activator, prostaglandin 
and insulin growth factor-1 (IGF-1) when compared to the normal bone tissue (93-95). BMPs 
are known to induce ectopic bone formation (96) and can help to stimulate the expression of 
hypertrophic markers collagen type X (Col X) and vascular endothelial growth factor (VEGF) 
(97). Pro-inflammatory cytokines are linked with increased MMP production in OA patients 
(98). There is a report that shows MMPs (MMP-2, -9, -13) are also elevated in OA 
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subchondral bone compared to the normal subchondral bone (66). Interestingly, TIMP-1 is 
also found to be up-regulated in OA subchondral bone (66).  
Also, synovial inflammation is one of the hallmarks of OA. In the past cartilage and bone are 
considered as a main contributors in OA pathogenesis. The importance of synovial cells in 
OA pathology is becoming more evident (99). Pro-inflammatory cytokines (IL-1β, IL-6, 
TNF-α), MMPs and aggrecanase are elevated in OA synovial tissue and synovial fluid (99, 
100). 
Multiple biomolecular factors produced in the OA joint affect chondrocytes and other cells 
and lead to pathological changes in OA. However, the roles of each biomolecular factors are 
still under evaluate. Understand the role of biomolecular factors on the chondrocytes may 
help for OA control and treatment. In addition, it may provide the clue for success of 
cartilage repair.  
1.4.2 Mechanical environment 
In addition to the potent soluble factors described in the previous section, the chondrocytes in 
articular cartilage are subjected to unique mechanical environments. These environments 
include the stiffness of the extracellular matrix, fluid flow, hydrostatic pressure, and 
deformation, and are changed with the onset of disease. In healthy cartilage, mechanical 
properties vary throughout the depth. When the joint is loaded, the combination of 
mechanical stimuli: tensile, shear and compressive stress are generated and distributed 
differently in the cartilage zones depending on the composition and organization. The low 
compressive modulus in the superficial zone allows it to go through a large compressive 
strain during joint articulation (101). In OA condition, the stiffness of the articular cartilage 
decreases and its permeability increases (102). 
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Moderate mechanical loading helps to maintain cartilage function and properties while 
abnormal loading can leads to cartilage damage and degradations as review in (103). The 
chondrocytes in articular cartilage seem to response to mechanical stimuli in the zone-
specific manner. Compressive stimulation is shown to enhance chondrocytes biosynthesis 
(104). Jeon et al. reported that the dynamic compression at 1Hz 50% compression can 
promote the biosynthesis of OA chondrocytes in a 2% alginate model. Their results also show 
that compressive loading can increase both pro-inflammatory cytokines (IL-1β) and anti-
inflammatory cytokines (IL-4). In addition, MMP-3 expression has shown to be significantly 
decreased with compressive stimulation only in the superficial zone constructs while MMP-2 
is significantly decreased in both superficial and middle deep constructs (43). Dynamic 
compression has been shown to reduce the effect of IL-1 in both superficial zone and middle 
deep zone chondrocytes (105).  
However, there needs to be more investigation in to the effect of mechanical loading, 
included compression or another type of load such as shear stimuli, on OA chondrocytes in 
order to broaden our understanding on the relationship between mechanical injury/stimulation 
and OA pathogenesis.  
1.5 Articular cartilage repair and current treatments 
As a result of no blood supply and limited chondrocyte proliferation, articular cartilage has 
poor repair capacity. In chondral damage, the chondrocytes, which are trapped in the ECM, 
have low ability to migrate and proliferate to repair the injury. If damage occurs to both 
cartilage and bone (osteochondral damage), mesenchymal stem cells from bone marrow can 
move to the injury site and repair with fibrocartilage formation (106). However, the repaired 
tissue has inferior mechanical properties to normal articular cartilage. To overcome the 
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symptoms of cartilage damage, many types of treatment have been performed such as 
medicine for pain relief or artificial joint replacement.  
1.5.1 Non-surgical methods 
The main aim of non-surgical method is to improve patient mobility and reduce pain. Weight 
loss and exercise are the non-pharmacological strategies for OA patients treatment (107). The 
slow acting medicine such as glucosamine, chondroitin sulfate and S-adenosyl methionine 
(SAM) are used for pain prevention and slow down cartilage degradation (108). In addition, 
pain–killer (paracetamol) or nonsteroidal anti-inflammatory drugs (NSAIDs) which are the 
cyclooxygenase inhibitor are used to treat OA patients for pain relief. NSAIDs have been the 
drugs of choice in the treatment of rheumatic disorders and other degenerative inflammatory 
joint diseases (107). However, NSAIDS which is cyclooxygenase (COX)-1 inhibitor has an 
upper gastrointestinal (GI) toxicity that is a main limitation of using (109). Currently, COX-2 
selective inhibitors with mild GI toxicity are used in clinical practice, although there are 
concerns over increased risk of cardiovascular events (110). Also, steroidal anti-
inflammatory, glucocorticoids is another option in OA treatment to prevent pain (111). 
Opioids are the last drugs for the patients who have uncontrolled pain or no response to other 
pharmacological treatments (112). Many compounds in the group of growth factors, matrix 
degradation enzyme inhibitors, anti-cytokines and various signaling pathways related to OA 
pathology inhibitors are being developed and evaluated in preclinical studies (108, 113-117). 
However, there is presently no single drug or combination of drugs for relieving pain and 
improving OA symptoms (118). 
1.5.2 Surgical methods 
Artificial joint replacement is a surgical procedure in which the arthritic joint is replaced with 
the prosthesis. The treatment is used with patients who have degenerative and advanced OA 
which less-invasive therapies have failed to treat. Approximately 40,000 hip and knees 
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replacements were performed in Australia in 2004 to 2005 (2). Artificial joint replacement 
restores the function of joint to nearly normal and it is effectively improve health-related 
quality of life in OA patients (119). However, joint replacement is costly and has a limited 
lifespan (10–20 years). Therefore, it is not suitable for younger or more active patients (120). 
Approximately AU$ 600 million was spent on hospital services in 2007 for OA patients and 
joint replacement was reported to be a major contributing factor of hospital cost (2). 
In addition to medicine and artificial joint replacement, there are many orthopedic procedures 
that have been performed to promote cartilage regeneration (121). The surgical procedures 
are commonly for osteochondral defect treatment. There is presently no standard surgical 
procedure for chondral defect treatment (122). A regenerative therapies such as cells-based 
repair may allow for delay of joint replacement, or if good enough, an alternative to joint 
replacement. The following are the current procedures that have been used or studied to 
repair and regenerate damaged cartilage. 
1.5.2.1 Debridement 
Debridement is based on cleaning and smoothing the defect area in the knee joint by 
removing the roughness of the cartilage surface (123). The technique is easy to perform, but 
the outcome still questionable as the temporary improvement are commonly experienced in 
the patients with advanced stages of degeneration (124). 
1.5.2.2 Microfracture 
Microfracture involves surgically creating multiple holes through the cartilage and 
subchondral bone, and allowing bone marrow stem cells (BMSCs) to enter to the defect site 
and repair the defect (125). The result is similar to natural osteochondral cartilage defect 
repair, resulting in fibrocartilage with inferior mechanical properties to normal articular 
cartilage. 
22 
 
1.5.2.3 Mosaicplasty (Osteochondral autograft transplantation surgery) 
In mosaicplasty, osteochondral plugs are removed from low-load bearing areas of the joint 
and transplanted in to the defect area (126). The success rate of this technique is high. 
However, the technique creates new defects at the donor site and there are limitations in 
donor supply. Further, cartilage-cartilage integration is limited. 
1.5.2.4 Osteochondral allograft transplantation 
Osteochondral allograft transplantation is similar to the autograft transplantation but the 
tissue is generally from a cadaveric donor (127). The outcome of osteochondral allograft 
transplantation is generally good. However, special care and treatment is required to limit the 
immunogenic reaction of osteochondral allograft such as high-pressure wash during harvest 
and transplantation to remove antigen presenting cells (APCs). 
1.5.2.5 Autologous chondrocyte implantation (ACI) 
In order to overcome a limited supply of healthy chondrocytes, cells harvested from the 
donor site are expanded in vitro and injected into the defect site (128). ACI has been used to 
treat patients clinically; however, chondrocyte isolation damages healthy area of cartilage 
may cause fibrocartilage healing at the operation site and the long term benefit of ACI still 
controversial (59, 129). This technique is the first cartilage tissue engineering approach to be 
applied clinically, and current cartilage tissue engineering aims to improve the method and 
outcomes using different cells, materials, and culture environments.  
1.6 Cartilage tissue engineering 
Articular cartilage has a low ability to repair itself and the current cartilage damage 
treatments have some limitations, as previously described. The field of tissue engineering 
continues to advance, and articular cartilage engineering is one promising approach for 
articular cartilage regeneration. One of the goals for cartilage tissue engineering is to produce 
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tissue, which has the structure, biochemical properties and biomechanical properties similar 
to normal adult cartilage. There are few studies that have developed tissue-engineered 
constructs with near-natural cartilage properties. For example, Revell et al reported that 3.75 
million bovine calf chondrocytes cultured in vitro using a self-assembling method for 2 
weeks have led to the production of cartilage tissue constructs with an aggregate modulus of 
127 ± 37 kPa and containing 8.2 ± 1.5% GAG per wet weight and 11 + 2% collagen per wet 
weight (130). Also, bovine chondrocytes in agarose hydrogels cultured for 56 days in serum-
free medium containing transient TGF-3 exposure achieved native tissue level of 
compressive modulus (0.8 MPa) and proteoglycan content (6-7% per wet weight) (131). 
However, there is still no human cartilage construct which has zonal structure, biochemical 
and biomechanical properties similar to native articular cartilage. 
1.6.1 Traditional approaches 
Success of tissue engineering approaches depends on the cell source, scaffold, and culture 
conditions (Fig 1.5). Many cell sources have been investigated for potential use in cartilage 
tissue engineering such as chondrocytes and mesenchymal stem cells from various tissues. 
Numerous materials both natural and synthetic have been evaluated their ability to support 
cartilage engineering in vitro and/or in vivo (132). One approach to find the optimal culture 
environment in vitro is to mimic the natural cellular environment. Potentially important 
signals include oxygen tension, mechanical stress and biochemical signals.  
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Figure 1.5: Overview of the tissue engineering approach for cartilage repair. 
1.6.1.1 Cell sources 
The ideal cell source for cartilage tissue engineering would be easy to access, have ability to 
expand, have ability to differentiate to form and maintain cartilage, and have little or no 
immunogenicity (133). Chondrocytes and MSCs are the major cells that have been used in 
cartilage tissue engineering. However, each cell type has both strong and weak points. 
1.6.1.1.1 Chondrocytes 
Chondrocytes from several cartilaginous tissues have been considered as a source of 
chondrocytes for cartilage tissue engineering such as nasal septum, costal cartilage and 
articular cartilage (134, 135). Autologous chondrocytes harvested from normal regions of 
articular cartilage and expanded in vitro have been used to treat cartilage defects (136). 
However, the protocol to harvest chondrocytes is invasive and causes donor-site morbidity 
such as fibrous tissue formation, cyst formation and joint space narrowing at the donor site 
(137). In the ACI protocol, approximately 300 to 500 mg of cartilage are obtained from a 
minor load-bearing area (138). About 1 million chondrocytes can be obtained from 1 gram of 
25 
 
articular cartilage (139). To get sufficient chondrocytes (about 3-5 million) needs to expand 
chondrocytes for 3 weeks in vitro (138). However, cell requirements for cartilage tissue 
engineering range from 20 to 100 million cells per mL (140). There is a report estimate the 
number of chondrocytes need for cartilage tissue engineering treatment (defect size 4 mm x 
40 mm with cell density 64 million cells/mL) are 320 million cells for 1 single focal defect 
(141). Therefore, large-scale cell expansion is needed to obtain enough cells for the treatment. 
Additionally, chondrocytes de-differentiate when expanded in monolayer culture, as is 
commonly shown by a shift in collagen expression from type II to type I (142, 143). Further, 
repair using these cells is normally fibrocartilaginous, similar to simpler microfracture 
treatment which recruits bone marrow into the defect (129). Another possible cell source for 
cartilage tissue engineering is allogeneic chondrocytes however, host immune response may 
still be an issue for clinical application (144). For research purposes, chondrocytes can also 
be obtained from human cartilage which is discarded during total joint replacement. 
1.6.1.1.2 Mesenchymal stem cells (MSCs) 
MSCs were first reported in 1974 by Friedenstein (145), and interest as a potential source for 
cell therapy and regenerative medicine has been rapidly increasing, due to their ability to 
proliferate and differentiate into various cell types of the mesodermal origin (146). MSCs 
have a fibroblast-like morphology and are adherent to tissue culture glass or plastic. Their 
immunophenotype is negative for hematopoietic markers (CD34-, CD45-, CD14-), and 
includes several positive stem cell markers such as CD13+, CD29+, CD44+, CD54+, CD166 
(SH3)+, CD73 (SH4)+, CD90 (Thy1)+, CD105 (SH2)+. They have the ability to differentiate 
into chondrocytes, adipocytes and osteoblasts. Additionally, colony-forming unit–fibroblast 
(CFU-F) and proliferation potential determined by the population doubling time are also 
criteria which are used to evaluate the capacity of MSCs. 
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1.6.1.1.2.1 Bone marrow stromal cells (BMSCs) 
The most common source of MSCs is the stroma of bone marrow. There is evidence that 
MSCs from bone marrow have higher chondrogenic potential than the MSCs from other 
origins such as lung or placenta (147). However, there are some problems associated with 
bone marrow stem cells including invasiveness of the bone marrow aspiration and decreased 
differentiation capacity with age of donor (148). For these reasons, researchers are looking 
for a new source of stem cells.  
1.6.1.1.2.2 Other sources of MSCs 
Many alternative sources have been studied, including amniotic fluid, synovial membrane, 
adipose tissue and umbilical cord blood (149-152). Among all these sources, adipose tissue 
from liposuction and umbilical cord blood seem to be convenient sources because both are 
discarded tissues. Mesenchymal stem cells derived from adipose tissue have been shown to 
differentiate into many mesodermal linage cell types including chondrocytes. Liposuction, 
which is used to collect the adipose tissue for MSCs isolation is not as invasive as bone 
marrow aspiration. However, low chondrogenic potential of adipose stem cells compared to 
bone marrow stem cells and lack of consistent isolation of MSCs from cord blood have been 
reported (151, 153). 
Human umbilical cord is an interesting tissue for the source of cells for cell therapy and tissue 
regeneration. Umbilical cord is a 60-70 cm tissue which links the fetus and placenta and is a 
discarded tissue following birth. Umbilical cord consists of 2 cord arteries and one cord vein, 
surrounded by mucous connective tissue, called Wharton’s jelly, and covered with amniotic 
epithelium (154). Mesenchymal stem cells have been isolated from several compartments of 
umbilical cord, such as cord vein and Wharton’s jelly, have shown the capacity of self–
renewal and mesodermal lineage differentiation (155, 156). Recently, Sarugaser et al. 
reported that human umbilical cord perivascular cells (HUCPVCs) isolated from the outer 
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margin of the umbilical cord vein and arteries have high proliferation rate when compared to 
BMSCs and suggested that HUCPVCs are an important cell source for allogeneic cell based 
therapy (157). There are still no consensus cellular markers for the stem cell population in 
HUCPVCs, however surface markers used to characterise HUCPVCs include CD45-, CD34-, 
CD44+, CD49e+, CD73+, CD90+ and CD105+ (154). Baksh et al. reported the potential of 
HUCPVCs to differentiate into adipocytes, osteoblasts and chondrocytes (158). They also 
reported that CD146+ cells which lack endothelial cell marker CD31 expression showed 
multilineage capacity whereas no significant in differentiation capacity was detected from 
CD146 negative HUCPVCs (158). In addition, HUCPVCs are non-alloreactive and exhibit 
immunosuppressive ability in vitro (159). HUCPVCs have been found to have ability to 
differentiate into chondrocytes in the conventional cell pellet culture (158). Although, pellet 
size (~1-3 mm) and shape (spherical) seems not applicable for clinical applications of 
cartilage tissue regeneration, there is a clinical trials for efficacy and safety of multiple 
autologous chondrocytes pellets to treat large cartilage defects (≥ 4 to 10 cm2) by co.don® 
AG company (160). 
1.6.1.1.2.3 Issues with MSCs 
Mesenchymal stem cells (MSCs) from various kinds of tissue seem to be promising cells for 
cartilage tissue engineering. However, using MSCs to engineer cartilage with a distinct zonal 
structure and function remains a major challenge. In addition, a standard protocol is needed to 
prevent hypertrophy of MSCs, especially BMSCs, during in vitro chondrogenesis, to 
maintain de novo cartilage and prevent the cartilage from turning into bone. Regulation of 
MSC hypertrophy in vitro has been only addressed to a limited extent. Also, MSCs which is 
induced to be chondrocytes in vitro cannot maintain their chondrogenic phenotype after 
transplantation to animal model. There is a report showed that MSCs derived chondrocytes 
pellets undergo hypertrophic changed (mineralized) as in endochondral ossification while the 
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chondrocytes pellets can maintain their phenotype in vivo (53). One more issue for BMSCs is 
the number of progenitor cells from bone marrow is reduced with age (161).  
1.6.1.2 Scaffolds 
Numerous materials, both natural and synthetic have been evaluated for their ability to 
support chondrogenesis in vitro and/or in vivo (132, 162-165). Scaffolds play a role in 
providing initial structure for tissue development. Scaffolds should be biodegradable and 
biocompatible, and allow for cell adherence and migration. In addition, for successful of 
cartilage repair, scaffolds would ideally provide the essential signals for the chondrocytes to 
activate anabolic activities. There are many natural materials such as alginate, agarose, 
collagen and fibrin, and synthetic materials like poly(glycolic acids) and poly(ethylene glycol) 
that have been investigated for cartilage applications (162-164, 166, 167). 
1.6.1.2.1 Synthetic scaffolds 
Synthetic scaffolds are widely used in bone and cartilage tissue engineering due to their 
preferable mechanical properties and amendable degradation rate (168). In addition, used of 
synthetic scaffolds eliminates the risk of infection transmission that may be present in natural 
scaffolds. However, the synthetic scaffold materials commonly lack the ability to provide 
signals to the cells. For example, poly(glycolic acid) (PGA), poly-(L-lactic acid) (PLA), or a 
copolymer of PGA and PLA (PLGA) have been used as scaffolds for cartilage tissue 
engineering but they lack signaling molecules, such as the Arg–Gly–Asp (RGD) sequence for 
cell attachment, and their degradation products may cause inflammation that possibly result 
in failure of the implant in vivo (169-171). The native cartilage ECM contains both adhesion 
proteins and growth factors to support cell adhesion and regulate cellular function, which 
synthetic scaffolds generally do not provide. However, the physical and chemical properties 
of synthetic scaffold can be modified to affect cellular behavior. For example, cell adhesion 
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molecules, enzymatic degradation sites or growth factor-binding regions can be incorporated 
into the synthetic scaffold to mediate cell-specific bioactivities (172-175). 
1.6.1.2.2 Natural scaffolds 
Several natural biomaterials have also been used to produce scaffolds (solids) and matrices 
(hydrogels) for cartilage tissue engineering. The natural biomaterials usually have 
biocompatible and biodegradable properties. Some of the materials, such as collagen, 
hyaluronan and chitosan, have been prepared as porous scaffolds (176, 177). However, 
porous scaffolds do not typically provide a true 3D environment and need an invasive 
delivery to the defect area. To overcome these limitations, much of the research in cartilage 
tissue engineering has focused on hydrogels such as alginate, agarose, chitosan and fibrin. 
1.6.1.2.2.1 Hydrogels 
Hydrogels are hydrated insoluble polymer networks, which mimic natural extracellular 
matrix, and are highly-interesting for cartilage tissue engineering application. Hydrogel have 
the advantages of being highly flexible for molding into any shape and injection into the 
defected side for clinical application. Also, some natural-derived hydrogels have cell 
attachment properties. However, the main disadvantage of hydrogels is low mechanical 
strength. 
Alginate is a natural polysaccharide derived from brown seaweed or bacteria that is 
commonly used to form hydrogels for cartilage tissue engineering. It is composed of a 
repeating disaccharide of (1,4)-linked -D-mannuronic acid (M) and α-L-guluronic acid (G) 
monomers arrange in linear, which can cross-linked to from a hydrogel by divalent cations 
such as Mg2+, Ca2+ (178). In tissue engineering application, cells and alginate solution are 
mixed, and the alginate is typically cross-linked in ~100 mM CaCl2 solution to form a tissue 
construct. Higher GAG synthesis has been shown by chondrocytes in alginate scaffolds when 
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compared to poly (glycolic acid) scaffolds (179-181). Interestingly, alginate pre-culture has 
been used to form scaffold-free in vitro constructs using zonal chondrocytes that maintained 
stratification and zonal function (182). However, alginate disadvantages are inferior 
mechanical rigidity and a low degradation rate. 
1.6.1.2.2.2 Extracellular matrix-based scaffolds 
Whereas natural and synthetic engineered scaffolds can provide an environment for new 
tissue formation, they do not directly apply the native ECM environment to the cells. It is 
well accepted that cell–matrix interactions play an important role in the development and 
regeneration of the cartilage tissue (183, 184). Thus, scaffolds which closely mimic cartilage 
ECM should be used for cartilage tissue engineering. Synthetic scaffolds lack this 
requirement, whereas scaffolds from natural materials such as collagen type II or hyaluronan, 
which are major components of cartilage ECM, can approximate the ECM microenvironment. 
However, cartilage has a specific zonal structure with ECM compositions that vary with 
depth. Therefore, it is difficult to completely recapitulate the natural ECM in any scaffold. A 
promising alternative is to use natural ECM, which provides the specific environments, 
natural tissue structure and natural biological signals to the tissue, as a biological scaffold for 
tissue engineering (185).  
The ECM is generally composed of a network of proteins, proteoglycans, glycoproteins, as 
described in section 1.2.2, and small molecules such as cytokines and growth factors. The 
ECM composition and structure influences the phenotype of the resident cells and vice versa. 
Using the natural ECM as a scaffold which also acts as a reservoir of growth factors and 
cytokines may provide the signals for new tissue formation. The proposed mechanisms 
through which ECM scaffolds support tissue reconstruction are contact guidance and 
molecular signaling (186). There is a report showing that the degradation products of ECM 
scaffolds have an effect on cell migration and cell proliferation in vitro and the effect is 
31 
 
opposite between progenitor cell, activated and mature cells. This finding suggests some role 
of the ECM on the tissue remodeling process (187). 
As there is a shortage of human tissue and organs for transplantation, the extracellular matrix 
(ECM) derived from animal tissue, are more interesting to use than autogenic ECM or 
allogeneic ECM. One main barrier for using xenogeneic ECM is the human immune response. 
Xenogeneic extracellular matrix has been successfully used as a scaffold in many tissue 
reconstructions such as skin, heart valve, and tendon (188-190). 
1.6.1.2.2.2.1 Immune response to xenogeneic extracellular matrix 
Based on the knowledge that the host immune response to xenogeneic tissue or organ 
transplants is due to the immune reaction to the xenogeneic antigen of the donor cells, 
decellularized xenogeneic ECM have been used as a scaffold for many tissue constructs to 
reduce the host immune response. 
While the components of ECM are highly conserved among species, the cellular components 
vary between species and lead to the activation of host immune response, which results with 
graft rejection. An alpha 1, 3 galactosyltransferase (α Gal (1-3) Gal) or Gal epitope is a 
known xeno-antigen on the animal cells that are commonly used for tissue transplant. This 
epitope is found in all mammals except humans and old world monkeys. In addition, there are 
other antigens, called, non-gal antigens on the cell component of animals such as N-
glycolylneuraminic acid (NeuGc) that can activate the human immune response. 
There are 3 types of the immune response to xenoantigen on the animal cells, hyperacute 
immune response, acute immune response and chronic immune response. Hyperacute 
immune response is caused by natural antibody that is already in all human. The antibodies 
cross reacts to the xenoantigen on the animal cells and activated complement cascade is the 
cause of hyperacute graft rejection. The xenoantigen on the animal cells also activates human 
32 
 
T cell lymphocyte and B cell lymphocytes. The acute immune response is seen after T-cell-
dependent elicited antibody response. The chronic immune response is developed in long-
survivals graft which unclear cause. Numerous methods have been used to treat xenogeneic 
ECM for medical use. 
1.6.1.2.2.2.2 Processing of extracellular matrix for medical use 
As the native extracellular matrix which contain both cells and extracellular matrix from 
animal can evoke the human immune response which end up with the graft rejection and also 
the other problem such as zoonosis, there are many processes were used to modify the ECM 
for medical use. Decellularization methods are used to remove cells and cellular components 
out from the tissue to reduce the host immune response. ECM modification is used to make 
the ECM to be a proper scaffold for the tissue construct. Sterilization is the final step to 
ensure that the ECM scaffold does not transfer the pathogen from the animal to the human. 
However, all the process can change the properties of the ECM. The sterilization method may 
not completely remove all pathogens such as DNA virus or RNA virus.  
1.6.1.2.2.2.2.1 Decellularization 
Decellularized tissues have been successfully used in many tissue engineering or tissue 
reconstruction application such as dermal, tendon and heart valve. Decellularization protocols 
include the combination of physical, chemical or enzymatic treatments. Physical treatments, 
such as snap freezing and mechanical force, are generally used for cell disruption. Then, 
enzymatic treatments; trypsin, endonucleases, exonucleases and/or chemical treatments; 
alkaline, acid, non-ionic or ionic detergent, zwitterionic detergents are used for solubilization 
of cytoplasmic and nuclear cellular components and removal of cellular debris from the tissue 
(191, 192). The ideal decellularization reagents should completely remove the cellular 
component from the tissue while the tissue can keep their biochemical component and their 
mechanical properties. Mechanical agitation is always used to facilitate chemical exposure 
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and cellular material removal. After the decellularization process, tissue must be extensively 
washed to remove all residual chemicals and enzyme left in the ECM. 
1.6.1.2.2.2.2.1.1 Decellularization of cartilage 
Cartilage ECM should be the optimal biological scaffold for cartilage tissue engineering as it 
can provide the real cartilage environment to the cells for neocartilage formation. However, 
not many studies have investigated cartilage ECM-derived scaffolds for cartilage tissue 
engineering. One reason might be because the dense cartilage does not allow the 
decellularization solution to penetrate into the tissue. Treatment of bovine cartilage with 2% 
SDS for 8 hours resulted in complete histological decellularization, but only 40% DNA 
reduction while the biochemical and mechanical properties are significantly decreased (193). 
They suggested that the decellularization treatment still needs to be optimized to maintain the 
biochemical properties and mechanical properties while removing the cellular components 
(193). However, crushing the tissue can help decellularization solution completely remove 
cellular component from the ECM and after freeze-dry the microfilament can from porous 
scaffold for cartilage (194-198).  
Elder, et al., 2009 studied the effects of five different decellularization treatments on agarose 
cartilage constructs after 4 weeks of culture. Their techniques are based on chemical 
treatments with sodium dodecyl sulfate (SDS), Triton X-100, Tributyl Phosphate or 
hypotonic/hypertonic solution additive with DNase and RNase. The results show that 2% 
SDS is the most promising reagent, which is similar to their results with bovine cartilage. 
Treatment of cartilage constructs with 2% SDS for 6-8 hours can completely remove cell 
nuclei by histological staining but not by DNA assay. However, the compressive modulus 
and GAG content are significantly decreased by this treatment. Triton X-100 and Tri-N-butyl 
Phosphate (TnBP) show less effect on the cartilage construct decellularization while 
hypotonic/hypertonic solution shows highest effect on the decellularization with highest 
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biochemical component reduction (199). Decellularization techniques for ECM and scaffolds 
preparation which commonly freeze-drying method were summarized in table 1.1. In addition, 
there is a recent report of a novel cartilage decellularized extracellular matrix hydrogel, which 
provided biocompatible microenvironment for cells and serve as printable materials for 
cartilage tissue engineering (200). Although, there are many reports on the ECM scaffold for 
cartilage tissue engineering, no zonal cartilage tissue engineered using ECM scaffold is 
reported so far.
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Table 1.1: Decellularization techniques and scaffold preparation for cartilage tissue engineering. 
 
ECM sources and 
form 
Decellularization method Decellularization results Scaffold preparation 
techniques 
Refs 
Immature bovine 
chondrocytes-
derived ECM from 
agarose 4 weeks 
cultured 
1. Treatment with 
1.1. 1% SDS 
1.2. 2% SDS 
1.3. 2% Tributyl phosphate 
1.4. 2% Triton X-100 
1.5. Hypotonic/hypertonic solution in 
combination with nuclease (DNase Type I, 
RNase) and EDTA in PBS 8 h 
 2. Washing in PBS 2 h 
H&E staining 
- 1% and 2% SDS complete 
elimination of cell nuclei 
- 2% TnBP or 2% Triton X-
100 no effect on the number 
of cell nuclei 
- Hypotonic/hypertonic 
treatment slight reduction in 
the number of cell nuclei 
DNA assay 
- 2% SDS DNA left 54% 
Not performed (199) 
 
Porcine chondrocyte 
derived ECM from 3 
weeks monolayer 
and 3 weeks pellet 
cultured 
1. Treatment scaffold with DNase Type I 
2. Washing in PBS 
DNA assay 
- DNA left <1% 
1. Washing with PBS 
2. Freeze-drying 
3. Sterilization by 99% 
alcohol10 h 
(201) 
Human MSC 
derived ECM, 
Human chondrocyte 
derived ECM from 
PLGA meshes 5-6 
days cultured 
1. Washing with PBS 
2. Washing with Milli-Q water 
3. Freeze and thaw 6 cycles 
4. Washing with Milli-Q water 
5. NH4OH treatment 48 h 
6. Washing with Milli-Q water 
7. Na3PO4 treatment 
8. Washing with Milli-Q water 
Fluorescent staining 
- Complete elimination of 
cell nuclei, F-actin, and cell 
membrane 
DNA assay 
- DNA left  <1% 
1. Freeze-drying 
2. Sterilization by ethylene 
oxide 
(202) 
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Human articular 
cartilage 
 
1. Washing with PBS 
2. Shattering of the tissue in PBS plus 
protease inhibitor (EDTA, 
phenylmethylsulfonyl fluoride)  
3. Incubation in Triton X-100 in hypotonic 
(Tris–HCl) 12 h 
4. Nuclease treatment (DNase Type I, 
RNase in hypotonic Tris–HCl) 12 h 
5. Washing with PBS 
Hoechst 33258 staining 
- Complete elimination of 
cell nuclei  
 
1. Making cartilage into a 
suspension. 3% (w/v) 
2. Freeze-drying 
3. Dehydrothermal 
treatment 24 h 
4. Cross-linking with 
carbodiimide 2 h 
5. Rinsing in PBS 
6. Sterilization by cobalt γ-
irradiation 
(196) 
Immature bovine 
articular cartilage 
explants 
1. Washing with NSS with protease 
inhibitors 
2. Freeze and thaw 1 cycle 
3. Treatment with 2% SDS in combination 
with nuclease (DNase Type I, RNase) and 
EDTA in PBS 8 h 
4. Washing in PBS 2 h 
H&E staining 
- Nearly complete 
elimination of cell nuclei 
DNA assay 
- DNA left 60% 
Not performed (193) 
Bovine articular 
cartilage 
1. Washing with PBS 
2. Freeze-drying 
3. Tissue grinding 
4. Trypsin treatment 24 h 
5. Washing with PBS 
6. Nuclease treatment (DNase Type I, 
RNase in hypotonic Tris–HCl) 4 h 
7. Hypotonic Tris–HCl treatment 20 h 
8. Incubation in Triton X-100 24 h 
9. Washing with PBS 
H&E staining 
- Complete elimination of 
cell nuclei 
DNA assay 
- DNA left ~1% 
 
1. Freeze-drying 
2. Cross linking with UV 
3. Sterilization by ethylene 
oxide 
 
(197) 
 
Porcine ear cartilage 
sheet (10, 30 μm x 6 
mm) 
1. 1% SDS treatment 24 h or7 days 
2. Washing with water 
DAPI staining 
- Complete elimination of 
cell nuclei 
Freeze-drying cartilage 
piece stacked layer by 
layer 
(203) 
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Porcine articular 
cartilage and bone 
blocks (length 50 
mm, width 10 mm 
and height 10 mm) 
1. Rinsing in PBS 
2. Freeze and thaw 2 cycles 
3. Freeze and thaw in hypotonic solution 2 
cycles 
3. Hypotonic Tris–HCl treatment 24 h 
4. 0.1% SDS–in hypotonic buffer plus 
protease inhibitor treatment 24 h 
5. Washing with PBS plus protease inhibitor 
25 h 
6. Nuclease treatment 3 h 
7. Washing with PBS plus protease inhibitor 
8. 0.1% Peracetic acid treatment 3 h 
9. Washing with PBS plus protease inhibitor 
25 h 
10. Repeat number of hypotonic/SDS  
1 (DC1), 3 (DC3) or 6 (DC6)cycles 
H&E staining 
- Complete elimination of 
cell nuclei 
DNA assay 
- DNA left 
DC1 (3 D 6 h) 48% 
DC3 (7 D 6 h) 9% 
DC6 (13 D 6 h) 1% 
Decellularized cartilage 
and bone block 
(204) 
Human articular 
cartilage 
1. Washing with PBS 
2. Shattering of the tissue in PBS plus 
protease inhibitor (EDTA, 
phenylmethylsulfonyl fluoride)  
3. Incubation in Triton X-100 in hypotonic 
Tris–HCl 12 h 
4. Nuclease treatment (DNase Type I, 
RNase in hypotonic Tris–HCl) 12 h 
5. Washing with PBS 
6. Shattering of the tissue in PBS plus 
protease inhibitor (EDTA, 
phenylmethylsulfonyl fluoride)  
7. Washing with PBS 
Not shown 1. Making cartilage into a 
suspension 3% (w/v) in 
PBS 
2. Freeze-drying 
3. Dehydrothermal 
treatment 24 h 
4. Cross-linking with 
carbodiimide 2 h 
5. Rinsing in PBS 
6. Sterilization by cobalt γ-
irradiation 
(195) 
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Porcine articular 
cartilage (d=8 mm, 
h=1 mm) 
1. Freeze-drying 
2. Treatment with hyaluronidase  
And trypsin 18 h 
3. Washing with DD water 
4. 50%/50% chloroform-methanol treatment 
72 h 
5. Washing with DD water 
DNA assay 
- DNA undetectable 
Decellularized cartilage (205) 
Bovine articular 
cartilage 
1. Washing with PBS 
2. Shattering of the tissue in PBS plus 
protease inhibitor (EDTA, 
phenylmethylsulfonyl fluoride)  
3. Incubation in Triton X-100 in hypotonic 
Tris–HCl 12 h 
4. Nuclease treatment (DNase Type I, 
RNase in hypotonic Tris–HCl) 12 h 
5. Washing with PBS 
Not shown 1. Making cartilage into a 
suspension 3% (w/v) in 
PBS 
2. Freeze-drying 
3. Treatment with genipin 
solution 
4. Sterilization by 20 kGy 
60Co radiation 
 
(206) 
Human nasal 
cartilage (hNSC) 
Porcine nasal 
cartilage (pNSC) 
(d = 5 mm, h = 1 
mm) 
Porcine meniscus 
(pMC) 
 
1. Washing with distilled water 24 h 
2. Sodium hydroxide (NaOH) treatment 
1.25-3 h 
3. Washing step  
4. Defatting in ethanol 3 h 
5. Guanidine hydrochloride (Gnd-HCl) and 
sodium acetate (NaOAc) treatment 96 h 
6. Washing step 
7. H2O2 treatment 48 h 
8. Washing step with sodium chloride (0.9% 
NaCl) 
9.pMC repeats for NaOH treatment and 
washing step 
H&E staining 
- Complete elimination of 
cell nuclei 
Decellularized cartilage (207) 
Porcine ear cartilage 
sheet (10 μm x 6 
mm) 
1. 1% SDS treatment 24 h 
2. Washing with water 
 
DAPI staining 
- Complete elimination of 
cell nuclei 
Freeze-drying cartilage 
piece stacked layer by 
layer 
(208) 
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1.6.1.2.2.2.2.1.2 Decellularization of in vitro-generated ECM 
As the problem of decellularization of compact cartilage is difficult, some researchers have 
tried to use ECM which is derived from in-vitro chondrogenesis of chondrocytes or stem cells 
as a source of ECM instead of ECM from native tissue. For example, Jin, et al., reported that 
the chondrocyte-seeded cell-derived ECM scaffolds prepared with a freeze-drying technique 
could support chondrocytes to from neocartilage both in vitro and in vivo (209, 210). Not 
only cartilage ECM- derived scaffold supports stem cells or chondrocytes for cartilage tissue 
formation, but also, adipose ECM-derived scaffold show the same effect on adipose stem 
cells for cartilage tissue formation (194, 195). 
1.6.1.2.2.2.2.2 Extracellular matrix modification 
The preparation of an ECM scaffold requires several processing steps that can affect both the 
structure and components of the ECM. Many methods, physical, chemical or enzymatic 
modification, have been used to modify the ECM, including hydration-dehydration, 
powdering, gelation, and cross-linking. Modification of ECM scaffolds by physical, chemical 
or enzymatic will lead to the appropriate structures for using or increase the strength of the 
scaffold. However, the modification on native ECM may change the chemical and physical 
properties of the ECM and changes the biocompatibility and biodegradable of the ECM. 
There are reports of successful production of cartilage ECM scaffolds for cartilage tissue 
engineering. After decellularization, native cartilage ECM has been modified by different 
techniques to produce the ECM scaffolds. The most common technique is a dehydration 
technique by freeze-drying, which creates a unidirectional porous scaffold by removing the 
ice crystals during lyophilization. Yang et. al., developed a porous scaffold derived from 
fresh human cartilage extracellular matrix (ECM) by physically shattered, decellularized, 
fabricated by simple freeze-drying and cross-linking (196). They found that the scaffold 
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could support the BMSCs to attach, expand and differentiate to chondrocytes. However, the 
freeze-dried scaffold did not have a strong structure, and was therefore cross-linked using UV 
light to increase the strength. Chemical cross-linking methods, such as carbodiimide 
treatment, have also been used for cartilage ECM scaffold constructs by Yang et al., (196). 
They reported that their ECM scaffold can support chondrogenesis, yet the chemically 
modified ECM scaffold had different properties than the native ECM scaffold. Further, we 
don’t know that the decellularized ECM and native cartilage have the same capacity to 
support the chondrogenesis of osteoarthritis chondrocytes.  
1.6.1.2.2.2.2.3 Sterilization 
Xenozoonosis is an infection associated with transplantation of an animal cell, tissue or organ 
into human. To prevent the xenozoonosis, several sterilization techniques have been used for 
the ECM: ethylene oxide (750 mg h−1) exposure, gamma irradiation (20 kGy) exposure or 
electron beam irradiation (22 kGy) exposure. The most common technique is gamma 
irradiation. The sterilization can prevent or reduce xeno-transmitted disease but it also can 
change the mechanical properties of the scaffold (211). 
1.6.1.3 Culture environment 
There are two types of experimental model systems for cartilage tissue engineering, in vitro 
models and in vivo (animal) models. When compared to animal models, the environment in 
vitro model is simpler and more controllable, making the interpretation of the experiment 
more straight forward. Whereas animal models have various variables to be considered such 
as type of animal, age and gender of animal, size of defect, etc., they can provide a more 
realistic environment for cartilage tissue formation than in vitro models. 
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1.6.1.3.1 In vitro models 
In vitro models give the vital detailed information on important parameters for cartilage 
tissue engineering, such as the proliferation and differentiation capacity of the cells, the 
interaction between cells and scaffold, and the effects of growth factors and mechanical 
stimuli. In vitro models can provide the optimized environments for neocartilage formation 
when using the appropriate cells, scaffolds, growth factors and bioreactor.  
Currently, there is no ideal culture system for cartilage tissue regeneration in vitro. One 
approach to find the optimal culture environment in vitro is in mimicking the natural cellular 
environment. There are many reports which show that culture systems which mimic the 
native cartilage tissue environment in vivo improve chondrogenesis. For example, hypoxia or 
cyclic compression increase GAG production (212, 213), which are desirable in the middle 
and deep zone. Shear stimulation increases PRG4 production in cartilage explants, which is 
desirable for the superficial zone (214, 215). 
1.6.1.3.1.1 Growth factors 
Chondrogenesis is modulated by growth factors. The positive effects of growth factors such 
as transforming growth factor-beta (TGF-1, TGF-2, TGF-3), bone morphogenetic 
proteins (BMPs), fibroblast growth factor-2 (FGF-2) and insulin-like growth factor-1 (IGF-1) 
have been shown on chondrogenic differentiation in many studies as reviewed elsewhere 
(216, 217). There are reports that adding FGF-2 to the proliferation medium enhances 
proliferation and chondrogenic differentiation of hMSCs (218). However, the effects of FGF2 
on HUCPVCs on proliferation and chondrogenic differentiation remain to be determined. 
PRG4 which is expressed in the superficial zone is induced by TGF-β (1–3), IGF-I, PDGF, 
and BMP7 (219-221) and cartilage intermediate layer protein (CILP), which is expressed 
mainly in the middle zone of human articular cartilage is induced by TGF-β1 (222). In 
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addition, TGF-1 has been shown to delay hypertrophic chondrocytes in murine limb bud 
mesenchymal cells (223).  
1.6.1.3.1.2 Oxygen tension 
Hypoxia is commonly found in articular cartilage, as it is avascular, and may be critical for 
chondrogenesis. Hypoxia has been reported to promote proliferation and tissue formation of 
bone marrow MSCs in vitro (224). Low oxygen (5% O2) significantly improved bone marrow 
MSC expansion while the maintaining multilineage differentiation capacity (225), and can 
also promote chondrogenesis in rat MSCs when compared to 20% O2 (normoxia) (226). Also, 
hypoxia has been shown to promote PRG4 gene expression of subpopulation chondrocytes 
(227). However, the results are not consistent for all cell types, as 2% O2 increased 
proliferation of murine adipose MSC but decreased chondrogenesis and osteogenesis (228) 
and human adipose MSC cultured under 5% O2 showed decreased proliferation and enhanced 
chondrogenesis (229). 
1.6.1.3.1.3 Mechanical stimuli 
In addition, mechanical stimuli have been shown to affect cartilage extracellular matrix 
synthesis in a frequency- and amplitude-dependent manner. GAG synthesis by chondrocytes 
in agarose scaffolds was inhibited by static and low- frequency strain (0.3 Hz) but stimulated 
by a frequency of 1 Hz in 15% strain amplitude (230). However, when the frequency was 
increased to 3 Hz, the level of GAG synthesis decreased (230). Chondrogenic differentiation 
of rabbit bone marrow MSCs has also been induced by cyclic compression in 10% strain 
frequency of 1 Hz for 4 h per day in agarose scaffolds (231). Also, cyclic compression (10% 
strain, 0.5-1 Hz) has been shown to maintain viability and induce chondrogenic 
differentiation of human bone marrow MSC in fibrin gel scaffolds (232).  
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Mechanical stimuli can be applied by using bioreactors, devices that provide physiological 
requirements of the cell such as nutrients, growth factors and mechanical environment (233). 
Various bioreactors have been used in cartilage and bone tissue engineering such as dynamic 
compression bioreactors (213), tensile bioreactors (234), hip simulator-based bioreactor (215) 
spinner flask (235) and rocker plate (Fig 1.6). Among all of these, dynamic compression 
bioreactors are most commonly used to improve matrix production in tissue-engineered 
cartilage (236). 
 
 
Figure 1.6: Bioreactors in cartilage and bone tissue. 
(A) dynamic compression bioreactor (B) tensile bioreactor (C) hip simulator-based bioreactor 
(D) spinner flask (E) rocker plate (adapted from (236)).  
D E 
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1.6.1.3.2 In vivo models 
Many questions in cartilage tissue engineering can be answered in vitro, such as the 
compatibility of cells and scaffold, and the effects of specific factors on cell proliferation and 
cell differentiation. However, an animal model is also needed to study the complex process of 
cartilage tissue formation and maturation and to bridge the gap between in vitro study and 
clinical study in human. The animal model provides an articular cartilage environment, 
appropriate for the study of the integration of engineered cartilage to the surrounding native 
tissues, and evaluation of safety and efficacy of new tissue-engineered cartilage.  
Various animals have been used for in vivo study, ranging from small animals, such as mouse 
and rat, to large animals such as horse. The choice of animal depends on the purpose of the 
study and certain animals may not suit all study questions. Early stages of development for 
cartilage repair studies can be done in small animal and confirmatory studies can be done in 
large animal. From a modeling perspective, the best animal model for translation to the clinic 
would be the most closely related species to human, i.e. non-human primate; however, this is 
not ethically acceptable. Each type of animal has its own strong points and limitations, as 
described in the following sections (Review in (237). 
1.6.1.3.2.1 Large animal 
Large animals, such as sheep, goats and horses, which have joint size and cartilage thickness 
that are relatively similar to humans are commonly used for late development and pivotal 
cartilage regeneration and cartilage repair studies (238). 
The horse (equine) has several advantages for cartilage tissue engineering research. Equine 
cartilage thickness (1.75 mm) and biochemical properties are close to that of human cartilage 
(2.35 mm) (239). Equine also have large joints suitable for multiple large defects. In addition, 
the heavy loading condition can be studied in this animal. Horse is the current preferred large 
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animal model for pre-clinical cartilage studies by the US FDA. However, horses are 
expensive to purchase and maintain, require large surgical and analytical facilities, and are 
also companion animals; therefore, there are ethical concerns in certain countries. Other large 
animals such as porcine, caprine, ovine and canine have smaller joint and thinner cartilage 
when compared to horse and human, but overcome some limitations of the equine model. 
Domestic pigs and mini-pigs (porcine) have been used for cartilage research, with mini-pigs 
being preferred as it is smaller, less aggressive and readily bred for research purpose. 
Cartilage thickness in the porcine stifle joint is about 1.5 mm, in which a partial cartilage 
defect can be created. The transgenic and knockout pigs for specific research purposes have 
successfully been developed (240, 241). However, pig has a rapid skeletal growth that differs 
from humans and specially bred pigs are costly to purchase and house. 
Goat (caprine) and sheep (ovine) are relatively inexpensive to procure and maintain 
compared to other large animals and are frequently used in cartilage research. The knee 
anatomy and characteristics of goat and sheep are similar, however sheep cartilage (0.6–1.3 
mm) is relatively thinner than goat (0.7–1.5 mm) (242). Both chondral and osteochondral 
defects can be created in these animals. However, the post operation recovery can be difficult 
to control and exercise protocols are difficult to apply because of the animal nature.  
On the other hand, dogs (canine) are easily trained and docile animal therefore, controlled 
weight bearing and exercise protocol are possible to implement. Also, the cartilage thickness 
in the canine is 0.95 mm, which gives the potential of forming partial-thickness cartilage 
defects to create. In addition, the control source dog is available and has been used in the 
research. However, it is expensive to buy and house and dog is common human pet therefore 
ethical concern is an issue. 
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1.6.1.3.2.2  Small animal 
While large animals approximate the human joint size and cartilage thickness, they are 
relatively expensive, and small animals may be useful in early screening experiments. 
However, small joint with thin cartilage are the disadvantages of the small animal model. 
Additionally, potential of self-repair which different nature with human and large animal 
model is the other disadvantage of small animal model. The small animal is practical for 
proof-of-concept or early stage of development (238). 
Rabbit (lapine) is a small animal that is widely used for the early development of cartilage 
repair. It is relatively inexpensive and easy to manage compared to large animals. In addition, 
the rabbit joint size is large enough to create cartilage defect. However, the thin cartilage (0.3 
mm) and the high potential of self-healing are disadvantages of the model. 
Rodent (mice and rats) models are widely used for screening biomaterials. The rat model is a 
cost effective model and nude rats, which allow xenogeneic cells or tissue implantation is 
available. Rat has a larger joint size than mouse, which enables the creation of cartilage 
defects, but thin cartilage (0.1 mm) and potential of self-repair are the limitations of the rat 
model. The mouse model has a similar cost-effectiveness as the rat model. Genetically 
modified mice, including immunocompromised, transgenic and knockout mice for specific 
research purposes are also available. Immunocompromised mice are valuable in xenogeneic 
or allogeneic cartilage research and transgenic and knockout mouse are beneficial for 
mechanistic study. The main disadvantages of the mouse model for cartilage repair are the 
small joint size and thin cartilage, which makes it difficult to create reproducible cartilage 
defects. Ectopic models, in which cartilage is grown outside the joint, are alternatives to the 
orthotopic models for cartilage repair. The most common ectopic model is subcutaneous 
implantation. This subcutaneous implantation model provides the physiological environment 
without loading condition and cartilage environment to tissue-engineered cartilage. Although 
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lack of cartilage environment is still being the main limitation of this model but the model is 
more closely physiological condition than in vitro culture condition. It can be used for a 
preliminary proof of concept and provide some information before going to study in a large 
animal model which costly and time consuming model.  
1.6.1.3.2.2.1.1 Full-thickness defect in mouse model 
Implantation of the cartilage tissue construct into to the pocket of the mouse skin is an easy 
access technique when compared with implantation of the construct in a cartilage defect in 
the joints of small and large animals. However, the major limitation of this model is that the 
subcutaneous environment is quite different from the native articular cartilage environment, 
lacking both biochemical and biomechanical factors common in the joint. 
The osteochondral tissue is the tissue composed of zonal cartilage and the underlying 
subchondral bone. The subchondral bone is composed of the subchondral bone plate (bony 
lamella) and the trabeculae of subchondral bone (trabeculae) which line under the calcified 
zone of cartilage respectively (243). The bony lamella is the inflexible area of subchondral 
bone and the trabeculae is the area containing blood vessels, cells and nerves. The cartilage 
defects can be categorized based on depth into 3 different types; partial thickness defect 
which the damage only in the articular cartilage, full-thickness defect which the damage of all 
cartilage layer, and osteochondral defect which the damage included subchondral bone as 
shown in Fig 1.7. 
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Figure 1.7: Cartilage defect classification. 
(A) normal cartilage, (B) partial thickness defect, (C) full-thickness defect, (D) osteochondral 
defect modified from (244). 
There are many reports on the influence of the surrounding environment on cell behavior, 
both in vitro and in vivo. When seeded into the mouse muscle of nude mice, chondrocytes 
underwent myoblastic differentiation at the border of mouse tissue (245). Also, Hunter, et al., 
studied the growth and maturation of four different engineered cartilages (agarose, fibrin, 
immature PGA, and mature PGA) in live and dead cartilage-explant defect compare to free 
swelling construct. The cartilage environment from vital cartilage explants affected the cell 
proliferation and matrix accumulation of the engineered cartilage in vitro culture dependent 
on the scaffold type; there was a negative effect for cell proliferation and chondrogenesis in 
agarose and fibrin scaffolds, but less effect in PGA scaffolds. The effect of devitalized tissue 
on construct maturation seem less effect compared to vital tissue (246). 
Mueller-Rath, et al., showed that repair tissue was formed in the cartilage defect of human 
osteochondral specimens after seeding with human chondrocytes in a collagen gel and 
maintaining subcutaneously in nude mice for 6 weeks. However, the repaired tissue contained 
little amounts of collagen type II (247). In addition, Schuller, et al., report the use of human 
cartilage defect in mouse model for human cartilage regeneration (248). Dedifferentiated 
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chondrocytes were used to fill chondral defects, covered with periosteum similar to the 
autologous chondrocyte transplantation technique, and placed subcutaneously in mice for 8 
weeks. Redifferentiation was evident at the border of cartilage discs, as shown by collagen II 
and GAG staining, whereas collagen I positive fibrous tissue was found at the center of the 
defect. However, chondrocytes seeded in the defect without the periosteum cover had similar 
redifferentiation results with the periosteum cover, but no fibrous tissue was found. This 
study supports the concept of using the cartilage defect to provide the cartilage environment 
for the cartilage tissue formation in a mouse model. However, this model is based on cell-
based therapy using full-thickness cells population. In addition, using human cartilage to 
provide the cartilage environment in the culture may not be practical because the shortage of 
normal human tissue for use. Therefore, a healthy osteochondral cartilage biopsy from animal 
might be the other option for this of model. There is a report on osteochondral biopsies model 
from bovine which have 3 types of defects: chondral defects, full-thickness defect and 
osteochondral defect for study cartilage repair in vitro (249). They found that the 
osteochondral biopsies were viable in vitro for at least 28 days, although the collagen type II 
and aggrecan gene expression of cartilage decreased overtime. Seeding chondrocytes into the 
3 different defects, the osteochondral defect was significantly more repair tissue than the 
chondral defect showed by Safranin o staining. Also, they found that the osteochondral 
biopsy model was shown more collagen II gene expression than cartilage-only explants. This 
report shows that the bovine osteochondral biopsy model provides the cartilage environment 
for supporting cartilage repair base on cell-base therapy in vivo. Therefore, the bovine 
osteochondral biopsy might be the best option for providing the cartilage environment for 
studying cartilage tissue repair in a subcutaneous mouse model. Nonetheless, there are no 
data on the effect of the cartilage environment from the osteochondral biopsy in a mouse 
model of the zonal cartilage regeneration characteristics. 
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1.6.2 Zonal approaches 
One of the issues in traditional cartilage tissue engineering is the difficulty in recreating the 
specific zonal structure of native cartilage, which was described in section 1.2.3. A relatively 
new branch of cartilage tissue engineering, termed ‘zonal cartilage tissue engineering’ has 
formed to address this issue due to the importance of the zonal structure for the function of 
native articular cartilage. This approach follows the basic principles described in section 1.6.1, 
but with subtle differences to focus on the zonal structure. Three main approaches to engineer 
cartilage with a zonal structure have been described by Klein, et al., (236).  
The first is a scaffold- and matrix-free approach, where zonal chondrocytes or bone marrow 
stem cells are cultured in micro mass pellet or subsequently seeded in a cell culture insert 
(e.g., Transwell®). These approaches have success for the biological properties of the 
constructs (specific matrix synthesis from specific cell population) for the zonal chondrocytes 
but this form of construct lacks cartilage mechanical properties (182, 227, 250). 
The second is a matrix-based approach, in which hydrogel matrices provide the structure and 
organization to the cartilage construct. The construct can form in various shapes by using 
different cross-linking protocols, UV light, enzyme or chemical cross linking. Nguyen, et al., 
used this approach to construct the zonal cartilage by the combination of the hydrogel 
components. They conclude that mixture of 9% chondroitin sulfate (CS), 2% matrix 
metalloproteinase sensitive peptide and 9% poly(ethylene glycol) (PEG) hydrogel results in 
superficial zone chondrocyte phenotypes from MSCs and low compressive modulus (209 
kPa), which is similar to superficial zone. The mixture of 10% PEG and 10% CS in a 
hydrogel resulted in middle zone chondrocyte phenotypes and intermediate compressive 
modulus construct (271 kPa), which is similar to the middle zone of cartilage. Finally, the 
mixture of 19% PEG and 1% hyaluronic acid (HA) resulted in deep zone chondrocyte 
behavior and highest compressive modulus construct (1227 kPa), similar to deep zone 
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cartilage (251). They also demonstrate that 3 layers which layer-by-layer organization of the 
specific biomaterial compositions with BMSC produces zone-specific chondrocytes and 
creates native-like articular cartilage with zone-specific mechanical and biochemical 
properties (252). However, the success of cartilage construct from this mixture scaffold is 
concluded only based on the compressive modulus and some cell phenotypes. The constructs 
do not completely mimic the real cartilage, which has high PRG4 secretion in the superficial 
zone. 
There are 3 main cell sources used for zonal chondrogenesis, full-thickness chondrocytes, 
zone-specific chondrocytes and MSC. There are reports that the chondrocytes from different 
zones of OA cartilage can maintain the zone-specific properties in culture and respond to 
stimuli in a zone-specific way (253). In addition, there are studies that use precursor/stem 
cells from bone marrow to differentiate to be chondrocytes from different zones, which is 
shown by the production of specific marker proteins (251). High GAG production is 
commonly used as a marker for middle and deep zone chondrocytes, whilst PRG4 is a 
common marker for superficial chondrocytes. Production of zone-specific chondrocytes from 
precursor cells needs further investigation.  
The third is a scaffold-based approach, in which scaffolds provide structure, mechanical 
strength and organization to the cartilage construct. The conventional type of scaffolds is 
difficult for uniform cells seeding. However, using additive manufacturing techniques (254) 
such as fused-deposition modeling (255), specific structures can be printed in different layers 
to give specific mechanical properties and/or biological properties (256). Some success has 
been reported engineering superficial zone articular cartilage by seeding MSC on oriented 
electrospun nanofibrous scaffolds, however, the superficial gene marker PRG4 was not 
evaluated in this study (257). The utility of scaffold–based approaches for zonal cartilage 
tissue engineering requires further evaluation. As discussed in 1.6.1.2.2.2., there is no natural 
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or synthetic engineered scaffold which can provide the real zonal environment to the cartilage 
construct. The cartilage ECM has a capacity to prepare as a zonal ECM scaffold which 
provides the specific ECM environment to the chondrocytes in each zone. A zonal ECM 
scaffold may provide the specific ECM environment on the zonal chondrogenesis of stem 
cells and/or chondrocytes, but this remains to be investigated. 
Additionally, specific mechanical environments may be needed from the specific zones. For 
example, PRG4, the marker for superficial zone chondrocytes, secretion by bovine cartilage 
explants increases when subjected to dynamic shear stimulation (214). Thus, the effect of 
shear stress for superficial zone chondrogenesis should be evaluated.  
1.7 Hypotheses and aims ........................................................................................................ 
Cartilage damage causes serious pain and disability, and does not heal naturally. Tissue 
engineering of cartilage has been proposed to treat cartilage damage. However, there are still 
gaps to bridge for successful articular cartilage engineering, with regards to cell sources, 
scaffolds and in vitro culture conditions to generate the important zonal structure of native 
articular cartilage. MSCs have potential for use in cartilage tissue engineering, but they are 
limited by several issues and additional work is needed to determine appropriate conditions 
for induction and maintenance of zonal chondrogenesis. Umbilical cord perivascular cells or 
chondrocytes obtained from OA patients are attractive as other cell sources for articular 
cartilage tissue engineering. However, as HUCPVCs are a new cell source, no intensive data 
exist for this cell type, and their characterization for cartilage tissue engineering is still 
required. Also, chondrocytes from OA patients have inferior capacity for matrix synthesis 
(258) and loss of zone-specific phenotype during expansion, therefore, optimal culture 
conditions involving mechanical stimuli and environmental factors must be identified to 
improve their biosynthetic activities and maintain the zonal property of chondrocytes. 
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Hypothesis 
Mimicking the natural cellular environment in vitro will influence chondrogenic 
differentiation in a zonal manner. 
Aims 
The overall aim of the thesis was to evaluate the effect of culture environments which mimic 
aspects of the native environment of cartilage on the chondrocytes subpopulation biosynthetic 
for zonal cartilage tissue engineering. 
The specific aims of the thesis are: 
1. To study the proliferation and differentiation ability of HUCPVCs to address their 
potential for zonal cartilage tissue engineering (Chapter 3); 
2. To study the effect of fluid shear stress on the chondrocytes from different zones 
(Chapter 4); 
3. To study the effect of decellularized extracellular matrix from different zones on the 
zonal chondrocytes (Chapter 5); 
4. To evaluate the effect of a healthy osteochondral environment from the cartilage 
explants on the zonal cartilage tissue engineering construct in the in vitro culture 
(Chapter 6); 
5. To evaluate the effect of a healthy osteochondral environment on the zonal cartilage 
tissue engineering construct in the SCID mouse model (Chapter 7); and 
6. To evaluate the effect of soluble factors secreted from osteoblasts and dynamic 
compressive stimuli on zonal chondrocytes (Chapter 8).  
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CHAPTER 2 : MATERIALS AND METHODS 
 
2.1 Introduction 
The common materials and methods which are used in chapter 3-8 are described in this 
chapter. Modified methods are explained in individual chapters. 
2.2 Chondrocytes cells isolation and expansions 
Cartilage, normally discarded following knee replacement surgery, was collected with written 
consent from patients at the Prince Charles Hospital (Brisbane, Australia). The ethics 
approval was obtained from Prince Charles Hospital and Queensland University of 
Technology (QUT). Cartilage was cut from OA knee joint replacement patient and 
transported on ice in sterile phosphate buffer saline (PBS) solution to the laboratory. 
Cartilage was washed with sterile PBS without calcium and magnesium (Invitrogen, Mt 
Waverley, Vic, Australia) containing, 50 U/mL penicillin/50 µg/mL streptomycin, (1% P/S) 
(Invitrogen, Mt Waverley, Vic, Australia) and the macroscopically normal cartilage of the 
femoral condyle was sliced using a scalpel blade. For the zonally enriched population of 
chondrocyte isolation, approximately 300-500 µm from the cartilage surfaces of the 
superficial zone cartilage (S) was sliced and processed separately from the remaining middle 
and deep zone cartilage (MD) (43, 259). Cartilage slices were minced, then washed with PBS 
containing 1% P/S and digested in 0.15% collagenase type 2 (Worthington, Lakewood, NJ, 
USA), which was resuspended in low glucose Dulbecco’s Modified Eagle’s Medium (LG-
DMEM) (Invitrogen, Mt Waverley, Vic, Australia), for 16 h at 37°C in an incubator with 
agitation. Once digested, the cell suspension was strained through cell strainer (100 μm pore 
size) (BD Biosciences, Eight Mile Plains, QLD, Australia). PBS was added to rinse the 
strainer and the cell suspension was centrifuged at 750 g for 5 min at room temperature (RT) 
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to obtain cell pellet. The pellet was washed with PBS containing (1% P/S) (Invitrogen, Mt 
Waverley, Vic, Australia) and centrifuged 3 times. After complete washing, the chondrocyte 
pellet was resuspended in expansion medium Low Glucose Dulbecco’s Modified Eagle’s 
Medium (LG-DMEM) which was composed of DMEM with 1.0 g/L D-glucose, 110 mg/L 
sodium pyruvate, 2 mM Glutamax (Invitrogen, Mt Waverley, Vic, Australia), 10 mM N-(2-
hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid) (HEPES) (Invitrogen, Mt Waverley, Vic, 
Australia), 0.1 mM non-essential amino acid (NEAA) ( Invitrogen, Mt Waverley, Vic, 
Australia), 0.4 mM L-proline (Sigma, St. Louis MO, USA), 1% P/S (Invitrogen, Mt 
Waverley, Vic, Australia), 0.1 mM L-ascorbic acid 2 phosphate trisodium salt (WAKO 
Chemical, Osaka, Japan), 10% foetal bovine serum (FBS) (BioWhittaker, Lonza, 
Walkersville, MD, USA). Cell number was counted using a haemocytometer. Chondrocytes 
were seeded on tissue culture plastic flasks (Nunc/Thermo Fisher Scientific, Roskilde, 
Denmark) at a density of 3 x 103 cells/cm2 and were cultured in expansion medium LG-
DMEM contains, 2 mM Glutamax, 10 mM HEPES, 0.1 mM NEAA, 0.4 mM L-proline, 1% 
P/S, 0.1 mM L-ascorbic acid 2 phosphate trisodium salt and 10% FBS at 37 °C in a 
humidified 5% CO2 incubator. Medium was changed every 3-4 days. For passaging when 
chondrocytes were reached confluence, cells were released from tissue culture flasks by 
washing them twice with PBS and incubated them at 37 °C in 0.25% trypsin with 1 mM 
ethylenediamine tetraacetic acid (EDTA) (GIBCO, Invitrogen, Mt Waverley, Vic, Australia) 
for 5 min. The trypsinization was stopped by expansion medium with 10% FBS. The cell 
suspension was collected and centrifuged at 750 g for 5 min at RT to obtain cell pellet. The 
chondrocytes were resuspended in appropriate media and used for subsequent experiments. 
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2.3 Chondrogenic differentiation in pellets 
Cells (2.5x105 cells per pellet) were resuspended in a chondrogenic media which composed 
of (HG-DMEM with 4.5 g/L D-glucose, 110 mg/L sodium pyruvate (Invitrogen, Mt 
Waverley, Vic, Australia), 2 mM Glutamax, 0.4 mM L-Proline, 10 mM HEPES, 0.1 mM 
NEAA, 1% P/S, 0.1 mM L-ascorbic acid 2 phosphate trisodium salt, 12.5 mg/mL bovine 
serum albumin (BSA, Sigma Aldrich, St. Louise, MO, USA), 1% (v/v) Insulin-Transferrin-
Sodium selenite (ITS +1, Sigma-Aldrich, St. Louis, MO, USA), 10-7M dexamethasone (DEX, 
Sigma-Aldrich, St. Louis, MO, USA) and 10 ng/mL Transforming Growth Factor (TGF-β1, 
Millipore, MA, USA or TGF-β3, GroPrep Bioreagents, Adelaide SA, Australia) (260, 261). 
The pellets were formed by centrifugation at 500 g for 5 min in 15 mL polypropylene tubes 
(BD Biosciences), as a standard model of chondrogenesis or in 96-well PCR plate (Micro 
Amp® Fast Optical 96-well, Life technology). Cell pellets were cultured in chondrogenic 
media up to the experimental plan. Medium was changed every 3 or 4 days for pellets 
cultured in 24-well plate and every other day for pellets cultured in 96-well PCR plate (259). 
2.4 Alginate-based hydrogel (alginate-gel) preparation 
Cells were resuspended in 2% (w/v) sterile alginate solution (PRONOVA UP LVG sodium 
alginate, FMC BioPolymer AS d/b/a NovaMatrix, Sandvika, Norway) in Milli-Q water at 
107cells/mL. Alginate discs were formed in stainless steel mold with dimensions of 1.5 mm 
height and 4 mm diameter (1.5 mm. x 4 mm Ø) between sterilized filter paper, and 
polymerized in 102 mM CaCl2 for 10 min. Each alginate disc contained 2x10
5 cells in 20 µL 
of alginate solution. After removing the CaCl2 solution, alginate discs were washed for 5 min 
with Phosphate Buffer Saline with calcium and magnesium (PBS+) (Invitrogen, Mt Waverley, 
Vic, Australia) and then were culture in serum free chondrogenic media (262). 
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2.5 Alginate-based hydrogel (alginate-gel) chondrogenic differentiation 
Chondrocytes alginate discs (2.0 x 105cells per disc) were cultured in serum free 
chondrogenic media as described in section 2.3. Alginate discs were cultured in chondrogenic 
media up to the experimental plan. Medium was changed every 3 or 4 days. 
2.6 Pulverization and decellularization of bovine cartilage 
Bovine knee joints were obtained from a local slaughterhouse (Hong Xuong Butchery, 
Australia) within 24 h of slaughter. The cartilage pieces were excised from the 4 bovine knee 
joints and washed three times with sterile PBS solution containing 1% P/S. The cartilage 
pieces were frozen at -80 °C overnight, and then lyophilized for 2 days in a freeze dryer 
(ALPHA2-4 LD Plus). An equal volume of glass beads was added to the 2 mL sterile 
cryovial® tube (SARSTEDT) with contain one third of dried cartilage pieces. The cartilage 
was pulverized in homogenizer (Mini-Beadbeater™, Biospec) for 2-4 min then kept at 4°C 
until use. After pulverization, the cartilage powder was resuspended in sterile distilled water 
(DW) and filtered through a cell strainer (100 μm pore size) (BD Biosciences). Then, the 
cartilage suspension was centrifuged to remove the supernatant. The cartilage pellet was 
frozen at -80°C before lyophilization in the freeze dryer (ALPHA2-4 LD Plus) for 2 days. 
The cartilage powder was then weighed and decellularized in 2% SDS solution including 0.5 
mg/mL DNase Type I (Sigma), 50 μg/mL RNase A (Invitrogen), 0.02% EDTA, and 1% P/S, 
in PBS at 37°C at the concentration of 0.035 g/mL for 24 h with agitation. Following the SDS 
treatment, the cartilage suspension was centrifuged at 3000g for 5 min and cartilage pellet 
was washed with 10x the volume of PBS for 2 h at 37°C with agitation, then washed five 
more times with PBS without incubation at 37°C (modified from ((193); (199). After 
washing, cartilage pellet was incubated with 10 mM Tris-HCL pH 7.5 containing 0.5 mg/mL 
DNase Type I (Sigma), 50 μg/mL RNase A (Invitrogen), and 1% P/S (Invitrogen) at 37°C 
with agitation for 24 h (modified from (197)). Then, cartilage pellet was washed again with 
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PBS for 5 times. The last waste was checked for alteration of the pH compared to PBS. The 
decellularized cartilage ECM was resuspended in standard chondrogenic medium without 
TGF-β 3 and ascorbic acid at 4°C until further use. 
2.7 Preparation of full-thickness defected in osteochondral discs 
Osteochondral cartilage was harvested from bovine knees by a sterile saw and 6 mm diameter 
osteochondral discs were cut from the osteochondral cartilage by sterile trephine with a spray 
of cold sterile PBS containing 1% P/S to reduce heat damaging of cartilage. Osteochondral 
discs were washed with cold sterile PBS containing 1% P/S for 1 time before placed in tissue 
culture flasks and maintained in expansion medium LG-DMEM with 10% FBS, as described 
in 2.2 for 3 days for sterility checks. The full-thickness defect was created in the 
osteochondral disc. The sterile biopsy punch 4 mm diameter (KAI Medical) was used to mark 
the defect area on the osteochondral discs. The full-thickness defect was made by dental burr 
which is a small rotary cutting tool used for cutting hard tissues, e.g., teeth, bone as detail 
described in Appendix B. 
2.8 PI staining 
Propidium iodide (PI) (Invitrogen) was used to stain DNA in decellularized cartilage powder. 
Decellularized cartilage was washed with PBS for 2 times, then incubated in PBS containing 
5 μg/mL PI for 5 min at 37°C and afterwards washed again with PBS for 2 times. 
Fluorescence images were observed with an epifluorescence microscope (Nikon, Tokyo, 
Japan) by using a green excitation filter and images were taken with a Roper Scientific 
camera (Photometrics, Tucson, AZ, USA) using the V++ Precision Digital Imaging System 
(Digital Optics, Auckland, NZ). The colors were added by ACDSee Pro 5 (ACD Systems 
International Inc, USA).  
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2.9 Sample processing for pellet histological samples 
Pellets samples were fixed in 4% (w/v) paraformaldehyde (PFA) in PBS for overnight at 4 °C 
and kept in PBS at 4°C for paraffin embedding. The pellet samples were changed to keep in 
70% alcohol prior to process for the dehydration in graded alcohol from 70% to 100% and 
xylene in tissue processor (Excelsior ES, Thermo Scientific) and then embedded in paraffin 
wax in paraffin embedder (Shandon Histocentre 3, Thermo Electron Corporation). 
2.10 Sample processing for alginate construct histological samples 
To stabilize alginate, alginate constructs were fixed in 4% (w/v) PFA containing 100 mM 
sodium cacodylate trihydrate (Sigma-Aldrich) and 10 mM CaCl2 (Sigma-Aldrich) overnight 
at 4 °C. The constructs were washed with Dulbecco's Phosphate-Buffered Saline (DPBS), 
Calcium, Magnesium (Invitrogen). After fixation, constructs were kept in 50 mM BaCl2 
solution containing 100 mM sodium cacodylate trihydrate at 4 °C overnight prior to process 
for paraffin embedding (263). For paraffin embedding, the samples were changed to keep in 
70% alcohol prior to process for dehydration in tissue processor (Excelsior ES) and then 
embedded in paraffin by paraffin embedder (Shandon Histocentre 3) 
2.11 Sample processing for alginate construct in osteochondral histological samples 
Alginate in osteochondral constructs was fixed in 4% PFA containing 10 mM CaCl2 and 100 
mM Sodium cacodylate for overnight at 4°C. The osteochondral constructs were washed with 
DPBS and then placed in cacodylate buffer which containing 50 mM CaCl2 and 100 mM 
Sodium cacodylate at 4°C overnight. The constructs were then decalcified in 5% formic acid 
(Fluka) at 4°C for 72 h with agitation. The decalcification was checked by physical tests 
including bending the specimen or inserting a pin. Once the decalcification was completed, 
the constructs were washed in PBS for 3 times with agitation. The last waste was checked for 
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alteration of the pH compared to PBS. Then, the constructs were placed in 70% alcohol prior 
to the process of dehydration and embedded in paraffin.  
For cryosection embedding, the fixation process and decalcification were the same as paraffin 
embedding process. But, constructs were kept in 50% O.C.T compound (Tissue-Tek ™, 
Sakura Finetek, Tokyo, Japan) in PBS+ for 3 h before embedded in OCT compound in 
cryosection embedding molds (Sakura Finetek, Tokyo, Japan) and snap freeze in liquid 
nitrogen. The O.C.T. embedded samples were kept in -80°C freezers before sectioning. 
2.12 Histology and immunofluorescence staining 
Histology and immunofluorescence were performed to determine the matrix synthesis in the 
samples. 
2.12.1 Tissue sectioning 
Samples embedded in paraffin were cut at 5 μm using Leica RM2235 microtome (Leica 
Biosystems, Wetzlar, Germany). Tissue sections were then mounted onto Menzel 
SuperFrost® Plus microscope slides (Thermo Fisher Scientific) and dried in a drying oven 
(Parallexx, Excalibur, CA, USA) at 50–60°C for 16 h. Samples embedded in O.C.T. 
compound were cut at 7 μm in Leica CM1850 cryostat (Leica Microsystems, Wetzlar, 
Germany) and collected on Menzel SuperFrost® Plus microscope slides (Thermo Fisher 
Scientific). 
2.12.2 Alcian blue staining from the section 
Paraffin embedded sections were stained with Alcian blue for the evaluation of the presence 
of glycosaminoglycans (GAGs) in the newly formed matrix. Sections were dewaxed in 
xylene 5 min 2 times and rehydrated in 100% alcohol 5 min 2 times, 95% alcohol 5 min, 70% 
alcohol 5 min and distilled water 5 min. After rehydration, sections were placed in 3% Acetic 
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acid for 3 min and were stained with 0.5 % Alcian blue in 3% Acetic acid pH 2.5 (FRONINE 
Laboratory supply) for 1 h. Then, sections were washed with running tap water for 2 min and 
rinsed with distilled water. Sections were counter stained with 0.1% (w/v) Nuclear-fast red 
(FRONINE Laboratory supply) for 20 min and washed in running tap water. Stained sections 
were then dehydrated in ascending concentration of ethanol from 70%, 90%, and 100% 
alcohol for 5 min each. After dehydration, sections were cleared with xylene for 10 min and 
mounted with DePeX mounting medium (BDH Laboratory Supplied, England). Sections 
were visualized using a light microscope (Axio Imager M2, Zeiss). In the case of O.C.T. 
embedded sections, dehydration process and dehydration process were skipped. 
2.12.3 Alcian blue staining for high cell density seeding 
To visualize proteoglycans in the well, chondrocytes in each well were fixed in 4% 
paraformaldehyde at 4 °C for 24 h after live/dead assay. Then, each well was stained with 0.5% 
Alcian blue solution for 30 min. Afterwards, samples were washed with tap water for 3 times 
and counter stained with Mayer’s Hematoxylin solution (MHS32-12, Sigma) for 5 min. After 
a rinsing with water for 3 times, images were taken with a scanner (CanoScan 8600F).  
2.12.4 Immunofluorescence staining 
For paraffin embedded section, tissue slides were dewaxed as in 2.12.2. A wax pen (Vector 
laboratories, Inc., Burlingame, CA, USA) was used to create hydrophobic boundaries around 
sections. The sections were incubated in 50 mM citric acid solution (pH 6.0) in a decloaking 
chamber (Biocare Medical) at 95°C for 5 min and, subsequently, treated with 0.1% (w/v) 
hyaluronidase from bovine testis (Sigma, H3506) and 0.1% (w/v) protease type XIV (Sigma, 
P5147) in PBS for 30 min at 37°C for antigen retrieval. After washing with PBS for 5 min 2 
times, sections were treated with 2% BSA in PBS for 1h at RT or with 2.5% normal horse 
serum (Vector laboratories, Burlingame, CA, USA) for 20 min at RT to block nonspecific 
binding. Sections were then stained with various primary antibodies against interested 
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proteins specific in each chapter overnight at 4°C in a humidified chamber. The commonly 
used antibodies were mouse anti-human collagen type I (1:300; I-8H5; MP Biomedicals, 
Solon, OH, USA), mouse anti-human collagen type II (1:200; II-II6B3; DSHB), mouse anti 
human ACAN (1:50; [MA75A95 (HAG7E1)] (ab22485), Abcam) or polyclonal mouse anti-
human ACAN (1:100; ABI031, Millipore and rabbit anti-human PRG4 (1:50; 28484, 
Abcam). After washing with PBS, the sections were incubated with fluorescence-labelled 
goat anti-mouse secondary antibody or goat anti-rabbit secondary antibody for PRG4 (1:200; 
Alexa Fluor® 488, Invitrogen or 1:200; Alexa Fluor® 633, Invitrogen) and 1:1000; DAPI 
(Invitrogen) for 1 h at RT. After washing with PBS for 5 min 2 times, the sections were 
mounted with a cover slip (Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany) 
using ProLong® Gold antifade reagent (Invitrogen). All immunofluorescence sections were 
observed and imaged with Zeiss fluorescence microscope (Axio Imager M2, Carl Zeiss, 
Oberkochen, Germany). Pictures were processed with the AxioVision software (Carl Zeiss). 
The minor changed of procedures were stated in each chapter. 
For cryosection embedding, sections were fixed in 100% cold acetone for 15 min. A wax pen 
was used to create hydrophobic boundaries around sections. Antigen retrieval was performed 
only for the collagen staining by applying 0.1% (w/v) hyaluronidase (Sigma) in PBS for 30 
min at 37°C. After washing with PBS for 5 min 2 times, sections were then blocked with 2% 
BSA in PBS for 1 h. Sections were then stained with various primary antibodies against 
interested proteins specific in each chapter overnight at 4°C in a humidified chamber. After 
washing with PBS, the sections were incubated with fluorescence-labeled secondary antibody 
and DAPI (Invitrogen) for 1 h at RT and were washed with PBS for 5 min 2 times. The 
sections were then mounted using ProLong® Gold antifade reagent (Invitrogen) and were 
observed and imaged with the Zeiss fluorescence microscope (Axio Imager M2, Carl Zeiss, 
Oberkochen, Germany). 
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2.13 Cell viability 
Viable and dead cells were shown by using fluorescein diacetate (FDA, Invitrogen) and 
propidium iodide (PI, Invitrogen) staining. FDA is taken up by only viable cells and 
enzymatically hydrolyzed to fluorescein inside the cells, while PI is penetrated into only dead 
cells and binds to nucleic acid inside dead cells. To perform live dead staining, the samples 
were transferred into 24-well plates (Nunc/ Thermo Fisher Scientific) and washed twice with 
1 mL PBS or PBS plus if the samples contains alginate. The samples were then incubated in 1 
mL PBS containing 10 μg/mL FDA and 5 μg/mL PI for 5 min at 37°C and afterwards the 
solution was removed and washed with PBS for 1 times. Visualize staining was observed 
using fluorescence (green excitation filter for PI, blue excitation filter for FDA). Fluorescence 
images were captured on an Eclipse TE2000-U microscope with T-FL epifluorescence 
attachment (Nikon, Tokyo, Japan) and a Roper Scientific camera (Photometrics, Tucson, AZ, 
USA) using the V++ Precision Digital Imaging System, Version 4.0 (Digital Optics, 
Auckland, NZ). The colors were added by ACDSee Pro 5 (ACD Systems International Inc, 
USA). 
2.14 DNA content 
Constructs were digested with 0.5 mg/mL Proteinase K solution (Invitrogen) in Phosphate 
buffered EDTA (PBE) at 60C for 18 h with agitation and digested samples were analyzed 
for DNA content, and GAG content.  
To quantify the DNA content of the digested samples the Quant-iT™ PicoGreen® dsDNA 
Assay kit (Invitrogen, Carlsbad, CA, USA) was used. Samples were diluted in appropriate 
dilutions with PBE and triplicates of each sample were transferred into black 96-well plates 
(Nunc/Thermo Fisher Scientific) for 100 μL per well. The same amount of PicoGreen® 
reagent was added to each sample and after mixing in the dark on a plate shaker for 5 min, 
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sample fluorescence was measured at RT using a POLARstar OPTIMA fluorescence 
microplate reader (BMG Labtech, Offenburg, Germany) at 480 nm excitation and 520 nm 
emission with the gain automatically adjusted to 80% of the standard with the highest DNA 
concentration. The results were standardized to a DNA amount based on a dilution series of 
the DNA standard provided by the PicoGreen® dsDNA assay kit. 
2.15 GAG content 
 The amount of sulfated GAG was analyzed by 1, 9 dimethyl methylene blue dye (DMMB, 
Sigma-Aldrich )-binding assay (264). Briefly, 30 μL of digested solution or standard shark 
chondroitin sulfate (Sigma-Aldrich) ranging from 0-100 μg/mL were transferred in triplicates 
into a clear 96-well plate then 270 μL of DMMB dye (46 μM DMMB chloride (Sigma) 
dissolved in glycine buffer (40 mM glycine, 40 mM sodium chloride, 0.02% (w/v) sodium 
azide, pH 3 (pellets) or pH 1.5 (Alginate constructs, medium) for modified reagent (265) 
were added and mixed. The solution was measured immediately in a Benchmark Plus 
Microplate Spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA) at 525 nm or 595 
nm wavelength. The GAG amount was standardized to a GAG amount based on a dilution 
series of the GAG standard. 
2.16 Gene expression 
Genes relevant to chondrogenesis, zonal marker protein and various cytokines and enzymes 
were analyzed by quantitative real-time reverse transcriptase-polymerase chain reaction 
(qRT-PCR) using SYBR Green detection chemistry.  
2.16.1 RNA extraction 
RNA was isolated using TRIzol® Reagent (Invitrogen) according to the manufacturer’s 
protocol. More specifically, samples that kept in TRIzol® Reagent at -80C freezer were 
thawed on ice and homogenized by passing through a 19 gauge needle on a 1 mL syringe for 
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20 times. To enable dissociation of nucleoprotein complex, samples were incubated for 5 min 
at RT. Then, 100 μL of chloroform (Sigma) was added to 500 μL TRIzol and shaken for 15 
sec. Samples were incubated for 5 min at RT for phase separation and then centrifuged for 15 
min at 12,000 g in a desktop centrifuge at 4°C. The upper aqueous phase was transferred to 
new 1.5 mL tubes (Eppendorf) on ice, 250 μL of chloroform was added and mixed for 5 min 
in an eppendorf shaker (Eppendorf Thermomixer®) at 1400 Revolutions per minute (RPM). 
Samples were centrifuged at full speed for 5 min at 4°C and the upper aqueous phase was 
transferred to new 1.5 mL tubes (Eppendorf) on ice. RNA was precipitated with 275 μL 
isopropanol (Sigma), 25 μL of sodium acetate (final concentration 0.3 M) and 1.58 μL of 
linear acrylamide (Ambion, Austin, TX, USA) (final concentration 15 μg/mL) and was then 
left at -20°C overnight. Precipitated RNA was centrifuged for 30 min at 12,000 g at 4°C. The 
isopropanol was carefully removed and the pellet was washed with 1000 μL of ice cold 70% 
ethanol (Sigma). The tubes were centrifuged for 5 min at 7,500 g at 4°C. Ethanol was taken 
off and samples centrifuged for 1 min with open lid at full speed. The residual ethanol was 
removed and pellets were air-dried for 5 min. The RNA pellets were then resuspended in 12 
μL RNase free ultra-pure water (Invitrogen). RNA concentration was determined using a 
NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific) with readings taken at 
260 nm and 280 nm. 
2.16.2 DNase treatment and reverse transcription for qRT-PCR 
To remove the contaminating DNA, DNase I Amplification Grade (Invitrogen) was used 
according to the manufacturer’s protocol. In brief, samples with 300 ng of total RNA and 
RNase free ultra-pure water was transferred into 0.2 mL PCR tubes on ice and the final 
volume was adjusted with RNase free ultra- pure water to 6.4 μL. Then 1.6 μL of DNase I in 
a reaction buffer (Deoxyribonuclease I kit, Invitrogen, Carlsbad, CA) were added and 
incubated for 15 min at RT. DNase I was deactivated by adding 0.8 μL of 25 mM EDTA 
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solution, pH 8 to each tube and heated at 65 °C for 10 min in a Peltier Thermal Cycler PTC 
200 (MJ Research, Ramsey, MN, USA). 
First strand complementary DNA (cDNA) synthesis was performed with the SuperScript™ 
III first-strand synthesis supermix for qRT-PCR (Invitrogen) to reverse-transcribe total RNA 
in 20 μL reactions 8 μL of DNase treated sample was mixed with 12 μL of a reverse 
transcriptase enzyme reaction mix containing RNaseOUT™, 2.5 μM oligonucleotides (dT), 
2.5 ng/μL random hexamer oligonucleotides, 10 mM MgCl2 and mixed deoxynucleoside 5’-
trisphosphates (dNTP). The mixture was gently mixed on a plate shaker at RT for 10 min. 
Then the reaction mixture was incubated at 50°C for 30 min and terminated the reaction 85°C 
for 5 min in a Peltier Thermal Cycler PTC 200 (MJ Research, Ramsey, MN, USA). The RNA 
templates were removed by adding 1 μL of E. coli RNase H and samples were incubated at 
37°C for 20 min. cDNA samples were stored at -80°C. 
2.16.3 Real-time PCR and data processing 
To determine the expression of relevant genes the SYBR® Green PCR Master Mix (Applied 
Biosystems, Foster City, CA, USA) and ABI PRISM 7500 Fast real-time PCR system 
(Applied Biosystems, Foster City, CA, USA) were used to carry out the PCR reaction. Each 
sample was evaluated in duplicates and compared to two housekeeping genes 18S or RPL13. 
For each 13 μL of reaction contained 1x SYBR® Green PCR Master Mix, 200 nm of each 
forward and reverse primers and approximately 1 ng cDNA. The PCR amplification protocol 
was done as follows, denaturation at 95°C for 10 min and 40 cycles of 95°C for 15 s and 
60°C for 60 s and melt curve analysis was performed. Amplification curves were analyzed 
with the 7500 System software (Applied Biosystems, CA, USA) by setting the baseline to 
accommodate the earliest amplification plot and selecting threshold values in the log-linear 
phase of the PCR cycle. The cycle threshold (Ct) value of each target gene for each sample 
was then normalized to the housekeeping genes (RPL13 or 18S) using the comparative Ct 
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method (2-∆ct). The primers used in the experiments were designed and used generally in the 
Cartilage Regeneration Groups (259). 
Table 2.1: List of primer sequences commonly used in the experiments for qRT-PCR. 
Gene 
symbol 
Sequence (5'->3') GenBank 
accession # 
Amplicon 
position 
COL1A1 F: CAGCCGCTTCACCTACAGC NM_000088 4335-4417 
 R: TTTTGTATTCAATCACTGTCTTGCC   
COL2A1 F: GGCAATAGCAGGTTCACGTACA NM_001844 4454-4532 
 R: CGATAACAGTCTTGCCCCACTT   
COL10A1 F: ACCCAACACCAAGACACAGTTCT NM_000493 201-264 
 R:TCTTACTGCTATACCTTTACTCTTTATGGTGTA   
ACAN F: GCCTGCGCTCCAATGACT NM_001135 739-844 
 R: TAATGGAACACGATGCCTTTCA   
PRG4 F: GAGTACCCAATCAAGGCATTATCA NM_005807 3431-3510 
 R: TCCATCTACTGGCTTACCATTGC   
 
2.17 Statistical analysis 
The results from each experiment were obtained from 3 donors each condition tests in at least 
duplicate. To determine differences between the experimental groups, data were examined 
for significant differences by analysis of variance (ANOVA), with p < 0.05 considered 
significant and Tukey's post-hoc testing was performed for multiple comparisons. All 
statistical analyses were performed using PASW® Statistics 19 (SPSS Inc., Chicago, USA). 
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CHAPTER 3 : HUMAN UMBILICAL CORD PERIVASCULAR 
CELLS AS A POTENTIAL ALLOGENEIC CELL SOURCE FOR 
ARTICULAR CARTILAGE TISSUE ENGINEERING 
 
3.1 Introduction 
Articular cartilage is a connective tissue with minimal capacity for healing after damage due 
in part to its hypocellular and avascular nature. Thus, cartilage damage commonly leads to 
osteoarthritis (OA), or degenerative joint disease, which is one of the most frequent causes of 
pain and disability in the elderly population. Less than 5% of people aged between 15 and 44 
show evidence of OA, but these numbers increase to 25-30% in the 45-64 age-group and 
more than 60% of people older than 65 years (266, 267). Approximately 15% of the 
Australian population suffers from arthritis and OA accounts for most of these cases (268). 
Treatment of late-stage osteoarthritis is commonly artificial joint replacement, which is 
limited in function and lifetime. Hence, articular cartilage is a prime candidate for tissue 
engineering-based treatments. While this research area has been investigated for over twenty 
years and progress has been made, there is still a need to define an optimal cell source, 
biomaterial scaffold or matrix, and culture conditions to produce high-quality cartilage tissues 
for clinical application. 
The lack of an optimal source of cells is one of the major problems limiting clinical 
application of tissue-engineered cartilage. Chondrocytes are limited in number (258), 
invasive to harvest (269), and dedifferentiate during expansion (270). Mesenchymal stem 
cells (MSCs) are an interesting potential source for cell therapy and regenerative medicine 
because they have the ability to proliferate and differentiate into various cell types of the 
mesodermal lineage, including chondrocytes. The most common source of MSCs is bone 
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marrow. However, there are some drawbacks to this source including invasiveness of bone 
marrow aspiration and reduction of differentiation capability with age (148).  
Umbilical cord is a discarded tissue that is collected non-invasively and is rich in MSCs in 
the perivascular region. Human umbilical cord perivascular cells (HUCPVCs) have the 
ability to differentiate into chondrocytes in the conventional cell pellet culture system with 
chondrogenic medium (158). Further, these cells appear to be non-immunogenic (154), 
implicating their use in allogeneic applications. Therefore, human umbilical cord perivascular 
cells (HUCPVCs) appear to be a promising source for allogeneic cell therapy and tissue 
regeneration. 
 Critical to their future clinical use is large-scale reproducible cellular expansion. Hence, 
expansion systems are needed that reduce or eliminate the reliance on large and variable 
amounts of xenogenic material (i.e. fetal bovine serum (FBS)). Also, there are reports that 
adding basic fibroblast growth factor (FGF2) to the proliferation medium enhances 
proliferation of bone marrow MSCs (218). However, the effects of FGF2 and low-serum 
medium on HUCPVCs in long-term culture remain to be determined and their chondrogenic 
capacity after large-scale expansion in clinically-relevant models remains to be characterized. 
We hypothesize that HUCPVCs can be expanded and induced to form de novo cartilage when 
cultured with appropriate conditions.  
Since human umbilical cord perivascular stem cells (HUCPVCs) are a new adult stem cell 
source, there are limited data on their proliferation and differentiation ability, which are 
defining characteristics of MSCs. Therefore, we studied the proliferation and multilineage 
differentiation capacity of HUCPVCs in different culture media with or without supplemental 
basic-fibroblast growth factor (b-FGF) for 7 patient samples which are commercially 
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available provided by Tissue Regeneration Therapeutics, Inc. (Tissue Regeneration 
Therapeutics, Canada). 
3.2 Materials and methods 
3.2.1 Proliferation assay 
HUCPVCs (passage 2, n= 7) were purchased from a commercial source (Tissue Regeneration 
Therapeutics, Canada) and cryopreserved in liquid nitrogen. The cells were thawed and 
plated at 3 x 103 cells per cm2 in T75 flask (Nunc) in 2 types of medium 10% fetal bovine 
serum (FBS, In vitro Technologies) in Low Glucose Dulbecco’s Modified Eagle’s Medium 
(LG-DMEM, Invitrogen) and MesenPRO RS™ (MesenPRO) which is a reduced serum (FBS 
2%) medium (Invitrogen) with and without 5 ng/mL fibroblast growth factor-2 (FGF2). Cells 
were incubated at 37 0C 5% CO2 for 7 days. Media were changed every 3 or 4 days. On days 
7, cells were trypsinized (0.05% trypsin/EDTA, Invitrogen) and counted by NucleoCounter 
(ChemoMetec, Denmark). Cells were subculture from passage 3 to passage 10. The number 
of population doublings (PD) at each passage was analyzed for all conditions by: PD = (log 
x1- log x0)/ log 2, where x0 is the initial cell number at the beginning of each passage and x1 is 
the final cell number at the end of each passage. 
3.2.2 Phenotypic characterization 
HUPVCs at passage 3, 4 and 8 were characterized by flow cytometric measurements for 
cellular markers. After trypsinization, ~ 1x105 cells were washed twice with phosphate buffer 
saline (PBS, Invitrogen) and stained with fluorescein isothiocyanate (FITC) or phycoerythrin 
(PE) conjugated mouse monoclonal antibodies. The markers which indicate an MSC 
phenotype such as CD45-, CD90+, CD105+ were analyzed by flow cytometry (154). Also, 
CD146+ and CD31- were analyzed (158). Briefly, HUCPVCs were incubated with blocking 
buffer (Hank’s balance salt solution (Invitrogen) containing 1% Bovine serum albumin, 1% 
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Penicillin/Streptomycin (Invitrogen) and 5% fetal bovine serum for 30 min at room 
temperature. After that, cells were mixed with various concentration of primary antibodies 
CD45 (mouse monoclonal anti- human CD45, Development Studies Hybridoma bank), 
CD105 (mouse monoclonal anti-human CD105, Development Studies Hybridoma bank), 
CD31-FITC (fluorescein isothiocyanate-conjugated mouse monoclonal anti-human CD31, 
Invitrogen), CD90-FITC (fluorescein isothiocyanate-conjugated mouse monoclonal anti-
human CD90, Chemicon) and CD146-PE (phycoerythrin-conjugated mouse monoclonal anti-
human CD146, BD Biosciences) and then were incubated on ice for 1 h. For CD31, CD90 
and CD146, cells were washed twice with LG-DMEM 10% FBS and resuspended in LG-
DMEM 10% FBS for analysis on a flow cytometer (Cytomics FC500, Beckman Coulter). For 
CD45, CD105, cells were washed twice with LG-DMEM 10% FBS and incubated with 
secondary antibody (FITC-conjugated goat anti-mouse antibody, Cal Tag Laboratories) in 
darkness on ice for 30 min. Cell were washed, resuspended and analyzed as previous. Cells 
which were stained with mouse anti-human IgG (Sapphire) were used as isotype control. 
Human mononuclear cells which were prepared by Lymphoprep (Lymphoprep™, Axis-
SHIELD PoC AS) were used as positive control cells for CD31 and CD45, while human 
fibroblast (nsHFS106, P7, Bank SIA Scientific) were used as positive control cells for CD90. 
Data from flow cytometer were analyzed by CXP software (Beckman Coulter). A 
fluorescence emission level greater than 99% of the isotype control cells, defines positive 
cells. If the percent of CD146+ less than 25% (normal about 50%), HUCPVCs was sorted 
and selected only CD146+ for differentiation assay. 
3.2.3 Multilineage differentiation assays 
HUCPVCs from passage 5 and/or 10 from both types of media with and without FGF2 were 
used to study their osteogenic, adipogenic and chondrogenic differentiation capacity. 
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3.2.4 Osteogenic differentiation 
HUCPVCs were plated at 6 x 103 cells /well in 24- well plate (Nunc). Cells were grown to 
confluence in growth medium and then differentiated in osteogenic growth media (LG-
DMEM, 10% FBS, 100 nM dexamethasone [DEX] (Sigma-Aldrich), 100 µM ascorbic acid 
(Sigma- Aldrich) and 2 mM β-glycerol phosphate (Sigma-Aldrich)) or (LG-DMEM 
(Invitrogen), 10% FBS, 100 nM DEX, 50 µM ascorbic acid and 10 mM β-glycerol 
phosphate) or (High- Glucose Dulbecco’s Modified Eagle’s Medium (HG-DMEM, 
Invitrogen), 10% FBS, 100 nM DEX, 50 µM ascorbic acid and 10 mM β-glycerol 
phosphate). Control cultures were maintained in growth medium. Media were changed every 
3 or 4 days. On week 4, cultures were stained with Alizarin Red S stain. In brief, cells were 
washed with PBS and fixed with methanol for 10 min. Then, cells were washed with ddH2O 
and incubated with 500 l alizarin red staining (500 mg Alizarin red (Sigma-Aldrich) in 50 
mL ddH2O pH 4.1) for 2 min. Cells were washed with ddH2O three times, dried at room 
temperature and documented by photomicroscopy. Calcium deposits stained orange-red in 
samples are defined as positive staining. 
3.2.5 Adipogenic differentiation 
HUCPVCs were plated at 4 x 104 cells/ well in 24- well plate. Cells were cultured to 
confluence in growth medium and differentiated in the presence of 4 adipogenic cocktails 
(LG-DMEM, 10% FBS, 100 nM DEX, 10 µg/mL insulin, 100 µM indomethacin (Sigma-
Aldrich) and 500 µM isobutylmethylxanthine (IBMX, Sigma-Aldrich) or (LG-DMEM, 10% 
FBS, 1µM DEX, 10 µg/mL insulin and 500 µM IBMX) or (HG-DMEM, 10 % FBS, 1 µM 
DEX, 10 µg/mL insulin, and 500 µM IBMX) and (HG-DMEM, 10% FBS, 100 nM DEX, 10 
µg/mL insulin, 100 µM indomethacin and 500 µM IBMX). Control cultures were maintained 
in growth medium. Media were changed every 3 or 4 days. On week 3, cultures were stained 
with oil red o stain. Briefly, working solution was prepared by diluted 6 mL of stock 0.5 g% 
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oil red o (Sigma-Aldrich) in 99% isopropanol with 4 mL of ddH2O. Cells were washed with 
PBS and incubated with 200 µL of working solution for 10 min. Cells were washed three 
times with ddH2O, added small amount of ddH2O to keep cells wet and documented by 
photomicroscopy. Fat droplets stained red in samples are defined as positive staining.  
3.2.6 Chondrogenic differentiation in pellets 
HUCPVCs (5 x 105 per pellet) were centrifuged at 500g for 5 min in 15 mL polypropylene 
tubes (BD Biosciences), as a standard model of chondrogenesis, and grown as pellets in 24- 
well plates. Pellets were cultured in chondrogenic growth medium (HG-DMEM contains 0.4 
mM L-proline, 110 µg/mL sodium pyruvate, 12.5 mg/mL BSA, 1% (v/v) Insulin-Transferrin-
Sodium selenite (ITS +1, Sigma-Aldrich), 0.1 mM L-ascorbic acid 2 phosphate trisodium 
salt, 10-7M DEX with 10 ng/mL Transforming Growth Factor (TGF-β1, Millipore). Media 
were changed every 3 or 4 days. On week 4, pellets were frozen in O.C.T. compound and 
cutting at 5 m, sectioned and stained with Safranin O to visualize GAG distribution. The 
histological staining was serviced by Mr. Donald Geyer. In brief, sections fixed in 100% cold 
acetone for 15 min and rehydrated. Samples were then incubated in Weigert’s iron 
haematoxylin (Sigma) for 10 min and washed under running tap water. Samples were treated 
with 0.001% (m/v) Fast Green FCF solution (Sigma) for 5 min and sections were quickly 
rinsed with 1 % (v/v) acetic acid for no more than 10 seconds. Finally, a 0.1% (m/v) Safranin 
O (Sigma) solution was applied to the samples for 5 min before they were dehydrated in 
graded ethanol series. GAG deposits stained red in samples are defined as positive staining.  
3.2.7 Hypoxia protocol 
To provide a hypoxic environment, the cell pellets in chondrogenic differentiation media 
(HG-DMEM contains 0.4 mM L-proline, 110 µg/mL sodium pyruvate, 12.5 mg/mL BSA, 
1% (v/v) Insulin-Transferrin-Sodium selenite (ITS +1, Sigma-Aldrich), 50 µg/mL ascorbic 
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acid, 0.1 µM DEX with 10 ng/mL Transforming Growth Factor (TGF-β1, Millipore or TGF-
β3, GroPrep Bioreagents) were maintained in a hypoxia chamber (BioSpherix, USA) with 
oxygen controlled to 5% O2 by automated injection of 95% N2/5% CO2. These low oxygen 
conditions have been shown to improve chondrogenesis by chondrocytes (271) and fat pad-
derived MSCs (272). 
3.2.8 Wet weight 
Excess fluid was removed from the cell pellets and the cell pellets were then weighed using a 
microbalance.  
3.2.9 Statistical analysis 
Population doublings were analyzed by analysis of variance (ANOVA), with p < 0.05 
considered significant and Turkey post-hoc testing where appropriate.  
3.3 Results 
3.3.1 Proliferation 
For clinical use, cell expansion with reduced or eliminated xenogenic material is needed. 
Also, FGF 2 has been reported to enhance the proliferation capacity of stem cells. Therefore, 
the effects of FGF2 and 2% serum media as MesenPRO on HUCPVCs proliferation were 
determined. HUCPVCs from 7 patients were cultured in 4 types of media; DMEM with 10% 
FBS +/- FGF2 and MesenPRO +/- FGF2. All cells exhibited a fibroblast-like morphology 
between the 3rd and 10th passage (Fig 3.1).  
HUCPVCs maintained their capacity to proliferate at least 56 days culture in all media. 
However, the proliferation of HUCPVCs dropped off toward the end. The clear decline was 
shown for all medium types at passage 10. The population doublings for 4-7 patients are 
shown in Fig 3.2 A. According to population doubling from 4-7 patients, the population 
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doubling of HUCPVCs in each passage exhibits the high standard deviation. The high 
standard deviation is because of patient variation. The population doubling of 2 examples 
which exhibit patient-patient variability are shown in Fig 3.2 B, C. Patient in Fig 3.2 B is 
sharply decreased the populations doubling in low serum medium (MesenPRO) since passage 
7 while a patient in Fig 3.2 A is slowly decreased.  
HUCPVCs cultured in DMEM with 10% FBS with and without FGF2 had higher population 
doublings than those cultured in MesenPRO with 2% FBS with and without FGF2 from 
passage 4 to passage 10 (Fig 3.2 A). There was a significant effect of media type (p = 0.01) 
and passage number (p < 0.001) on HUCPVCs population doublings up to passage 10, but 
FGF2 had no significant effect (p = 0.75). The average weekly population doublings for 
HUCPVCs cultured in DMEM with 10% FBS +/- FGF2 and MesenPRO +/- FGF2 were 3.74, 
3.65, 2.78 and 2.84, respectively. The averages of total population doublings over the entire 
culture period in DMEM with 10% FBS +/- FGF2 and MesenPRO +/- FGF2 were 24.75, 
25.80, 16.30 and 18.30 respectively.  
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Figure 3.1: Phase-contrast images of HUCPVCs expanded in different media. 
10% Fetal Bovine Serum in Low Glucose Dulbecco’s Modified Eagle’s Medium and 
MesenPRO RS with and without 5 ng/mL Fibroblast growth factor-2 (FGF2) at passages 5, 8 
& 10. 
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Figure 3.2: Population doublings from 7 patients ranging from passage 3 to passage 10. 
(A) Population doublings average of 7 patients (B, C) Population doublings for 2 examples 
showing patient-patient variability. 
3.3.2 Phenotypic characterization 
HUCPVCs passage 3 which is the earliest passage that we have thawed from cryopreserved 
to analyses their cell surface marker. The result showed that HUCPVCs at passage 3 were 
negative for CD31 which is an endothelial cells surface marker and CD45 which is a 
hematopoietic cells surface marker, as shown by flow cytometry (Fig 3.3). In addition, 
HUCPVCs were positive for CD90, CD105 and CD146 which are the cell surface marker for 
stem cells (Fig 3.3). The percentages of HUCPVC passage 3 positive for CD31, CD45, 
CD90, CD105 and CD146 were 2.58%, 2.89%, 46.05%, 26.52% and 28.81% respectively. In 
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order to know that there are any difference of cell surface markers between the early passage 
and older passage ~ 2x105 HUCPVCs from passage 4 and passage 8 were analyzed for 
CD146 marker. HUCPVCs showed slightly higher CD146 expression at passage 8 than 
passage 4. The percentage of HUCPVC positive for CD146 at passage 4 is 91.44% and 
passage 8 is 96.24%. 
 
Figure 3.3: The histogram of HUCPVCs for CD31, CD45, CD90, CD105 and CD 146 from 
passage 3 and histogram of HUCPVCs for CD146 from passage 4 and passage 8.  
The histogram displays the fluorescence intensity on the X axis and cell count on the Y axis. 
The red curves represent the fluorescence intensity and distribution of isotype control; the 
blue curves represent fluorescence intensity and distribution of each specific surface marker 
staining and the purple curves represent overlapping fluorescence intensity areas of the 
specific surface marker staining that similar to isotype control. 
3.3.3 Multilineage differentiation assays 
HUCPVCs from 4 different expansions medium were evaluated their multilineage 
differentiation capacity in various adipogenic and osteogenic conditions and one 
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chondrogenic condition. Adipogenesis, osteogenesis and chondrogenesis were detected by 
staining with Oil red O, Alizarin red and Safranin O, respectively. The results show that 
HUCPVCs passage 5 or passage 10 was not successful in regard to adipogenic differentiation 
(no red staining of fat droplets found), osteogenic differentiation (no orange-red precipitate 
staining of calcium found) and chondrogenic differentiation (no red staining of GAG found) 
in our experiments (Fig 3.4-3.6).  
 
Figure 3.4: Adipogenic differentiations of HUCPVCs expanded in MesenPRO plus 5 ng/mL 
of FGF2. 
No fat vacuole was found in both control sample (A) and differentiation sample (B). Scale 
bar is 500 um. 
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Figure 3.5: Osteogenic differentiations of HUCPVCs expanded in MesenPRO plus 5 ng/mL 
of FGF2. 
No mineralization was found in both control sample (A) and differentiation sample (B). Scale 
bar is 500 um. 
 
Figure 3.6: Safranin O/Fast Green staining of pellets cultured for 28 days in chondrogenic 
medium. 
HUCPVCs were expanded in (A) DMEM+10% FBS, (B) DMEM+10% FBS+5 ng/mL 
FGF2, (C) MesenPRO RS, and (D) MesenPRO RS + 5 ng/mL FGF2. No chondrogenesis was 
observed in the samples (would appear as red staining of GAG). Scale bar is 100 um. 
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Our research showed that the human umbilical cord perivascular cells (HUCPVCs) were 
incapable of adipogenic differentiation and non-stable osteogenic differentiation using 
differentiation cocktails commonly used in our laboratory and the literature (158, 273) Also, 
HUCPVCs were incapable of chondrogenic differentiation by using our chondrogenesis 
protocol, which includes transforming growth factor β1 (TGF-β1). However, Baksh, et al 
successfully chondrogenically differentiated HUCPVCs using chondrogenic media including 
TGF-β3 (158). There is also evidence that hypoxia promotes chondrogenesis in MSCs (272) 
and human osteoarthritic chondrocytes (274).  
In order to definitively evaluate the chondrogenic capacity of HUCPVCs, a differentiation 
experiment using the media employed by Baksh, et al., in normoxia and hypoxia conditions, 
with control cultures of chondrocytes and fibroblasts. The result showed that the wet weight 
(an indicator of chondrogenesis) of chondrocyte pellets in both differentiation media 
containing TGF-β1 and TGF-ß3 are higher than in fibroblast pellet and HUCPVC pellets. 
There was no difference in wet weight of HUCPVC pellets and fibroblast pellets in 
differentiation media when compared to control medium, while the wet weight of 
chondrocyte pellets increased around 2-fold of control wet weight (Fig 3.7). In addition, no 
positive staining for sulfated glycosaminoglycans by safranin-O staining was found in 
HUCPVCs and fibroblast pellets in all conditions. 
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Figure 3.7: Effects of culture conditions on pellets wet weight following 3 weeks of 
chondrogenic cultures. 
Chondrocytes, HUCPVCs and fibroblasts were cultured in chondrogenic media contained 10 
ng/mL TGF-β1 or TGF-β3, whereas control medium contained no growth factors. Oxygen 
was supplied as normoxia (21% O2) and hypoxia (5% O2).  
3.4 Discussion 
The human umbilical cord comprising of two umbilical arteries, umbilical vein, cord lining, 
Wharton’s jelly and perivascular region which directly surrounds the vessels (275). Umbilical 
cord-derived mesenchymal stem cells are isolated from various compartments of the 
umbilical cord, are a potential cell use for cartilage tissue engineering (276, 277). Among the 
diverse sources, cells isolated from Wharton’s jelly have received the most extensive study 
(278). Mennan et al. report umbilical cord-derived MSCs from different cord regions in the 
same individual showed the potential to differentiate to varying degrees but did not 
demonstrate any region better than others for chondrogenic differentiation (276). However, 
HUCPVCs from the perivascular region were not included in their study. As the data on the 
chondrogenic differentiation capacity of HUCPVCs are limited (158, 279), the properties of 
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HUCPVCs as an alternative cell sources for cartilage tissue engineering need to be 
confirmed. 
Because of their expected future clinical use, large-scale reproducible cellular expansion of 
stem cells is needed. The high expansion capacity is shown by low population doubling time 
or high population doublings. The results indicated that the HUCPVCs have high 
proliferation capacity (average weekly population doubling approximately 2.8-3.7 in 4 types 
of media) and this capacity can be maintained over at least 56 days in vitro expansion system. 
The population doublings declined at the late passage and clearly declined at passage 10, a 
sign of senescence. However, the population doubling from each patient indicated that 
HUCPVCs from different patients have different rates of senescence. Although lower 
population doublings of HUCPVCs (average weekly population doubling about 2.8) were 
found in low serum media (MesenPRO 2% serum media) than standard 10% FCS DMEM 
(average weekly population doubling about 3.7), the proliferation capacity of HUCPVCs in 
low serum media is still higher than other cell types such as chondrocytes. Nonetheless, both 
culture media were useful for large-scale expansion of HUCPVCs, indicating that future low-
serum or serum-free expansion methods may be feasible for future clinical applications. 
However, expansion from P3-P10 was ~350 times greater for the high serum media. Thus, 
further work is required to define low-serum or serum-free conditions for HUCPVCs 
expansion. The 5 ng/mL FGF2 had no significant effect on HUCPVCs expansion capacity. 
The result may be due to relatively high levels of FGF2 in serum (1-100 ng/mL) (280), hiding 
the effect of the added FGF2. 
The results of HUCPVCs characterization in our experiments were similar to the previous 
reports. HUCPVCs were positive for stem cell markers CD90 and CD105 and were positive 
for perivascular cell marker CD146. However, CD146 is also positive in endothelial cells 
(281). HUCPVCs were negative for CD31, which is an endothelial cell marker, and were 
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negative for CD45, which is hematopoietic cell marker. This indicates that HUCPVCs are not 
endothelial cells or contaminated with hematopoietic cells such as lymphocytes. In addition, 
we found that CD146 cells surface marker was present in the passage 4 and passage 8 with 
different fluorescence intensity. The result demonstrated that HUCPVCs in the higher 
passage as passage 8 have slightly higher expression of CD146 than HUCPVCs in the lower 
passage. When compared to the report from Baksh, et al., that P3 HUCPVCs are 52% 
positive for CD146 (158), the CD146+ sub-population in our experiment are lower as 28.81% 
at the same passage but more prominent in the late passage (P4 91.44%, P8 96.24%). 
However, HUCPVCs which we use in our experiment were cryopreserved cells. Freeze-
thawing cells may affect the CD146- HUCPVC sub-population and allow CD146+ to 
dominate the culture. A similar situation has been reported in freeze-thawing HUCPVCs, 
where MHC-/- sub-population of freeze-thawed HUCPVCs increased from 65% at P0 to 95% 
at P5, while MHC-/- percentage of non-frozen HUCPVCs increased only from 20% at P0 to 
30% at P5 (157). 
No multilineage differentiation capacity was found in our differentiation experiments. One 
possible explanation is the HUCPVCs passage 5 and passage 10 lost their differentiation 
capacity in the late passage as the multilineage differentiation capacity as previously reported 
is at passage 3 (158). However, differentiation assays were tested in HUCPVCs passage 4 
which is the lowest passage that we could use to set up experiment. The result remained the 
same (data not shown). As reported by Baksh et.al. CD146 positive HUCPVCs have higher 
multilineage differentiation capacity than CD146 negative HUCPVCs. Therefore, we sorted 
HUCPVCs at passage 4 for CD146 positive by MACS® Cell Separation technique and 
subsequently cultured those for 2 passages. Adipogenesis and Osteogenesis were analyzed 
with several adipogenic media and osteogenic media. The result of adipogenesis and 
osteogenesis were remained negative. We assume that HUCPVCs in our experiment should 
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have ability to differentiate into adipocytes, osteoblasts and chondrocytes as our HUCPVCs 
have high CD146 expression. The negative result for multilineage differentiation of 
HUCPVCs may indicate that the multilineage differentiation capacity of HUCPVCs do not 
rely on only CD146 expression. Additional evidence supports this hypothesis; BMSCs are 
only 15% CD146+, but maintain multilineage differentiation capacity (158). In addition, 
chondrogenic potential, measured by GAG production of BMSCs is equivalent between 
unsorted BMSCs and CD146+ sorted HUCPVCs, although osteogenic potential and 
adipogenic potential are lower in BMSCs (158). Extensive chondrogenic differentiation 
experiments in hypoxic conditions also were not successful. The result indicates that 
HUCPVCs lost their multilineage differentiation capacity after large scale expansion at high 
passage number (P5, P10). Therefore, HUCPVCs may not be a preferred cell for cartilage 
tissue engineering, especially in the high passage as in our study.  
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CHAPTER 4 : THE EFFECT OF ROCKER PLATE SHEAR STRESS 
ON CHONDROCYTES CHONDROGENESIS 
 
4.1 Introduction 
Articular cartilage is a load-bearing tissue which commonly receives mechanical stimuli such 
as compressive stress, shear stress and hydrostatic pressure (282). Mechanical stimuli have 
been shown to affect cartilage extracellular matrix synthesis both in vivo and in vitro (283) 
(284). During joint loading in vivo, chondrocytes are subjected to a variety of mechanical 
stimuli which influence the cell’s metabolism through a phenomenon called 
mechanotransduction (285), the mechanisms through which chondrocytes convert the 
mechanical signal they receive to be biochemical signal, which regulates anabolic and 
catabolic activities of chondrocytes via transcriptional regulation (286). Increase in matrix 
synthesis in response to loading are exemplified directly in laboratory studies (287, 288), as 
well as indirectly in vivo where load-bearing areas are shown to have higher aggrecan content 
than unloaded regions (46). 
Understanding chondrocyte mechanotransduction could lead to improvements in the 
properties of tissue-engineered cartilage through application of specific loads in a bioreactor. 
Reports suggest that static compression decreases GAG and collagen synthesis, whereas 
cyclic loading, or dynamic compression, has a positive effect on ECM production depending 
on the compression amplitude, frequency and duration(287, 289). Increased matrix synthesis 
was reported for a physiological range of cyclic compression (290). Also, dynamic shear 
stress has been studied for its effect on matrix synthesis of cartilage explants (291). The 
results show that tissue shear loading using 1–3% sinusoidal shear strain amplitudes and 
frequencies between 0.01 and 1.0 Hz stimulates protein and proteoglycans synthesis in 
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cartilage explants. Hydrodynamic shear stress in a tissue-culture mixed flask and rotating 
wall bioreactor improves the matrix properties of engineered cartilage (284). Fluid induced 
shear stress by a cone viscometer also increased GAG synthesis by human and bovine 
chondrocytes in high density monolayer (292, 293). The role of all these stimuli in regulating 
chondrocyte matrix synthesis is still under investigation. 
It is known that chondrocytes are exposed to different mechanical stimuli depending on their 
zone location (10, 11). For example, superficial zone chondrocytes are subjected to higher 
shear stress than deeper zone chondrocytes (39). Dynamic shear stimulation with amplitude 
of only 3% stimulates PRG4 synthesis in bovine cartilage samples (214) and oscillatory 
surface motion also up-regulates PRG4 of bovine chondrocytes seeded on three dimensional 
scaffolds (215). Ogawa et al., has been suggested that fluid induced shear stress unregulated 
PRG4 gene expression via the increases secretion of PGE2 and PTHrP in chondrocyte (294).  
Fluid induced shear stress created by rocker plate has been shown to promote GAG and 
collagen secretion of human tenocyte monolayers culture (295) and collagen secretion of 
human progenitor cells (296). A rocker plate bioreactor can create shear environments to 
monolayer chondrocytes and increase nutrient and oxygen transfer by movement of the 
medium (233, 297). Subpopulation chondrocytes in articular cartilage experience different 
level of tension and shear stress. There is a report show that subpopulation chondrocytes 
differentially respond to stimuli created by oscillatory tensile loading (234). Nevertheless, 
there are no studies on the effect of fluid shear stress on human zonal chondrocyte 
subpopulations. This leads to the question which effect fluid induced shear stress will have on 
ECM molecule production in zonal chondrocyte subpopulations. 
We therefore hypothesized that fluid-induced shear stress produced by a rocker plate 
bioreactor affects the biosynthesis of zonal chondrocytes differently regarding their zonal 
origin. 
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The objective of this study was to determine the effects of fluid induced shear stress 
generated by a rocker plate bioreactor on human superficial (S) and middle deep (MD) 
chondrocyte subpopulations in high density monolayer culture. 
4.2 Materials and methods 
4.2.1 Chondrocyte isolation and cultivation and analysis 
Superficial (S) and middle deep (MD) chondrocytes were isolated from 3 knee replacement 
OA patients (298). After expansion for 2 passages as protocol in section 2.2, S and MD 
chondrocytes were resuspended in expansion medium consisted of LG-DMEM (Invitrogen) 
with 10% FBS (Lonza) and additives (details in section 2.2) and seeded on 24 well plates at 
200,000 cells/well. The chondrocyte seeded plates were kept in static condition for 8 h to 
allow the chondrocytes to attach before media was changed to serum-free chondrogenic 
medium (details in section 2.3). One sample set was cultured on a rocker plate bioreactor at 
the speed of 6 RPM and the angle of 15° 16 h a day, while the other sample set was kept 
under static condition. At day 14, three biological replicates from each patient were processed 
for RNA isolation. RNA was extracted from the each well using TRIzol (Invitrogen). After 
DNase treatment (DNase I, Invitrogen), cDNA was synthesized using SuperScript™ III first-
strand synthesis supermix for qRT-PCR (Invitrogen). All cDNA were analyzed for gene 
expression level in duplicate using Express SYBR GreenERTM qPCR supermix universal kit 
(Invitrogen) and a 7500 fast real-time PCR system (Applied Biosystems, CA, USA). The 
cycle threshold (Ct) value of each gene (ACAN, COL2A1, COL1A1, COL10A1 and PRG4) 
was normalized to the housekeeping gene (ΔCt), RPL13rRNA, using the comparative Ct 
method (2–ΔCt) (details in section 2.16). Two further replicates were processed for GAG 
(section 2.15) and Pico Green (DNA) assays (section 2.14), while the last sample was 
processed for FDA/PI staining (live/dead) assay (section 2.13) and for histological staining of 
GAG (Alcian blue staining in section 2.12.3). 
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4.2.2 Statistics 
SPSS (version 19.0) was used to perform the statistical analysis. Gene expression and GAG 
per DNA data obtained from both conditions are represented in bar graphs, showing the 
standard deviation from 6-8 samples (2-3 patients). Effects of rocker plate condition were 
tested using one-way analysis of variance (ANOVA). If significant differences were detected 
between conditions, Tukey’s post-hoc test was performed. For all tests, p < 0.05 was 
considered significant. 
4.3 Results 
4.3.1 Chondrocytes morphology and cell viability 
By day 14, chondrocytes were formed a cell layer on the surface of the well plate. The 
chondrocytes morphology under the microscope was shown in (Fig 4.1). Chondrocytes 
exhibited a round morphology at day 0, 8 hours after seeding (Fig 4.1 A, D). After 14 days of 
culture the cells had a mainly fibroblast appearance, with a few round shaped cells with 
matrix deposition (Fig 4.1 B, C, E, F) and completely cover the well area (Fig 4.5). There 
was no clear difference in cell morphology between superficial (S) and middle deep (MD) 
chondrocytes or between static and rocker plate cultures observed under the phase contrast 
microscope (Fig 4.1). 
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Figure 4.1: Chondrocyte morphology as observed under the phase contrast microscope 
(magnification 10 X). 
Superficial (S) (A-C) and middle deep (MD) (D-F) chondrocytes seeded at 105 cells/cm2 are 
shown at day 0 (A, D) and at day 14 in rocker plate culture condition (B, E) and static culture 
(C-F). 
Cell viability of chondrocytes cultured under static condition and a rocker plate is shown in 
Fig 4.2. Dead cells are sparsely distributed in both cell types and conditions, but no obvious 
difference between the groups was observed. Chondrocytes showed fibroblastic morphology 
both in S and MD but clearly seen in superficial chondrocytes.  
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Figure 4.2: Cell viability of high density seeded zonal chondrocytes (S and MD) after 14 days 
of culture. 
Fluorescence microscope 10X images show chondrocytes Live (FDA, A-D) and DEAD (PI, 
E-H) staining of S chondrocytes (A, C, E, G) and MD chondrocytes  (B, F, D, H) after 14 
days in static (A, B, E, F) and rocker plate (C, D, G ,H) culture. 
4.3.2 Gene expression 
After 14 days of cultivation, gene expression levels of ACAN, COL2A1, PRG4, COL1A1 and 
COL10A1 gene expression were not statistically different between the rocker plate group and 
the static control group p > 0.05 (Fig 4.3). However, chondrogenic gene expression of ACAN, 
COL2A1 (Fig 4.3 A, B) and the hypertrophy marker COL10A1 (Fig 4.3 E) showed the same 
trend in both superficial and middle deep zone chondrocytes towards slightly increased 
expression in the rocker plate group when compared to the static control group (P = 0.087, P 
= 0.16 and P = 0.096 respectively). COL1A1 gene expression (Fig 4.3 D) showed a trend of 
slightly elevated expression in MD chondrocytes compared to S chondrocytes (P=0.064). 
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Figure 4.3: Effect of fluid shear stress on gene expression levels. 
Chondrogenic (ACAN (A), COL2A1 (B), PRG4 (C)), fibroblastic (COL1A1 (D)) and 
hypertrophic (COL10A1 (E)) gene expression levels normalized to housekeeping gene RPL13 
in high density seeded (100,000 cells/cm2) chondrocyte subpopulation (S and MD). Rocker 
plate group (6 rpm, Rocker) compared to a static control group (Static) after 14 days of 
culture in serum-free chondrogenic media. Data represents the mean ± SD, n = 8 (3 patients) 
in the S and n = 6 (2 patients) in the MD samples. 
4.3.3 GAG and DNA content 
Fluid shear stress had no significant effect on the GAG content between experimental groups 
p > 0.05 (Fig 4.4). DNA content followed the same pattern in both S and MD chondrocytes 
(Fig 4.4 C). GAG content normalized to DNA revealed no significant differences in all 
groups and conditions after 14 days of culture (Fig 4.4). The level of GAG released to the 
media was not different with the GAG retain in the chondrocytes layer (Fig 4.4 B).  
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Figure 4.4: Effect of fluid shear stress on GAG and DNA content. 
Fluid shear induced changes in GAG content (in the cell sheets and secreted) and DNA 
content, as well as GAG/DNA in zonal chondrocyte subpopulations (S and MD) of high 
density monolayer culture. (A) GAG content per well (B), GAG released into the medium 
(C), DNA content per well and (D) GAG content normalized to DNA at day 14 of high 
density seeded (100,000 cells/cm2) chondrocyte subpopulations (S and MD) exhibited to fluid 
shear (Rocker) and static control (Static). Data represents the mean ± SD, n = 6 (3 patients) in 
the S and n = 4 (2 patients) in the MD samples. 
4.3.4 Histology 
Alcian blue staining showed a similar intensity in both static control and rocker plate cultures 
(Fig. 4.5). Also, no clearly visible differences could be determined between S (Fig. 4.5 A, C) 
and MD chondrocytes (Fig. 4.5 B, D). Among all tested groups, a stronger staining intensity 
was found in the center of the well when compared to the outer areas of the well. 
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Figure 4.5: Alcian blue staining of subpopulation chondrocytes. 
Alcian blue staining of high density seeded superficial (A, C) and middle deep (B, D) 
chondrocytes after chondrogenic differentiation for 14 days in static (A, B) and rocker plate 
(C, D) cultures. 
4.4 Discussion 
We chose a high cell density model to study the effects of fluid shear on zonal chondrocyte 
subpopulations as the cells are directly exposed to the moving media and directly subjected to 
fluid shear stress. Chondrocytes cultured in hydrogels however, are surrounded by a matrix 
and therefore not directly subjected to fluid shear stress generated by a rocker plate bioreactor. 
Chondrocytes in high cell density seeding when directly exposed to the fluid induced shear 
stress might potent activated mechanotransduction signal when compared to chondrocytes 
embedded in hydrogel or extracellular matrix. We chose to use a rocker plate as a simple and 
accessible bioreactor to study the effect of shear stimuli. More defined studies could be 
performed in the future with more sophisticated parallel-plate bioreactors with specified shear 
stresses (299). In this experiment, we chose the culture conditions with 8 h rocker plate off 
time to mimic the general human activity with has 8 h rest. The low speed rocker plate 
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protocol (6 RPM) has been used to increase the medium perfusion to cells and scaffold on 
osteogenesis experiments in our laboratory. Additionally, the low speed rocker plate protocol 
has been recently reported to increase matrix synthesis of tenocytes (295). A culture time of 
14 days was chosen as the time is sufficient to observe changes in protein, 
glycosaminoglycan, lipid and mineral content. 
The analysis of chondrogenic gene expression for ACAN and COL2A1, no statistical 
significant differences could be determined among all tested groups (Rocker plate S and MD 
chondrocytes, static control plate S and MD chondrocytes). Also, GAG/DNA (Fig 4.4 D) and 
Alcian blue staining (Fig 4.5) revealed no significant differences between the rocker plate and 
the static control groups (Fig 4.3A). These results suggest that fluid induced shear stress 
created by a rocker plate bioreactor in this experiment does not have a significant effect on 
chondrogenesis of chondrocytes seeded in high density monolayer culture. A possible 
explanation could be the relatively low velocity used for the experimental rocker plate group 
of 6 rpm 16 h a day for 14 days and cloud not created optimal direct mechanotransduction 
effect. Nevertheless, the trends of slightly elevated chondrogenic gene transcript levels in the 
shear exposed groups were likely to be due to the improved transport of nutrients and oxygen 
to the cells.  
In addition, analysis of GAGs secreted into the medium by high density seeded chondrocytes 
revealed that only about the half of GAGs produced were retained in the cell sheet (see Fig 
4.4 A, B). An application of this model for cartilage tissue engineering purposes may 
therefore not be suitable as produced matrix molecules are not retained in the cell sheet.  
Although previous work reported the benefits of dynamic contact shear stress on PRG4 gene 
expression (214, 215), a PRG4 promoting effect was not induced by fluid shear stress on 
chondrocytes seeded in high density in our study. A possible explanation might be the 
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difference shear stress type and the model that is used in this study. Chondrocytes in this high 
cell density seeding model are in direct contact with the moving medium which exerts shear 
stress to the cells without any extracellular matrix to transfer the shear stimuli. As previously 
reported by Grad, et al., PRG4 gene expression was increased in response to shear stress in 
hydrogel encapsulated chondrocytes (215). It is possible that shear stress directed to 
chondrocytes may activate an alternate signal transduction pathway compared to tissue shear 
stress, which deforms the ECM and the PCM surrounding the cells. 
Alternatively, chondrocytes in this model may not completely exhibit a chondrogenic 
phenotype, as evidenced by the presence of fibroblastic chondrocytes at day 14 of cultivation 
(Fig. 4.2 A-D). Our data do not include gene expression levels at day 0, however, thus 
limiting the understanding of overall chondrogenesis present in the cultures. Fibroblasts 
themselves have been reported to increase collagen production in osteogenic medium and 
significantly increased collagen production in rocker plate culture compared to static control 
(296).  
In this high density model system, as opposed to traditional monolayer culture, some cells 
attach to tissue culture plastic (fibroblast phenotype) while others appear round in a 
chondrogenic phenotype. Nevertheless, particularly after 14 days of culture in serum-free 
chondrogenic media, fibroblastic morphology was found in all conditions and S and MD cells 
which leads to the conclusion that the cells did not redifferentiate completely and behave like 
fibroblasts, which is also supported by the relatively high collagen type I transcript levels and 
low expression of chondrogenic marker genes (Fig. 4.3). It should be added that only a few 
round cells were visible in the microscopic images, while most of the cells exhibited a 
fibroblastic phenotype (Fig. 4.2) which may lead to an overall decrease of chondrogenic gene 
expression in this model system. Taken together, these results suggest that in this model 
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system zonal chondrocyte subpopulations do not respond differently to fluid-induced shear 
stress. 
Previous studies demonstrated that fluid shear stress can induce apoptosis in monolayer 
chondrocytes at higher shear stress levels (300). However, cell death was not increased by 
fluid shear in this study (Fig. 4.2) that might indicate the low shear stress level of our regimen.  
In conclusion, fluid induced shear stress created by a rocker plate at 6 RPM for 16 h a day for 
a culture period of 14 days did not result in statistically significant effects on redifferentiation 
of high density seeded chondrocytes in our study. Therefore, it is not surprising that no 
statistically relevant differences of chondrogenic markers (ACAN, COL2A1, PRG4 gene 
expression, GAG per DNA and GAG staining) were found for S and MD chondrocytes in 
both, static and rocker plate conditions. The extensive reviews on the effect of fluid induced 
shear stress on bone cells showed that bone cell response to fluid induced shear stress 
dependence on flow regimes, cell type and soluble factors (301). The protocol for shear 
stimuli application to high density monolayer, including the speed of the rocker plate and the 
duration, needs to be optimized in order to enhance chondrocyte redifferentiation and 
improve ECM molecule production and retention in vitro. Also, the protocol may be further 
improved by a combination of this model system with culture conditions such as low oxygen 
tension (227, 274) which contribute to chondrogenic redifferentiation of cells in vitro, as 
media movement may provide an enhanced transport of nutrients and oxygen to cells in tissue 
engineered constructs.  
Alternatively, chondrocytes could be encapsulated in hydrogels and exposed to dynamic 
contact shear stress (supporting this, cyclic matrix deformation was proven to be a key 
stimulator for ECM molecule gene expression in cartilage explants (302) and could have a 
similar effect on tissue engineered constructs (303) instead of fluid induced shear in this 
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model system. Therefore, the effects of dynamic contact shear on hydrogel encapsulated 
chondrocytes are currently being examined by another PhD student in our group.  
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CHAPTER 5 : THE POTENTIAL OF DECELLULARIZEDBOVINE 
CARTILAGE POWDER FOR CARTILAGE TISSUE ENGINEERING 
 
5.1 Introduction 
Since articular cartilage has a poor self-repairing capacity, many repair techniques have been 
developed to treat the cartilage injury. These include microfracture, osteochondral autograft 
transplantation, and autologous chondrocyte implantation (304). However, these techniques 
generally result in tissue with inferior properties compared to native hyaline cartilage tissue. 
Tissue-engineered cartilage which combines cells, a scaffold, and growth factors is an 
additional approach to create replacement tissue to repair cartilage defects. Central to 
scaffold-based tissue engineering is the recreation of a 3D extracellular substrate that mimics 
the natural ECM environment of that tissue. The ECM is important for tissue function as it 
provides critical mechanical properties as well as signals to the resident cells (305, 306). The 
ECM contained within cartilage is secreted and maintained by chondrocytes. 
ECM-derived scaffolds are increasingly attractive for tissue engineering and have been 
successfully used in tissue engineering paradigms in both preclinical studies and clinical 
studies such as skin (188), small intestinal submucosa (307), and heart valve (189). A healthy 
autologous source of ECM is preferred to avoid a significant host immune response. However, 
for cartilage tissue engineering, it would be detrimental to remove a small amount of healthy 
cartilage from patients suffering from OA, creating new defects in tissue that is normally 
limited in its ability to heal. Allogeneic or xenogeneic are the other potential sources of 
cartilage ECM; however this tissue will induce a host immune response. In addition, safety 
and efficiency of using allogeneic or xenogeneic are questionable (121).  
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A main barrier to xenogeneic transplantation is the presence of natural antibodies in the 
human host to the surface xenoantigens such as galactose -α-(1, 3)-galactose (Gal epitope) 
that cause hyperacute rejection (308). There are reports that decellularization of ECM reduces 
the immunogenicity of the tissue, which is useful for clinical application such as in a vascular 
tissue (309) and liver (310). Decellularized cartilage ECM, which reduces the immunogenic 
cellular component, has shown good biocompatibility for the growth of chondrocytes (311). 
In addition, there are the studies that show chondrocytes adhere to freeze-thawed 
extracellular matrix and synthesize new cartilage matrix both in vitro and in vivo (312, 313). 
However decellularized cartilage matrix has not been widely studied because cartilage is a 
dense tissue, from which it is difficult to remove the cell component. Pulverization of 
cartilage into a powder form might be useful in facilitating removal of the cellular 
components from ECM, as the small size of the ECM particles and more exposed area to 
decellularization reagent allows for rapid infiltration of decellularized reagent to the 
chondrocytes and ECM compounds. However, the pulverization and decellularization of 
cartilage may also change the biochemical composition and ultrastructures of the ECM which, 
in turn may affect the cellular response. 
Cartilage has anisotropic architecture with “zonal” regions that differ in composition and 
function. While some success is reported for tissue-engineered cartilage, these natural and 
synthetic scaffolds are predominantly isotropic and do not effectively mimic the nature of 
zonal cartilage. This is an important issue, as chondrocytes in the different zones of cartilage 
are subjected to different types of mechanical stimuli, oxygen tension, biochemical 
composition and ultrastructures of ECM. Additionally the chondrocytes in different zones 
secrete different levels of biological factors. For example, superficial chondrocytes produce 
more PRG4 than middle and deep zone chondrocytes, while the middle and deep zone 
chondrocytes produce more GAG than superficial chondrocytes (10). Due to these significant 
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regional differences within cartilage, an ideal scaffold should reflect this zonal structure to 
provide specific environments to the chondrocytes.  
We hypothesized that pulverization of bovine cartilage into a powder will enable the 
extraction of the cellular component, and this decellularized cartilage will provide a similar 
effect to non-decellularized cartilage for chondrocyte chondrogenesis. Additionally, using 
decellularized cartilage ECM from each zone of cartilage will promote the zonal 
chondrogenesis of chondrocytes from their respective zones. 
Therefore, the first aim of this study was to determine the effect of decellularized bovine 
cartilage on human chondrocyte chondrogenesis compared to non-decellularized bovine 
cartilage. The second aim was to determine the effects of zonal decellularized bovine 
cartilage on zonal chondrocyte chondrogenesis.  
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5.2 Materials and methods 
An overview of the experimental design is shown in Fig 5.1. Briefly, bovine cartilage was cut 
and pulverized to make cartilage powder, as described in section 2.6. Half of the cartilage 
powder was then decellularized. Human full-thickness chondrocytes were isolated (as 
described in section 2.2.) and mixed with native or decellularized cartilage powder, or 
without cartilage powder as a no ECM control. Chondrocytes with and without ECM were 
spun down to form pellets and were cultured in serum-free chondrogenic medium for 14 days 
and then terminated for analysis. 
 
Figure 5.1: Overview of the experimental design for the first chondrogenic differentiation 
experiment. 
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5.2.1 Decellularization of bovine cartilage 
For the first experiment, the cartilage powder was weighed and decellularized by incubated in 
2% SDS included 0.5 mg/mL DNase Type I (Sigma), 50 μg/mL RNase A (Invitrogen), 
0.02% EDTA, and 1% P/S (Invitrogen), in PBS at 37°C at the concentration of 0.05 g/mL 
with agitation for 8h (193, 199). Following the SDS treatment, the constructs were washed 
with 10x the volume of PBS for 2 h at 37°C with agitation, then washed five more times with 
PBS without incubation at 37°C. Finally, the supernatant was checked with a pH paper to 
ensure the pH was the same as PBS. PI staining was used to check DNA residual in the 
decellularized cartilage as details described in section 2.8. The decellularized cartilage ECM 
was resuspended in standard chondrogenic medium without TGF-β 3 and ascorbic acid as 
described in section 2.3 and stored at 4°C until use. 
For the second experiment, one more step was added before the decellularization step and 
one additional washing step was added to improve the decellularized process as detail 
described in section 2.6.  
5.2.2 Chondrogenic differentiation for the first experiment 
Chondrocytes isolated from OA patients passage 1, 250,000 cells/pellet were mixed with 
naturals bovine cartilage powder or decellularized cartilage powder (4 mg/pellet) and 
cultured in serum-free chondrogenic medium as described in Section 2.3. The mixture was 
then added into 96 well PCR plates (Micro AMP fast optical) and centrifuged at 500 g for 5 
min to form pellets. Pellets were cultured for 14 days at 37 °C, 5 % CO2 with chondrogenic 
medium changes every other day. The chondrogenic gene expression, live dead assay and 
histology of the cartilage powder-chondrocytes pellet was analyzed and compared with 
chondrocyte-only pellet at Day 14 (Fig 5.1) as the protocol described in section 2.16, 2.13 
and 2.12.2 respectively. 
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5.2.3 Chondrogenic differentiation for the second experiments 
Superficial, middle deep and full-thickness chondrocytes (Passage 2, 250,000 cells/pellet) 
from three OA patients were mixed with the pooled decellularized superficial, middle deep 
and full-thickness ECM from four bovines at the concentration of 2 mg/pellet, and pellets 
were formed, as 5.2.2. The experimental groups were divided into 5 different groups: 1) 
superficial chondrocytes with superficial ECM (SS), 2) full-thickness chondrocytes with 
superficial ECM (FS), 3) middle deep chondrocytes with middle deep ECM (MM), 4) full-
thickness chondrocytes with middle deep ECM (FM) and 5) full-thickness chondrocytes with 
full-thickness ECM (FF) (Fig 5.2). The chondrocytes ECM pellets were cultured for 28 days. 
The chondrogenic medium was replaced every other day. At day 28, duplicate samples from 
each group were analyzed for chondrogenic gene expression, GAG and DNA assays 
histology and live dead assay as the protocol described in section 2.16, 2.15, 2.14, 2.12.2 and 
2.13 respectively. The control was the superficial, middle deep and full-thickness 
chondrocytes pellet without ECM. ECM pellets were frozen and lyophilized prior to digest 
with 0.5 mg/mL proteinase K solution (Invitrogen) for GAG and DNA assays. 
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Figure 5.2: Overview of the experimental design for the second chondrogenic differentiation 
experiment. 
S = Superficial, M = Middle deep and F=Full-thickness. 
5.2.4 Histology and gene expression 
Samples were stained with Alcian blue for the presence of glycosaminoglycans (GAGs), as 
described in 2.12.2. Immunofluorescence was used to detect the collagen type I, collagen 
type II, aggrecan and PRG4 produced from the chondrocytes follow the protocol described in 
section 2.12.4. 2.5% normal horse serum (Vector laboratories, Burlingame, CA, USA) was 
used for blocking non-specific staining. Polyclonal mouse anti human ACAN (1:100; 
ABI031, Millipore) was used. The controls were performed by omitting the primary 
antibody. All histological sections were observed with a fluorescence microscope (Axio 
Imager M2, Zeiss) 
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Quantitative Real Time PCR was performed in a 7500 fast real-time PCR system (Applied 
Biosystems, CA, USA). The cycle threshold (Ct) value of each gene was normalized to the 
housekeeping gene (ΔCt), RPL13rRNA, using the comparative Ct method (2–ΔCt), as 
described in section 2.16. 
5.2.5 Statistics 
SPSS (version 19.0) was used to perform the statistical analysis. Gene expression and GAG 
per DNA data obtained from all groups are represented in a bar graph, showing the variations 
from 3-8 samples (1 patient) in the first experiment and 4-6 samples (2-3 patients) in the 
second experiment. Effects of ECM additive condition were tested using ANOVA for all tests; 
p < 0.05 was considered significant. 
5.3 Results 
5.3.1 Characterization of decellularization process 
Residual DNA content decreased from 0 - 48 h of decellularization, as shown by PI staining 
(Fig 5.3 A-H). Decellularized cartilage powder showed no DNA present by PI staining at 48 
h (Fig 5.3 H). 
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Figure 5.3: Propidium Iodide (PI) staining of cartilage powder to show DNA content after a 
range of times in decellularization solution. 
PI staining following 0 h (A), 2 h (B), 4 h (C), 8 h (D), 12 h (E), 24 h (F), 36 h (G) and 48 h 
(H) after decellularization. DNA content in the decellularized ECM decreased with time in 
the decellularization solution. No DNA was observed after 48 h of decellularization.  
After 14 days in chondrogenic medium in the first experiment, ECM formed a loose pellet 
both in native cartilage ECM and decellularized ECM. The pellet diameters in the 
chondrocyte pellets, the chondrocyte with native ECM pellets and chondrocyte with 
decellularized ECM pellets are 1.17+0.13 mm, 2.25+0.31 mm and 2.66+0.35 mm 
respectively (Fig 5.1). However, all the pellets were mechanically weak, with some pellets 
broken when handling those using forceps. 
5.3.2 Cell viability for the first experiment 
FDA/PI staining showed that the viable chondrocytes were not homogeneously distributed in 
the pellets (Fig 5.4 A, D) and the viable chondrocytes density was low in both the ECM 
additive groups (Fig 5.4 B, E and C, F). In the control pellets, at the surface the vital 
chondrocytes, which stained by FDA were found at the area close to the margin (Fig 5.4 A) 
and the dead cells which stained by PI were found at the area closed to the center (Fig 5.4 D). 
110 
 
 
Figure 5.4: Cell viability with Fluorescein diacetate (A-C)/Propidium iodide (D-F) (FDA/PI). 
Live dead staining after 14 days in chondrogenic medium, chondrocytes showed low viability 
in the Full-thickness chondrocytes pellet (A, D), Full-thickness chondrocytes with native 
ECM pellet (B, E) and Full-thickness chondrocytes with decellularized ECM pellet (C, F). 
Fluorescence was observed under a Nikon Eclipse epifluorescence microscope at 4X. 
5.3.3 Histology for the first experiment 
GAG was detected by Alcian blue staining in all pellets and the chondrocytes plus native 
ECM pellets showed strongly positive staining. The chondrocyte/ECM ratio was low in both 
ECM-adding groups when compared to chondrocytes control pellet. The chondrocytes fairly 
homogeneously distributed in both ECM-adding groups. 
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Figure 5.5: Alcian blue staining showing GAG distribution. 
Alcian blue staining after 14 days in chondrogenic medium for pellets using full-thickness 
chondrocytes without ECM (A), with native ECM (B) and with decellularized ECM (C). 
5.3.4 Gene expression for the first experiment 
After14 days in vitro, aggrecan gene expression showed a trend of down-regulation in ECM 
additive groups compared to the chondrocytes control pellets group, but the significant 
difference was found only in the native ECM additive group when compared to pellet control 
group (p < 0.05) (Fig. 5.6). There were no significant differences between the native ECM 
additive group and the decellularized ECM additive group. There were also no significant 
differences in COL2A1 and COL1A1 gene expression between any groups. 
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Figure 5.6: Effect of bovine ECM on full-thickness chondrocytes gene expression levels of 
ACAN, COL2A1, and COL1A1. 
Chondrogenic genes, ACAN (A), COL2A1 (B) and fibroblastic gene, COL1A1 (C) expression 
normalized to housekeeping gene (RPL13) at day 14 in serum free chondrogenic medium. X 
= Full-thickness chondrocytes control pellet (n = 3), N = Full-thickness chondrocytes with 
native bovine ECM pellet (n = 8), and D = Full-thickness chondrocytes with decellularized 
bovine ECM pellet (n = 6). P < 0.05(*) was considered significant. 
From the first experiments, there were no statistical differences in chondrogenic gene 
expression and fibroblastic gene expression of the decellularized and native ECM additive 
group. The results indicate that decellularized bovine ECM can be used as a scaffold for in 
vitro cartilage tissue engineered the same as native bovine ECM. Therefore, the second 
experiment studied only the effect of decellularized bovine ECM.  
5.3.5 Pellet morphology and cell viability 
The effect of zonal ECM was analyzed from superficial and middle deep chondrocytes mixed 
with ECM from their zone compared to full-thickness chondrocytes mixed with ECM from 
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each zone and full-thickness chondrocytes mixed with full-thickness ECM. Because the 
pellets with ECM in first experiment were not entirely cohesive, the second experiment was 
designed to reduce the amount of ECM from 4 mg/pellet to 2 mg/pellet and increase the 
culture time from 14 days to 28 days. After culture for 28 days, the chondrocyte ECM formed 
firm pellets unlike weak formed pellets in the first experiment. The pellet size for the ECM 
additive groups were bigger than chondrocyte control pellets as shown in Fig 5.7. 
 
Figure 5.7: Chondrocyte pellets at day 28 under the phase contrast microscope (4X). 
Superficial chondrocytes (A), Middle deep chondrocytes (B), Full-thickness chondrocytes 
(C), Superficial chondrocytes with superficial ECM (D), Full-thickness chondrocytes with 
superficial ECM (E), Middle deep chondrocytes with middle deep ECM (F), Full-thickness 
chondrocytes with middle deep ECM (G), Full-thickness chondrocytes with full-thickness 
ECM (H). 
FDA/PI staining showed that the chondrocytes viability was high in all pellets (Fig 5.8). The 
vital chondrocytes were homogeneously distributed in the pellet. There were no obvious 
differences among the groups. 
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Figure 5.8: Cell viability with fluorescein diacetate (A-E)/propidium iodide (F-J) (FDA/PI). 
After 28 days in chondrogenic medium, chondrocytes showed high viability in the ECM 
chondrocytes pellets: (A, F) Superficial chondrocytes with superficial ECM, (B, G) Full-
thickness chondrocytes with superficial ECM, (C, H) Middle deep chondrocytes with middle 
deep ECM, (D, I) Full-thickness chondrocytes with middle deep ECM, (E, J) Full-thickness 
chondrocytes with full-thickness ECM. Fluorescence was observed under a Nikon Eclipse 
epifluorescence microscope at 4X. 
5.3.6 Gene expression 
When comparing to control superficial chondrocyte pellets, the ECM additive pellets had 
significantly increased ACAN gene expression of superficial chondrocytes in superficial ECM 
and middle deep chondrocytes in the middle deep ECM (Fig 5.9 A). For the group of full-
thickness chondrocytes mixed with full-thickness ECM, the ACAN gene expression was not 
different to full-thickness chondrocytes without ECM additive (Fig 5.9 A). COL2A1 gene 
expression, another common marker for chondrocyte chondrogenesis was not statistically 
different between groups (Fig 5.9 B). PRG4 gene expression, which is a superficial 
chondrocyte marker, was expressed more highly by superficial chondrocyte than the middle 
deep and full-thickness chondrocytes, and the highest gene expression was shown in the 
superficial cells mixed with superficial ECM. The PRG4 gene expression in superficial cells 
mixed with superficial ECM was statistical difference with all of the other groups (Fig 5.9 C). 
The fibroblastic marker, COL1A1, gene expression, was not significantly different in all 
groups (Fig 5.9 D). The hypertrophic marker, the COL10A1, showed the converse trend to 
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chondrogenic gene expression. Full-thickness chondrocytes mixed with the superficial ECM 
had the highest COL10A1 gene expression, when compared to the other groups, and the 
expression was statistically different to superficial chondrocyte mixed with superficial ECM, 
middle deep chondrocytes mixed with middle deep ECM, full-thickness chondrocytes mixed 
with full-thickness ECM and superficial chondrocytes and full-thickness chondrocytes 
without any ECM additive (Fig 5.9 E). 
 
Figure 5.9: Effect of bovine zonal ECM on subpopulation chondrocytes gene expression 
levels. 
Chondrogenic (ACAN (A), (COL2A1 (B), PRG4(C)), fibroblastic (COL1A1 (D)) and 
hypertrophic (COL10A1 (E)) gene expression at day 28 normalized to housekeeping gene 
(RPL13) in 8 groups of pellets. S-NoECM = Superficial chondrocytes no ECM added, MD-
NoECM = Middle deep chondrocytes no ECM added, F-NoECM = Full-thickness 
chondrocytes no ECM added, S-SECM = Superficial chondrocytes with superficial ECM, F-
SECM = Full-thickness chondrocytes with superficial ECM, MD-MDECM = Middle deep 
chondrocytes with middle deep ECM, F-MDECM = Full-thickness chondrocytes with middle 
deep ECM, F-FECM = Full-thickness chondrocytes with full-thickness ECM. Data represent 
mean ± SD (n = 4-6, 3 patients). P<0.05 (*) was considered significant. 
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5.3.7 GAG and DNA content 
GAG in the pellets after 28 days of culture was determined to evaluate the effect of ECM 
additives on the overall matrix level. GAG levels showed the same trend with the ACAN 
gene expression (Fig 5.10 A). GAG levels were significantly higher in the chondrocytes 
mixed with their own environment both superficial chondrocytes mixed with superficial 
ECM and middle deep chondrocytes mixed with middle deep ECM when compared to 
superficial chondrocyte and middle deep chondrocytes, respectively. In addition, middle deep 
chondrocytes mixed with middle deep ECM was significantly different with superficial 
chondrocyte. The level of GAG in full-thickness chondrocyte pellets was not statistically 
different with full-thickness chondrocytes mixed with any type of ECM (Fig 5.10 A). The 
level of DNA in pellets was not statistically different between groups (Fig 5.10 B). The 
results show that superficial chondrocytes in superficial ECM, middle deep chondrocytes in 
middle deep ECM and full-thickness chondrocytes in full-thickness ECM have significantly 
more GAG/DNA when compared to superficial chondrocytes pellet and the superficial 
chondrocytes in superficial ECM, middle deep chondrocytes in middle deep ECM and full-
thickness chondrocytes in full-thickness ECM also have significant difference GAG /DNA 
when compared to full-thickness chondrocyte pellets (Fig 5.10 C). However, the GAG and 
DNA level of each type of ECM at day 0 and day 28 do not determine in this experiment. 
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Figure 5.10: Effect of bovine zonal ECM on subpopulation chondrocyte GAG and DNA 
content. 
A) GAG content per pellet (B) DNA content per pellet, and (C) GAG content normalized to 
DNA in 8 groups of pellets after 28 days of culture. S-NoECM = Superficial chondrocytes no 
ECM added, MD-NoECM = Middle deep chondrocytes no ECM added, F-NoECM = Full-
thickness chondrocytes no ECM added, S-SECM = Superficial chondrocytes with superficial 
ECM, F-SECM = Full-thickness chondrocytes with superficial ECM, MD-MDECM = 
Middle deep chondrocytes with middle deep ECM, F-MDECM = Full -thickness 
chondrocytes with middle deep ECM, F-FECM = Full-thickness chondrocytes with full-
thickness ECM. Data represent mean + SD (n = 6, 3 patients). P<0.05(*) was considered 
significant. 
5.3.8 Histology and immunofluorescence 
After 28 days in chondrogenic medium, Alcian blue staining and immunofluorescence was 
performed for all ECM additive pellet groups. Alcian blue stained all pellets. The 
chondrocyte distribution appeared homogeneous in all chondrocyte ECM pellets (Fig 5.11 
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A1-A5). Immunofluorescence was used to detect aggrecan, collagen type II, PRG4 and 
collagen type I secreted from chondrocytes in the pellets. 
Aggrecan was detected in all chondrocyte ECM groups. However, there were difficulties to 
detect different levels of aggrecan in the pellets because all chondrocyte ECM pellets have 
the bovine ECM, which can stain by the aggrecan polyclonal antibody (Fig 5.11 B1-B5). 
Collagen type II was strongly positive in the bovine ECM additive in the pellets. The strong 
positive collagen type II stained in ECM might obscure the staining of chondrocytes, as there 
seems to have a low secretion of the collagen type II, when compared to the amount of 
collagen type II in the ECM additive (Fig 5.11 C1-C5). 
PRG4 was marginally detected in all of the ECM additive constructs (Fig 5.11 D1-D5). 
Collagen type I was slightly positive in all groups (Fig 5.11 E1-E5). The least staining was in 
the superficial chondrocytes mixed with the superficial ECM group (Fig 5.11 E1). The 
magnify figure of each individual with specific fluorescence staining is shown in each inset 
figure. 
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Figure 5.11: Alcian blue and immunofluorescence images of various collagenous proteins of 
ECM additive pellet groups. 
Chondrocytes pellets at day 28 stained with Alcian blue counter stained with Nuclear-fast red 
(A) and immunofluorescence, Aggrecan (B), collagen type II (C), PRG4 (D) and collagen 
type I (E) for all ECM additive pellet groups: Superficial chondrocytes with superficial ECM 
(1), Full-thickness chondrocytes with superficial ECM (2), Middle deep chondrocytes with 
middle deep ECM (3), Full-thickness chondrocytes with middle deep ECM (4), Full-
thickness chondrocytes with full-thickness ECM (5). The figure insets are 7 x magnifications 
corresponding to the 10 µm scale bar in E5. DAPI (blue) was used to stain nuclei, and Alexa 
633 (red) was used to stain the matrix molecules.  
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5.4 Discussion 
ECM, which provides the natural structural and anchoring support to the resident cells, also 
provides the signals to direct cell fate and function through the cell–matrix interactions (314). 
Instead of searching for the natural or synthetic material that mimics the nature of articular 
cartilage scaffold, we studied the possibility of using the decellularized cartilage ECM from 
the animal sources as scaffold for zonal cartilage tissue engineering in vitro. Our 
collaborators have recently reported that the human chondrocytes in combination with 
pulverized native human ECM enhanced their chondrogenic gene expression and the 
pulverized cartilage is well integrated into cartilage constructs after 14 days of cultivation 
(315). To use the animal ECM in the cartilage tissue engineering, the cellular part of the 
cartilage might activate the immune response of the host cells. Therefore, we decellularized 
the cartilage to remove the immune stimulating components. The decellularization protocol 
was slightly modified from the work of Elder, that was used to decellularize bovine calf 
cartilage explants (193).  
The first experiment was set up to determine if decellularized ECM and native ECM have the 
same effect on chondrocyte chondrogenesis when compared to conventional control pellet. 
The results seem to support the hypothesis that decellularized ECM which is extensively 
processed with physical and chemical reagents, behaves similarly to native cartilage in terms 
of affecting chondrocytes gene expression. For example, we did not find statistical 
differences of ACAN, COL2A1 and COL1A1 gene expression between groups with native 
bovine cartilage and decellularized bovine cartilage. 
 Although, we found that native and decellularized ECM showed a trend to lower aggrecan 
gene expression than control pellets, this might be due to use of a ratio of ECM to cells that 
was too high, which limited nutrient and growth factor transport, as found in large micromass 
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culture systems (316). In addition, the large quantity of added ECM adding resulted in large 
pellets, which were difficult to handle. Therefore, we was reduced the amount of ECM by 
half and increased the time of cultivation to 28 days in subsequent experiments; this led to 
well-integrated and firm cell-ECM pellets (Fig 5.7). Additionally, the chondrocyte 
distribution of the pellet after reduced amount of the ECM adding was homogeneous and 
chondrocyte viability was high (Fig 5.8). 
Superficial chondrocyte subpopulations mixed with their own ECM appeared to be the most 
favorable condition for zonal chondrogenesis of the superficial zone. These conditions 
showed a trend of higher ACAN gene expression than superficial chondrocyte without ECM 
additive (Fig 5.9 A). Also, the positive effect of zone-specific ECM on superficial 
chondrocyte gene expression (PRG4) was also demonstrated, as the highest gene expression 
was also found in the superficial chondrocytes mixed with the superficial ECM (Fig 5.9 C). 
These finding suggests the potential use of zone-specific ECM as a scaffold for zonal 
cartilage tissue engineering especially for superficial zone of cartilage. 
The results on the superficial chondrocytes marker and chondrogenic marker seem to show 
the low competence of the full-thickness chondrocyte mixed with the zone-specific ECM 
compared to zone-specific chondrocytes. However, PRG4 localization by 
immunofluorescence staining in all ECM additive groups, despite differences in PRG4 gene 
expression (Fig 5.11 D). These results might be due to lack of retention of PRG4 in the 
matrix, or post-translational modifications (317).  
The use of full-thickness chondrocytes with the superficial zone ECM led to the up-
regulation of the hypertrophic gene. However, the use of full-thickness chondrocytes with the 
middle deep zone ECM does not show the effect. The full-thickness chondrocytes that 
majority might be middle deep chondrocytes by ratio may lead to the effect of using full-
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thickness chondrocytes with middle deep ECM or full-thickness ECM does not show any 
significant differences. These in vitro results suggest that the zone-specific chondrocytes may 
be the preferable cell choices for zonal cartilage tissue engineering instead of the commonly 
used full-thickness chondrocytes especially in the superficial zone because the chondrocytes 
use with the zone specific ECM do not show any significant difference on up regulation of 
unwanted gene COL10A1, while full-thickness chondrocytes mixed with superficial ECM 
show the highest gene expression. 
GAG level of superficial chondrocytes mixed with superficial ECM support the ACAN gene 
expression. Also, the GAG level in full-thickness chondrocyte pellets was not statistically 
different with full-thickness chondrocytes mixed with any type of ECM (Fig 5.10 A) and 
DNA level in the pellets was not statistically different between groups (Fig 5.10 B). These 
results seem to indicate that GAG and DNA retained in each type of decellularized ECM 
have less interference effect on GAG and DNA level of the ECM additive pellet. These may 
be due to decellularized protocol complete eliminating GAG and DNA of the decellularized 
ECM. Therefore, GAG and DNA level in the chondrocyte ECM pellet seem to reflect the 
chondrocyte activity. Superficial chondrocyte and full-thickness chondrocyte mixed with the 
same superficial ECM, but only superficial chondrocyte have significant differences of 
GAG/DNA when compared to superficial and full-thickness chondrocyte pellet. Also middle 
deep chondrocyte and full-thickness chondrocyte mixed with the same middle deep ECM 
show the same pattern. These seem to indicate the superior GAG production of specific zone 
chondrocyte mixed with own zone ECM compared to full-thickness chondrocyte mixed with 
the same ECM. However, lack of the GAG and DNA level of ECM only pellets at Day 0 and 
Day 28 leaves the interpretation of GAG and DNA of the chondrocytes ECM pellets is 
questionable and it is a limiting of this experiment. 
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The clinical application of pulverized decellularized bovine cartilage is not limited just for 
use as a scaffold for cartilage tissue engineering in vitro; it may be possible to use this 
approach to improve the ACI treatment in OA patients. ACI has been successfully clinically 
applied for cartilage defect treatment. However, a large number of chondrocytes is required 
to fill large defects (141, 318). The pulverized and decellularized ECM may mix with the 
other filling material such as fibrin glue or platelet rich plasma (PRP) with or without cells 
and be used as an injectable paste to fill the cartilage defect. In addition, chondrocytes can be 
obtained from minced fresh patient cartilage and mixed with the pulverized and 
decellularized ECM. The pulverized ECM can increase the volume of the filling material and 
reduce the number of chondrocytes needed to fill the defect. In addition, the ECM additive in 
the defect might reduce the healing time of the cartilage defect in patient. The idea of using 
minced tissue was support by the successfully use of bone paste in the bone fracture 
treatment (319). For cartilage restoration, the Cartilage Autograft Implantation System 
(CAIS), in which fresh minced patient cartilage is placed on scaffold and defect area using 
fibrin glue, showed promising result in clinical trials (320). This product uses minced 
cartilage as a cell source for cartilage repair. Minced fresh patient cartilage as a chondrocyte 
source may be applied in the future with allo- or xeno-cartilage powder as a scaffold for one-
step operation ACI treatment. BioCartilage®, micronized allogeneic cartilage, is available for 
implantation with PRP in a microfracture defect (321). However, the uses of xeno-cartilage 
are needed future extensive study. 
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CHAPTER 6 : THE POTENTIAL OF DECELLULARIZED BOVINE 
CARTILAGE POWDER AND ALGINATE IN A FULL-THICKNESS 
DEFECT MODEL FOR IN VITRO ZONAL CARTILAGE TISSUE 
ENGINEERING 
 
6.1 Introduction 
Articular cartilage is a connective tissue with only limited capacity for self-repair once it is 
damaged (322). As an alternative to existing surgical methods, cartilage tissue engineering is 
a promising approach to treat local defects using cultured cells, biochemical signals and 
biomaterial scaffolds. The properties of these scaffolds are of crucial importance for 
successful in vitro engineering of this avascular and a neural tissue. In native cartilage, 
chondrocytes are surrounded by an abundant extracellular matrix (ECM) which varies in 
composition, structure and its mechanical properties throughout the depth (323). Currently, 
there is no natural or synthetic scaffold that completely mimics the ECM of cartilage. 
However, the cartilage environment clearly plays a significant role in influencing 
chondrocyte behavior (324). A scaffold derived from the ECM of cartilage may therefore 
provide a specific environment similar to native tissue and improve redifferentiation and 
ECM molecule production by encapsulated cells 
Decellularized tissue has been used previously as a scaffold for tissue engineering for 
different tissues including skin (325), blood vessels (326) and urinary bladder (327). ECM-
derived scaffolds have also been studied for their benefits in cartilage tissue engineering both 
in vitro and in animal models (209, 210), where production and retention of GAGs was 
significantly increased with time. Additionally, a porous scaffold derived from porcine 
articular cartilage ECM has been shown to induce chondrogenesis of human adipose-derived 
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adult stem cells in vitro (194). Thus, a scaffold derived from native cartilage is promising for 
cartilage tissue engineering in vitro and in vivo. 
Our previous studies (see Chapter 5) revealed that PRG4 and ACAN gene expression of 
superficial zone chondrocytes was increased in pellet cultures mixed with decellularized 
ECM from the zone of their origin when compared to pellets without additives. These 
outcomes indicated the potential use of decellularized bovine ECM for tissue engineering of 
zonal cartilage constructs. 
However, using decellularized cartilage ECM powder for zonal cartilage tissue engineering in 
the form of chondrocytes ECM pellets as studied in Chapter 5 may not be suitable for 
cartilage tissue engineering, as this model is very difficult to apply in zonal layers. Also, 
pellet cultures are difficult to scale up to dimensions of useful cartilage constructs as nutrient 
and oxygen transports are limited.  
A more established material platform for cartilage tissue engineering is natural hydrogels. 
Alginate is one of the natural hydrogels that has been used extensively as a scaffold for 
cartilage tissue engineering. Alginate provides a 3-dimensional environment to the 
chondrocytes and maintains a spherical chondrocyte phenotype (328, 329) and are easy to 
cast into a specific shape in order to achieve zonal cartilage constructs for clinical 
application. However, chondrocytes encapsulated in alginate lack cell-ECM interactions 
present in the native cartilage. We therefore hypothesized that adding zonal ECM powder to 
alginate constructs will allow the establishment of cell-ECM interactions and enhance matrix 
synthesis compared to the common full-thickness constructs in vitro. 
While adding ECM may provide chondrocytes-ECM interactions in alginate constructs, this 
environment is still missing key factors experienced by the chondrocytes in situ. 
Chondrocytes in the joint are not only exposed to the ECM, but also to various soluble factors 
from the subchondral bone and synovium. Bone cells produce a broad range of growth 
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factors and cytokines, including TGF–β, IGF-1 and FGF-2 (330). One approach to simulate 
this environment for in vitro cartilage tissue engineering is a full-thickness defect in an 
osteochondral disc model (full-thickness defect model), where the alginate/ECM powder 
construct is placed in a generated cartilage defect site of a condyle. Soluble factors from the 
surrounding cartilage and bone cells may thereby promote chondrogenesis in the defect site. 
We hypothesized that this full-thickness defect model would enable diffusion of soluble 
factors from the surrounding cartilage and the subchondral bone to encapsulated cells and 
provide an appropriate zonal environment.  
This study therefore aimed to evaluate the effects of zonal ECM powder added to alginate 
constructs on matrix synthesis by embedded zonal chondrocytes compared to full-thickness 
ECM powder with full-thickness chondrocytes and control full-thickness chondrocytes 
without ECM powder. Also, the potential of the full-thickness defect model for in vitro 
cartilage tissue engineering was analyzed. 
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6.2 Material and methods 
 
Figure 6.1: Overview of the experimental design for zonal chondrogenesis in free-swelling 
and full-thickness defect models. 
Human chondrocytes are isolated from the superficial zone (S), middle deep zone (M), or 
full-thickness (F) cartilage and combined in alginate hydrogels with or without bovine 
cartilage powder from the S, M or F regions. +OD = placed in osteochondral disc with full-
thickness defect. 
6.2.1 Human cartilage isolation 
Cartilage was harvested from 3 OA knee joint replacement patients. Superficial, middle deep 
or full-thickness chondrocytes were isolated from cartilage and were expanded to passage 2 
(P2) as detail described in section 2.2.  
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6.2.2 Pulverization and decellularization of bovine cartilage 
Four bovine knee joints were obtained from a local slaughterhouse via the Hong Xuong 
Butchery (QLD, Australia) within 24 h after animal slaughter. Half of the cartilage was 
pulverized and decellularized using a protocol described in section 2.6. 
6.2.3 Preparation of osteochondral discs with full-thickness defected  
Osteochondral cartilage was harvested from bovine knees by a sterile saw and the 6 mm 
diameter osteochondral discs were cut from the osteochondral cartilage by sterile trephine. 
Full-thickness 4 mm diameter defects were made by a dental burr, as described in Appendix 
B. The 6 mm osteochondral discs with 4 mm diameter full-thickness defect shown in Fig 6.1. 
6.2.4 Chondrogenic differentiation 
107 cells/mL of superficial (S), middle deep (MD) and full-thickness chondrocytes (P2) 
pooled from 3 patients were mixed with sterile 2% alginate dissolved in Milli-Q water with 
superficial, middle deep and full-thickness decellularized bovine cartilage. The final amount 
of decellularized bovine cartilage powder in each construct was 1.6 mg in 20 µL of cells 
alginate construct. 15 µL of middle deep or full-thickness chondrocyte-alginate solution with 
the ECM powder (middle deep ECM or full-thickness ECM) were added to the full-thickness 
defect model, respectively. Constructs were cross-linked in 102 mM CaCl2 for 10 min. After 
solidification of alginate constructs, 1µL of 200 mM EDTA solution was added to the 
constructs to dissolve alginate cross-links at the surface of the bottom layer. Then, 5 µL of 
superficial or full-thickness chondrocytes alginate solution with ECM (superficial or full- 
thickness) was added on top to obtain a zonal alginate hydrogel or full-thickness alginate 
hydrogel, respectively. Bilayered constructs were covered with a filter paper soaked in102 
mM CaCl2 solution for 2 min and then transferred to a CaCl2 bath for 8 more min. The 
constructs were washed two times in PBS with 1 mM CaCl2 before culture in the standard 
chondrogenic medium as described in section 2.5. Free swelling control constructs were 
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produced in a similar way in the stainless steel mold. First, sterile filter paper was soaked 
with 102 mM CaCl2 solution and laid it under the mold. Then, 15 µL of middle deep with 
ECM powder (middle deep ECM) or full-thickness chondrocyte-alginate solution with or 
without ECM powder (full-thickness ECM) were added to the stainless steel mold. The mold 
was then covered with the CaCl2 soaked filter paper and placed the mold to CaCl2 bath for 10 
min. 1 µL of 200 mM EDTA solution was added to the constructs. Then, 5 µL of superficial 
chondrocytes with superficial ECM or full-thickness chondrocytes alginate solution with or 
without full-thickness ECM was added on top. Bilayered constructs were covered with a filter 
paper soaked in 102 mM CaCl2 solution for 2 min and then transferred to a CaCl2 bath for 8 
more min. After the construct was removed from the mold, the constructs were washed two 
times in PBS with 1 mM CaCl2 before culture in the standard chondrogenic medium as 
described in section 2.5. 
Alginate constructs containing 2x105 cells with or without 1.6 mg ECM powder were 
cultured in serum free chondrogenic medium HG-DMEM, (Invitrogen) at 37 °C and 5 % CO2 
for 28 days. At Day 14, the constructs were terminated for chondrogenic gene expression 
analysis. At day 28, constructs were terminated for live/dead assay (section 2.13), DNA 
content and GAG analysis at pH 1.5 (section 2.14-2.15), histology and immunofluorescence 
staining (section 2.12). The samples for GAG and DNA assays were frozen and lyophilized 
before proteinase K digestion. 
6.2.5 Histology 
After 4 weeks of culture, constructs were retrieved from 24-well tissue culture plates (Nunc). 
Alginate constructs in free-swelling culture and alginate constructs in full-thickness defects 
were processed as detailed in sections 2.10 and 2.11, respectively. Then, constructs were 
embedded in paraffin wax and sectioned at 5 μm thickness as described in section 2.12.1. 
After that, sections were stained with Alcian blue in order to evaluate the presence of 
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glycosaminoglycans (GAGs) in the newly formed matrix as described in section 2.12.2. 
Immunofluorescence was used to evaluate the secretion of collagen I, collagen II, aggrecan 
and PRG4 as described in 2.12.4. Controls were performed by omitting the primary antibody. 
All histological sections were observed with a fluorescence microscope (Axio Imager M2, 
Zeiss). 
6.2.6 Gene expression 
RNA was extracted from each construct using TRIzol® (Invitrogen) reagent, as described in 
section 2.16.1. Before homogenization by passing through a 19 gauge needle, 3 mm glass 
beads (Sigma) were added into each tube and placed in a Homogenizer (Mini Beadbeater, 
Biospec). The samples were homogenized twice for 1 min per cycle. Samples were then 
transferred to new Eppendorf tubes and were further homogenized by needle. Contaminating 
DNA was removed by treatment with DNase I (Invitrogen) prior to cDNA synthesis as details 
explained in section 2.16.2. All cDNA samples were analyzed for gene expression levels in 
duplicate using Express SYBR GreenERTM qPCR supermix universal kit (Invitrogen) and a 
7500HT fast real-time PCR system (Applied Biosystems, CA, USA). The cycle threshold (Ct) 
value of each gene was normalized to the housekeeping gene (ΔCt), 18SrRNA, using the 
comparative Ct method (2–ΔCt), as described in section 2.16.3. 
6.2.7 Statistics 
SPSS (version 19.0) was used to perform the statistical analysis. Gene expression and GAG 
per DNA data obtained from all groups are represented in bar graphs as mean + SD, showing 
the variations from 3 - 4 constructs (pooled from 3 OA patients). The statistical significance 
of the differences in each condition was tested using Univariate ANOVA with Tukey’s post 
hoc test. For all tests, p < 0.05 was considered significant. 
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6.3 Results 
6.3.1 Cell viability 
Independent from the culture condition, chondrocytes exhibited a high viability rate in all 
constructs, based on live/dead staining (Fig 6.2). Viable cells were homogeneously 
distributed in all construct types (Fig 6.2 A-E). 
 
Figure 6.2: Cell viability of chondrocytes in alginate constructs with and without ECM 
additive in a free-swelling or in an osteochondral disc. 
Live dead staining using fluorescein diacetate (A-E, viable cells) and propidium iodide (F-J, 
dead cells) after 28 days of culture in chondrogenic medium. Epifluorescence images are 
shown for (A, F) Control free-swelling full-thickness chondrocyte alginate construct without 
ECM, (B, G) free-swelling full-thickness chondrocyte alginate construct with full-thickness 
ECM, (C, H) free-swelling zonal chondrocyte alginate construct with zonal ECM, (D, I) full-
thickness chondrocytes alginate construct with full-thickness ECM in the full-thickness 
defect of osteochondral disc model, and (E, J) zonal chondrocyte alginate construct with 
zonal ECM in the full-thickness defect of osteochondral disc model. 
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6.3.2 Gene expression 
There were no statistically significant differences in ACAN expression between all tested 
groups (p = 0.11) (Fig 6.2 A). Gene expression of the other chondrogenic marker COL2A1 
was highest in zonal ECM constructs cultured under free-swelling condition (6.6 + 4.0 x 10-6) 
and were statistically significant different to full-thickness construct (6.8 + 1.7 x 10-7, p = 
0.02) and control no-ECM constructs (8.4 + 6.8 x 10-7, p = 0.02) cultured under free-swelling 
condition (Fig 6.3 B). For superficial zone marker PRG4, chondrocytes cultured in free-
swelling with ECM additive full-thickness constructs expressed a significantly higher level of 
PRG4 (2.0 + 0.9 x10-4) when compared to those both full-thickness (3.7 + 1.6x 10-5, p = 0.01) 
and zonal constructs (3.1 + 1.7 x10-5, p = 0.01) in the full-thickness defect of osteochondral 
disc model (Fig 6.3 C). Dedifferentiated chondrocyte marker COL1A1 expression was 
highest in zonal free-swelling constructs (5.0 + 1.7x10-4), with significant differences to both 
full-thickness (1.0 + 0.1x10-4, p = 0.015) and zonal constructs (1.7 + 1.8x10-4, p = 0.04) in the 
full-thickness defect of osteochondral disc model (Fig 6.3 D). Additionally, COL10A1, a 
hypertrophy marker gene, expression was lowest in the ECM additive full-thickness defect of 
osteochondral disc model, with statistically significant differences (p < 0.05) with ECM 
additive full-thickness free-swelling constructs (Fig 6.3 E). 
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Figure 6.3: Effect of bovine zonal ECM and/or osteochondral environment on alginate 
encapsulated chondrocytes gene expression levels. 
Chondrogenic (A-C: ACAN, COL2A1, PRG4), fibroblastic (D: COL1A1) and hypertrophic 
(E: COL10A1) gene expression normalized to housekeeping gene (18SrRNA). Free = Free-
swelling, Osteochondral = full-thickness defect of osteochondral disc model, Full = full-
thickness construct, Zonal = zonal construct, No = no ECM added, ECM = ECM added. Data 
represent mean + SD (Free swelling n=3, full-thickness defect of osteochondral disc model 
n=4, except # n = 2, and ^ n = 1 (not include in statistical analysis)). P < 0.05 (*) was 
considered significant. 
6.3.3 GAG and DNA content 
GAG production and retention was significantly higher (p < 0.05) in both osteochondral disc 
model constructs (zonal 43.5 + 19.6 μg, full-thickness 76.0 + 30.5 μg) than all free-swelling 
constructs (zonal (5.9 + 1.4 μg), full-thickness (5.1 + 1.2 μg) and no ECM control (3.2 + 0.6 
μg) (Fig 6.3.A). There were no significant differences between free-swelling construct types. 
DNA content was similar between all groups, except for the zonal constructs in the full-
thickness defect of osteochondral disc model, which had less DNA than the free-swelling 
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control without ECM (p < 0.05) (Fig 6.3.B). GAG per DNA in the full-thickness defect of 
osteochondral disc model for both zonal and full-thickness constructs (zonal 38.0 + 11.8, full-
thickness 44.6 + 12.9) were significantly higher (p < 0.05) than all of the free-swelling 
groups (zonal 4.0 + 0.4, full-thickness 3.6 + 0.5, noECM control 1.8 + 0.5) (Fig 6.3 C). There 
were no differences in GAG production between zonal and non-zonal constructs within both 
free-swelling and full-thickness defect model conditions. 
 
Figure 6.4: Effect of bovine zonal ECM and the osteochondral environment on alginate 
encapsulated chondrocytes GAG synthesis and retention. 
(A) GAG content per construct (B) DNA content per construct (C) GAG content normalized 
to DNA content per construct. Free = Free-swelling, Osteochondral = full-thickness defect of 
osteochondral disc model, Full = full-thickness construct, Zonal = zonal construct, No = no 
ECM added, ECM = ECM added. Data represent mean + SD (n = 4). P < 0.05 (*) was 
considered significant. 
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6.3.4 Histology and immunofluorescence 
Alcian blue staining for GAGs revealed a generally stronger intensity in the constructs mixed 
with ECM (Fig 6.5 A3-A6) compared to no ECM controls (Fig 6.5 A2). The density and 
distribution of chondrocytes in these constructs was similar to native bovine cartilage control 
(Fig 6.5 A1). Aggrecan was marginally positive in sections of bovine cartilage (Fig 6.5 B1). 
Constructs including bovine decellularized ECM stained positive for aggrecan with varying 
intensity (Fig 6.5 B2-B6). Similarly, all constructs stained positive for collagen type II, with 
varying intensity. Bovine cartilage exhibited a strongly positive staining for collagen type II 
(Fig. 6.5 C1). Also, all groups containing added ECM had a stronger staining intensity (Fig 
6.5 C3-C5) than constructs without additives (Fig 6.5 C2). All construct groups stained 
positive for PRG4 with varying intensity (Fig 6.5 D2-D6). Staining in bovine cartilage was 
the strongest in the superficial layer, but was also detected evenly distributed in the 
interterritorial matrix (Fig 6.5 D1). Bovine cartilage stained slightly positive for collagen type 
I and superficial layer stained stronger than middle deep area (Fig 6.5 E1). However, 
Immunofluorescence staining of collagen type I was slightly positive only in zonal free-
swelling constructs (Fig 6.5 E4) and negative in all the rest of constructs types (Fig 6.5 E2, 
E3, E5, E6)  
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Figure 6.5: Alcian blue and immunofluorescence images of various collagenous proteins of 
alginate encapsulated chondrocytes with ECM additive in free-swelling and in a full-
thickness defect model compared to non ECM additive and cartilage. 
Sections of bovine cartilage (1) and alginate construct sections in free-swelling (2-4) and in a 
full-thickness defect model (5-6) at day 28 stained with Alcian blue (A) and 
immunofluorescence, ACAN (B), collagen type II (C), PRG4 (D) and collagen type I (E) in 
alginate constructs with (3-6) or without decellularized ECM additive (2). Images are shown 
for (2) free-swelling full-thickness chondrocyte alginate construct without ECM, (3) free-
swelling full-thickness chondrocyte alginate construct with full-thickness ECM, (4) free-
swelling zonal chondrocyte alginate construct with zonal ECM, (5) full-thickness 
chondrocyte alginate construct with full-thickness ECM in the full-thickness defect of 
osteochondral disc model, and (6) zonal chondrocyte alginate construct with zonal ECM in 
the full-thickness defect of osteochondral disc model. The figure insets are 7 x magnifications 
corresponding to the 10 µm scale bar in E6. DAPI (blue) was used to stain nuclei, and Alexa 
633 (red) was used to stain the matrix molecules. 
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6.4 Discussion 
There are several reports showing the benefit of using of native ECM or decellularized ECM 
in various from such as porous freeze-dry scaffold (194, 331-333), decellularized cartilage 
scaffold (207), and combination of nanofibrous ECM with synthetic scaffold (334) for 
cartilage tissue engineering. However, the current cartilage ECM scaffolds still have some 
limitations and need to be improved. The limitations of porous freeze-dried scaffolds include 
scaffold contraction during in vitro culture (194), insufficient in mechanical strength (194), 
and negative influences on seeding cells from crosslinking treatments (333). The limitations 
of decellularized whole tissue scaffold include long processing times compared to minced 
cartilage (207), and difficulties in cell infiltration. In this study, we developed and evaluated a 
simple decellularized ECM alginate scaffold in combination with a cartilage defect model as 
a culture environment for zonal cartilage tissue engineering.  
Decellularized ECM powder derived from full-thickness or zonal bovine cartilage seems to 
affect chondrogenesis of chondrocytes encapsulated in alginate constructs in this study. 
However, the effects were mixed and depended on the context of the model. In free-swelling 
alginate constructs, chondrocytes responded to the addition of zonal ECM by significantly 
increasing expression of COL2A1 (Fig 6.3 B), the most prominent marker of articular 
cartilage, whereas other genes were not significantly affected. On the other hand, the addition 
of ECM to alginate constructs did not affect the proteoglycan content, normalized to DNA, in 
both zonal and non-zonal groups under free-swelling condition (See Fig 6.4 C). These 
findings are also supported by immunofluorescence images of aggrecan in these constructs 
(See Fig 6.5 B2-B4).  
In Chapter 5, we found that superficial chondrocytes mixed with decellularized ECM derived 
from its zone of origin exhibited an increased transcription of ACAN and PRG4 genes 
compared to chondrocyte pellets without ECM. In the pellet system, cells are in close 
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proximity to the added ECM, allowing direct interaction between them. Based on the 
promising results from Chapter 5, and advantages of hydrogel systems for large and 
controllable tissue-engineered constructs, we attempted to extend the model to encapsulation 
of ECM powder and chondrocytes in an alginate hydrogels. However, the effects of added 
ECM were not as clear in the hydrogel models as in the pellet culture models. This may be 
due to the small amounts of pulverized ECM in the constructs and the presence of alginate 
network, which only enabled minimal direct chondrocyte/ECM interaction and randomly 
effects. This explanation is supported by Alcian blue staining and immunofluorescence 
images where it can be observed that most cells were not in close contact to co-embedded 
ECM powder. The simplicity and practicality of the ECM-alginate scaffold model is 
attractive for future investigation, but further optimization need to be done for zonal cartilage 
tissue engineering. 
We aimed to improve the free-swelling model by incorporating the ECM-alginate constructs 
in a full-thickness defect model, thereby providing the surrounding cartilage and the 
subchondral bone environment to encapsulated cells. The major increases in GAG per DNA 
were evident for constructs with ECM in the full-thickness defect model when compared to 
no ECM control constructs at day 28 (See Fig 6.4 C). These results seem to show a positive 
effect of the osteochondral environment on GAG retention in this model. However, lack of 
cell-free gels in the full-thickness defect model could not rule out the possibility of up- take 
of GAG from the bovine cartilage. 
The previous report showed that adjacent tissues (cartilage, bone) affect GAG amount 
secreted by chondrocytes in tissue-engineered construct with in an in vitro culture (335). 
They also showed that bone environment has a stronger positive effect than cartilage 
environment on GAG production in the in vitro culture (335). However, the effect of factors 
provided by native cartilage and bone in the full-thickness defect model may have 
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overpowered the effects of ECM powder in the hydrogel constructs, as we could not find a 
significant difference in the biological response of encapsulated chondrocytes in both zonal 
and non-zonal constructs cultured in the full-thickness defect model. 
Although the significant difference was shown only in full-thickness with ECM additive 
constructs in free swelling culture compare to osteochondral culture because of the low 
number of samples, this osteochondral culture model seems to reduce unwanted gene such as 
hypertrophic gene (COL10A1) expression compare to free swelling culture (Fig 6.4 E). 
Although PRG4 expression was lower in the full-thickness defect model, this finding could 
not be confirmed on protein level analyzed by immunofluorescence staining. Also, low PRG4 
gene expression in the full-thickness defect model might be improved by combination this 
model with other types of stimuli for in vitro culture such as contact shear stress which shown 
to increase the PRG4 gene expression in cartilage explant in the previous reports (214, 215).  
Experiments conducted in this chapter indicated some beneficial effects of the healthy 
osteochondral environment on chondrogenesis for hydrogel constructs. This is different with 
the previous report on chondrocytes encapsulated in agarose gel culture inside chondral 
defect explant which showed the lower GAG production than free swelling control (246, 336). 
This work seems to support an assumption that the osteochondral model is superior to a 
cartilage-only model for the in vitro culture environment. Also, an osteochondral culture 
model was reported provided more stable environment than chondral culture model (249). 
The high viability of cells and their behavior in these constructs suggests this in vitro model, 
which mimics some of the complexities of the native joint environment, may be useful to 
screen tissue-engineered cartilage strategies prior to testing in animal models. Animal models 
are also important as translational tools for clinical application. This small full-thickness 
defect model also offers the potential of evaluating cartilage repair strategies in small animal 
models (e.g. mouse or rat) via subcutaneous implantation. While such subcutaneous models 
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lack several features of the joint, the full-thickness defect model provides the surrounding 
cartilage environment for hydrogel constructs which has been shown to have beneficial 
effects on chondrogenesis. Therefore, we tested this model in vivo through the experiments in 
Chapter 7. 
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CHAPTER 7 : ZONAL CHONDROGENESIS IN A 
SUBCUTANEOUS FULL-THICKNESS DEFECT MODEL IN MOUSE 
 
7.1 Introduction 
Articular cartilage is an avascular load-bearing tissue with low intrinsic repair capacity. 
Within the cartilage, chondrocytes from different depth zones are subjected to different 
environments, including varying oxygen tension and surrounding matrix properties, and 
behave differently. Cartilage tissue engineering is a promising cartilage repair approach, but 
development of this zonal structure of native cartilage has not been robustly demonstrated in 
repair tissues. To develop and evaluate tissue engineering techniques for cartilage repair, in 
vitro cultures and animal models are widely used methods. 
Animal models are used to evaluate cartilage regeneration techniques in vivo. Cartilage tissue 
engineering approached have been evaluated in preclinical studies through various animal 
models both in large animals such as, horse and pig (337, 338), and small animals such as 
mice and rabbits (339, 340). The small animal is commonly used for primary investigations 
or proof of concept whereas the large animal which have joint anatomy and joint properties 
closer to human are used for confirmation (237). 
Mouse is the most economical animal model. It is easy to access and handle. However, mice 
have small joints and mouse cartilage is very thin, for example the thickness of murine 
medial femoral condyle is 0.1 mm (242). Thus, it is difficult to create cartilage defects in 
mouse models. Therefore the most common model for in vivo cartilage tissue engineering 
studies is subcutaneous implantation in the backs of immunocompromised mice. The 
subcutaneous immunocompromised mouse model may provide basic information on tissue 
engineered cartilage under the in vivo condition. However, one reason to use an animal model 
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is to explore cell growth and differentiation within an articular environment (Reviews in 
(341). Lack of surrounding articular tissue, lack of synovial fluid and limited mechanical 
stimuli are the limitations of the common subcutaneous mouse model.  
Osteochondral discs with full-thickness cartilage defects can provide the cartilage 
environment and bone environment to cartilage constructs. There are several reports using the 
cartilage defect in cartilage discs or osteochondral discs for study cartilage tissue repair both 
in vitro and in mice model (246, 247, 249, 335, 342). 
There is reported use of the chondral defect in human osteochondral discs for studying human 
cartilage regeneration in a nude mouse model. The chondrocytes were seeded to the chondral 
defect with and without periosteal cover. The GAG secretion of the seeding chondrocytes in 
the periosteal covered defect was found only at the area close to the native cartilage and the 
fibrous tissue was found at the center of defect. However, they found that the uncovered 
defects have the similar result of chondrogenesis with the periosteal cover but no fibrous 
tissue in the center of the defect (248). This report shows the possibility to use the chondral 
defect in the osteochondral discs in nude mouse model for studying the cartilage tissue 
engineering in vivo. However, there is a report showing that tissue-engineered cartilage 
construct culture in ring of bone has a significantly higher GAG production than a culture in a 
ring of cartilage both in vitro and in nude mice (335, 342). Therefore, the full-thickness 
defect in osteochondral discs which provides the direct contact of cartilage construct to bone 
might be a better model than a cartilage only defect model. 
Also, there is a report showed that the bovine chondrocytes seed in different depths of bovine 
cartilage defects: chondral, full-thickness and osteochondral in osteochondral discs have 
different GAG production (249). The osteochondral defect has significantly more GAG 
production than the chondral defect, but no significant differences in GAG production 
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between full-thickness defect and osteochondral defect. These results suggest that full-
thickness defect in bovine osteochondral cartilage discs can be used to promote GAG 
production of bovine chondrocytes in an in vitro model (249).  
However, there is no information on the effect of the bovine full-thickness defect model on 
zonal cartilage tissue construct in the subcutaneous immunocompromised (NOD-SCID) 
mouse model. We hypothesized that the full-thickness defect model provides a zonal 
cartilage and bone environment to zonal cartilage constructs which may support 
chondrogenesis of human OA chondrocytes both in vitro and in animal model. Therefore, this 
chapter aims to study the chondrogenesis of zonal and non-zonal human chondrocyte 
constructs in a bovine full-thickness defect model in both in vitro and in a subcutaneous 
NOD-SCID mouse model. 
7.2 Materials and methods 
An overview of the experimental design is shown in Fig 7.1. Briefly, bovine cartilage with 
subchondral bone was cut by saw and trephine to make osteochondral discs and the full-
thickness defect in the osteochondral disc was made by a dental burr. The isolated human 
zonal chondrocytes and full-thickness chondrocytes were mixed in 2% alginate and were 
cross-linked for the zonal constructs and full-thickness constructs and placed in the full-
thickness defect model. One set of chondrocytes constructs in full-thickness defects were 
implanted subcutaneously in NOD-SCID mice and the other set were cultured in serum free 
chondrogenic medium for 42 days (section 2.5) and then terminated for gene expression, 
histology and biochemical analysis.  
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Figure 7.1: Overview of the experimental design for zonal chondrogenesis in a full-thickness 
defect of osteochondral disc placed subcutaneously in a NOD-SCID mouse and in vitro. 
7.2.1 Chondrocyte isolation and alginate discs preparation 
Articular cartilage was harvested from OA patient as shown in section 2.2. Chondrocytes 
from middle and deep zone and full-thickness chondrocytes were then resuspended in a 2% 
sodium alginate (PRONOVA ® NovaMatrix) and adjusted to a concentration of 10 × 106 
cells/mL. The 15 µL of cell alginate mixture was added to a custom-made mold (1.5 mm x 4 
mm Ø) and placed it in 102 mM CaCl2 solution for cross-linked. After 10 min, the alginate 
discs were removed from the mold and the discs were rinsed two times with Dulbecco's 
Phosphate-Buffered Saline plus Calcium, Magnesium (DPBS) (Invitrogen) and kept it in LG-
DMEM supplemented with 10% foetal bovine serum (BioWhittaker), 50 μg/mL ascorbic acid 
(Sigma), 1% glutamine (Invitrogen) and 1% of the P/S (Invitrogen) for constructs assembly 
process. 
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7.2.2 Preparation of full-thickness defected in osteochondral discs and construct 
assembly 
Osteochondral cartilage was harvested from bovine knees by a sterile saw and 6 mm diameter 
osteochondral discs were cut and 4 mm diameter full-thickness defects were made as 
described in Appendix B. For zonal construct assembly, the middle and deep zone alginate 
disc was placed in the defect and 5 µL of superficial cells alginate mixture was added to the 
top of middle and deep zone alginate disc. For full constructs assembly, the full-thickness 
alginate disc was placed in the defected and 5 µL of full-thickness cells alginate mixture was 
on top of the full-thickness alginate disc. The osteochondral discs with the alginate constructs 
were then places in the 102 mM CaCl2 solution bath. After 10 min, the constructs were 
washed with PBS+ (Invitrogen) 2 times and transferred to in vitro cultivation or NOD-SCID 
mice. 
7.2.3 Animals and surgery 
All animal experiments were performed in accordance with Animal Care and Use Committee 
guidelines of Queensland University of Technology. All mice were housed in a light and 
temperature-controlled environment and given food and water. Among these, 7 NOD-SCID 
mice 4 osteochondral discs per animal were implanted subcutaneously with zonal constructs 
and full-thickness constructs. After surgery, the mice were allowed to move freely within 
their cages. The NOD-SCID mice were sacrificed at day 42. The osteochondral discs were 
removed. The live/dead assay (section 2.13), gene expression (section 2.16), DNA, GAG 
assays (section 2.14-2.15) and histological evaluation (section 2.12) were carried out at day 
42. 
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7.2.4 In vitro chondrogenic differentiation 
Matching constructs were cultured in vitro in serum-free chondrogenic medium with 10 
ng/mL recombinant human transforming growth factor-β1 (TGF-β1, Millipore) as detailed in 
section 2.5. The medium was changed every 2–3 days. Samples were collected at week 6. 
Viability was determined by FDA/PI staining (section 2.13). Gene expression (section 2.16), 
DNA, GAG assays (section 2.14-2.15) and histological evaluations (section 2.12) were 
performed at day 0 and 42. 
7.2.5 Histology 
After 6 weeks, the osteochondral constructs were retrieved from the 24-well tissue culture 
plate (Nunc) in vitro culture and the animals. The animals were euthanized at 6 weeks. The 
dissected osteochondral constructs were examined grossly and photographed (Fig 7.2). The 
specimens from both in vitro and in vivo were processed as shown in section 2.11. The 
samples were stained with Alcian blue for the evaluation of the presence of 
glycosaminoglycans (GAGs) in the newly formed matrix (section 2.12.2). The secretion of 
aggrecan, collagen type II and I and PRG4 were detected by immunofluorescence method as 
described in section 2.12.4. 
7.2.6 Gene expression 
For RNA isolation, alginate discs were removed from osteochondral constructs. The alginate 
discs were dissolved in 0.5 mL TRIzol (Invitrogen), mixed well and then frozen in liquid 
nitrogen, and stored at −80°C until used. The samples were thawed on ice and homogenized 
by pestle and processed as shown in section 2.16. The cDNA samples were analyzed by 
quantitative real-time polymerase chain reaction (qRT-PCR) using Express SYBR 
GreenER™ qPCR supermix universal kit (Invitrogen) and ABI Prism 7700 Sequence 
Detection System (Applied Biosystems). The cycle threshold (Ct) of each gene was 
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normalized to the house keeping gene RPL13. The calculation for relative expression changes 
were performed using the comparative Ct method (2-∆Ct).  
7.2.7 Statistics 
SPSS (version 19.0) was used to perform the statistical analysis. Gene expression and GAG 
per DNA data obtained from all groups are represented in bar graphs as mean + SD, showing 
the variations from 4 samples. The statistical significance of the differences in each condition 
was tested using Univariate ANOVA, with Tukey’s post hoc test. For all tests, p < 0.05 was 
considered significant. 
7.3 Results 
7.3.1 Macroscopic view and histology 
The full-thickness defect model is shown in Fig 7.2. The alginate construct was stabilized 
well in the osteochondral discs in vitro (Fig 7.2 A, B). In SCID mice, the osteochondral 
implanted discs were fixed well into SCID mouse tissue and the osteochondral disc was 
surrounded with mouse tissue. Vascularized tissue was attached to the osteochondral disc 
(Fig 7.2 C, D). 
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Figure 7.2: Osteochondral constructs following 42 days in vitro and subcutaneous in NOD-
SCID mice. 
Full-thickness defect model at 42 days of in vitro culture (A, B), or subcutaneous 
implantation in a NOD-SCID mouse (C, D). The arrow in (C) indicates a blood vessel. 
The full-thickness defect model retrieved from SCID mice at day 42 stained by Alcian blue 
observed under low magnification microscope are shown in Fig 7.3 A, B full-thickness 
construct (A) and zonal constructs (B). GAG positive stain was observed in the alginate 
construct and cartilage, but a negative stain was observed in bone part. Mouse tissue, which 
slightly stained by Alcian blue was observed surrounding the osteochondral discs. The 
superficial layer in some construct was detached from the zonal construct as shown by the 
thin layer in Fig 7.3 A. The Alcian blue stained of mouse fibrous tissue surround the 
construct observed in high magnification was shown in Fig 7.3 B. The suspicious fibroblast 
mouse cells were also found invaded into the border area of cartilage constructs and full-
thickness defect (Fig 7.3 B). 
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Figure 7.3: Histology of osteochondral discs after 42 days subcutaneous in NOD-SCID mice. 
Osteochondral discs with implanted (A) full-thickness construct or (B) zonal construct after 
42 days subcutaneous in NOD-SCID mice. Sections were stained with Alcian blue and 
counter-stained with haematoxylin observed and imaged with a Midi histology slide scanner. 
The image showed round chondrocyte-like cells embedded in alginate constructs (deep blue) 
in an osteochondral disc composed of cartilage (blue) and bone (pink) and small, flat 
fibroblast-like cells at the top layer of the disc (pink or light blue). The arrow indicates 
fibroblast-like cell invasion into the defect gap and surrounding the alginate construct in 
fibrous tissue. 
7.3.2 Cell viability 
Chondrocyte viability after 42 days in vitro or in vivo was similar in all constructs, as shown 
by FDA/PI stain. The vital chondrocytes were homogeneously distributed throughout the 
constructs (Fig 7.4). However, low chondrocyte viability was observed in zonal constructs 
retrieved from SCID mice after 42 days (Fig 7.4 F). 
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Figure 7.4: Cell viability of chondrocytes in alginate constructs in an osteochondral disc 
retrieved from in vitro culture and SCID mice. 
Live dead staining with Fluorescein diacetate (A-F, live cells)/Propidium iodide (G-L, dead 
cells) (FDA/PI) at day 0 (Full-thickness construct A, G: Zonal construct B, H), after 42 days 
in vitro (Full-thickness construct C, I: Zonal construct D, J), and after 42 days subcutaneous 
in a SCID mouse model (Full-thickness construct E, K: Zonal construct F, L). 
7.3.3 Gene expression 
The gene expression levels of the chondrocytes in the constructs after culture in chondrogenic 
medium for 42 days were measured and normalized to housekeeping gene RPL13. The 
overall gene expression of chondrogenic markers (ACAN, COL2A1), superficial chondrocytes 
marker (PRG4) and fibroblastic marker (COL1A1) showed no statistical difference between 
zonal and full-thickness constructs both in vitro and in SCID mice (Fig 7.5). The ACAN gene 
expressions of the chondrocytes at day 42 in the in vitro and mouse model were not 
statistically different from day 0 (Fig 7.5 A). COL2A1 gene expression, at day 42 of full-
thickness constructs and zonal constructs in vitro were statistically different with the gene 
expression at day 0 (Fig 7.5 B, P = 0.004, full-thickness constructs and P = 0.000, zonal 
constructs). At day 42, the COL2A1 gene expression was highest in the zonal construct in 
vitro model (2.98 + 0.46) and statistically different with the zonal construct (0.02 + 0.02) and 
full-thickness constructs (0.04 + 0.03) in mouse model. Also, the COL2A1 gene expressions 
of full-thickness construct in vitro (2.00 + 1.49) was statistically different with zonal and full-
thickness constructs in mouse model (Fig 7.5 B). PRG4 gene expression was statistically 
different between day 0 (Full 0.08 + 0.02, Zonal 0.08 + 0.04) and zonal constructs in vitro 
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model day 42 (0.61 + 0.37) (Fig 7.5 C). There was no statistical difference between the in 
vitro model and in vivo model.  
On the other hand, the fibroblastic gene expression COL1A1 of chondrocytes in both full-
thickness and zonal constructs at day 42 has a trend toward higher in the mouse model group 
while has a trend toward lower with the in vitro group when compared to at day 0. However, 
the statistically different were found only at day 42 between full-thickness constructs in the 
mouse model (18.09 + 3.36) compared to zonal constructs in the in vitro model (2.03 + 1.50) 
and zonal constructs in the mouse model (19.33 + 15.74) compared to full-thickness 
constructs (4.06 + 3.05) and zonal constructs in the in vitro model (2.03 + 1.50) (Fig 7.5 D). 
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Figure 7.5: Gene expression levels of chondrocytes in alginate constructs in an osteochondral 
disc retrieved from in vitro culture and SCID mice. 
Chondrogenic gene expression ACAN (A), COL2A1 (B), Superficial chondrocytes marker 
PRG4 gene expression (C) and fibroblastic marker COL1A1 gene expression (D) normalized 
to housekeeping gene (RPL13RNA) (mean ± SD, n=4 ). 0 = Day 0, 42 = Day 42, Full= Full-
thickness constructs, Zonal = Zonal constructs, in vitro = in vitro culture, Mice = constructs 
in mouse model. P < 0.05 (*) was considered significant. There were no detectable 
differences in gene expression between full-thickness and zonal constructs within a culture 
type. There were significant differences between in vitro and in vivo models, with higher 
COL2A1 expression, and lowerCOL1A1 expression, in vitro. COL2A1 was also up regulated 
in vitro at day 42, with respect to day 0, and PRG4 expression was higher PRG4 at day 42 
than day 0 for zonal constructs in vitro. 
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7.3.4 GAG and DNA content 
The GAG accumulation was highest in the zonal construct placed in full-thickness defect in 
vitro model. The GAG level of zonal constructs in vitro on day 42 (331.43 + 130.68 
μg/construct) was significantly higher than D0 samples, D42 full-thickness constructs in vitro, 
and D42 of both full-thickness constructs and zonal constructs. Also, the GAG level of full-
thickness constructs in vitro at day 42 (171.17 + 32.78 μg/construct) was significantly 
different from D0, D42 of zonal constructs in vitro and D42 of both full-thickness constructs 
and zonal constructs (Fig 7.6 A). The number of cells assumed by the DNA value showed 
that the DNA of zonal construct in the mouse model was significantly different with the other 
group (Fig 7.6 B). GAG normalized by DNA showed the same pattern with GAG level. The 
highest GAG per DNA was found in zonal construct in vitro model (42.20 + 4.35 μg/μg) and 
shown statistical difference with both day 0 groups, both day 42 groups in mouse model and 
day 42 full-thickness constructs in vitro model. Also, the GAG per DNA of full-thickness 
construct in vitro at day 42 (20.19 + 4.26 μg/μg) was significant difference with day 0 
samples, day 42 of zonal constructs in vitro and day42 in the mouse model. 
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Figure 7.6: GAG and DNA content of chondrocytes in alginate constructs in an osteochondral 
disc retrieved from in vitro culture and SCID mice. 
A) GAG content per construct (B) DNA content per samples (C) GAG content normalized to 
DNA (mean ± SD, n = 4 ).0 = Day 0, 42 = Day 42, Full= Full-thickness constructs, Zonal = 
Zonal constructs, In vitro = in vitro culture, Mice = constructs in mouse model. P < 0.05(*) 
was considered significant. Significantly more GAG accumulated in in vitro constructs than 
those implanted in mice. These constructs also showed a significant increase from day 0 to 
day 42. DNA content was similar between all groups and time-points, apart from zonal in 
vivo constructs which had less DNA. Thus, differences in matrix accumulation remained 
evident when GAG was normalized to DNA content. 
7.3.5 Immunofluorescence 
Immunofluorescence staining of aggrecan, collagen type II, proteoglycan 4 and 
collagen type I are shown in Fig 7.7. No fluorescent staining was observed in the IgG 
negative control in all groups of samples (Fig 7.7 A1- 6). The immunofluorescence images of 
aggrecan at day 42 of cultivation were showed slightly more positive cells in the full-
thickness construct in vitro model (Fig 7.7 B2) compared to in mouse model (Fig 7.7 B3) and 
day 0 (Fig7.7 B1). Similarly, the constructs showed positive staining of collagen type II in the 
155 
 
full-thickness constructs (Fig 7.7 C2) and zonal constructs (Fig 7.7 C5) cultured in vitro 
model but the positive staining was not observed in the full-thickness construct in mouse 
model (Fig 7.7 C3) and day 0 (Fig7.7 C1, C4). Also, both zonal and full-thickness constructs 
were slightly positive for PRG4 in vitro culture at day 42 (Fig 7.7 D2, D5) and at day 0 (Fig 
7.7 D1, D4) but no positive staining was found in the mouse model (Fig 7.7 D3, D6). There 
was positive staining for collagen type I in both full-thickness and zonal constructs cultured 
in vitro model (Fig 7.7 E2, E5) and in mouse model (Fig 7.7 E3, E6) after 42 days but the 
constructs cultured in vitro model were stained stronger than in mouse model.  
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Figure 7.7: Immunofluorescence images of various collagenous proteins of chondrocytes in 
alginate constructs in an osteochondral disc retrieved from in vitro culture and SCID mice. 
Chondrocyte pellets at day 0 (1, 4) and 42 (2, 3, 5, 6) stained with immunofluorescence were 
photograph with Zeiss microscope (20X). The figures were showed the immunofluorescence 
image of IGG (A1 - A6), ACAN (B1 - B6), collagen type II (C1 - C6), PRG4 (D1 - D6) and 
collagen type I (E1 - E6) respectively in full-thickness construct (1 - 3), zonal constructs (4 - 
6) at day 0 (1, 4) and day 42 in vitro model (2, 5) and in the subcutaneous SCID mouse model 
(3, 6). ). The figure insets are 7 x magnifications corresponding to the 10 µm scale bar in E6. 
DAPI (blue) was used to stain nuclei, and Alexa 488 (green) was used to stain the matrix 
molecules. 
7.4 Discussion 
The immunodeficient mouse model is the most practical model used to investigate the 
xenogeneic tissue-engineered cartilage constructs in vivo. However, the subcutaneous 
environment lacks the joint environment and minimal mechanical stimuli. Although the 
subcutaneous model has less mechanical stimuli than the normal joint environment, this 
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feature may be beneficial for study of specific factors without interference from mechanical 
stimuli conditions. We hypothesized that the full-thickness defect in osteochondral discs 
could provide the cartilage and bone environment to tissue-engineered cartilage in a mouse 
model. Therefore we used the full-thickness defect in osteochondral discs to provide the 
cartilage and bone environment to constructs in subcutaneous in SCID mice. To evaluate only 
the effect of full-thickness defect model, we designed the experiment using alginate 
constructs instead of alginate ECM constructs as in chapter 6. 
The different in vitro and in vivo behaviors of the full-thickness defect model were clearly 
shown by GAG accumulation in the constructs (Fig 7.6 C). The GAG per DNA of constructs 
in the mouse model was significant lower than the same type of construct in the in vitro 
culture, which was supported by immunofluorescence staining (Fig 7.7 B). However, there 
were no significant differences in ACAN gene expression (Fig 7.5 A). This apparent 
discrepancy may be due to the fact that GAG was accumulated for 6 weeks but the aggrecan 
gene expression is detected at the week 6 time point. In agreement with our findings, others 
have reported that ACAN gene expression of porcine chondrocytes in alginate in a SCID 
mouse model was significantly decreased at week 6 (343). The higher GAG production of 
chondrocytes in the zonal constructs when compared to full-thickness construct in the in vitro 
culture (Fig 7.6 C) seem to show a benefit of a zonal construct in the full-thickness defect 
model for in vitro culture. 
It is interesting to note that COL2A1 expression was still higher in the in vitro constructs after 
6 weeks (Fig 7.5 B). The collagen type II immunofluorescence supported the gene expression, 
as it was positive in the in vitro culture (Fig 7.7 C2, C5), but negative in mouse model (Fig 
7.7 C3). These results indicated the inferior of the full-thickness defect model in SCID mice 
compared to in vitro culture on the chondrocyte chondrogenic gene expression and matrix 
synthesis. The reduction of COL2A1 gene expression of porcine chondrocytes in SCID 
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mouse model was also reported by Wang (343). As well, low production of collagen type II 
have been observed in the human chondrocytes from OA patient with collagen gel seeded in 
the cartilage defect of the osteochondral discs at 6 weeks in nude mouse model. (247).  
Although, there was no statistical difference of the PRG4 gene expression in mice when 
compared to in vitro culture (Fig 7.5 C). However, the PRG4 immunofluorescent staining 
was negative in both types of constructs in the mouse model (Fig 7.7 D3, D6).These results 
seem to support the conclusion that the full-thickness defect in SCID mouse model could not 
elicit the same effect as in vitro culture on chondrocytes chondrogenesis.  
We also found that the fibroblastic marker COL1A1 gene expression was significantly higher 
in mice when compared to in vitro culture at day 42 (Fig 7.5 D). However, the collagen type I 
immunofluorescent staining was more positive in the full-thickness constructs in vitro culture 
(Fig 7.7 E 2, E5) than in mouse model (Fig E3, E6). The higher collagen type I gene 
expression but lower immunofluorescent positive stained for collagen type I in SCID mouse 
when compared to in vitro culture might possible due to the invading of mouse fibroblastic 
cells in to the full-thickness defects. The mouse fibroblastic cells may have contaminated the 
RNA isolation and gene expression process and caused the higher collagen type I gene 
expression of the construct from mice when compared to the in vitro cultures. The invading 
of mouse fibroblastic cells to the construct was assumed by the cell morphology in the Alcian 
blue staining in Fig 7.3 C. We did not specifically identify cells from different species, 
however, through use of a primary antibody that is specific only to mouse cells, such as 
monoclonal antibody for mouse MHC class I (344). 
The positive effect of the full-thickness defect on the GAG accumulation of chondrocytes in 
vitro was consistently found in this experiment and the previous experiment (chapter 6). 
However, lack of the cell-free gel controls leaves open the question of the source of the GAG. 
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There is a report showing that bovine chondrocytes cultured in devitalized and vital bone 
rings reach significantly higher GAG content when compared to chondrocytes cultured in an 
articular cartilage ring in vitro culture and mouse model (335, 342). They speculate that 
adjacent bone may provide the soluble chondrogenic factors to enhance chondrogenesis (345). 
The inferior results in the mouse model may be due to more restricted nutrient and growth 
factor transport to the constructs in vivo when compared to in vitro culture. In addition, the 
chondrocytes in the constructs might not be in a healthy condition as cells stay in low nutrient 
conditions before the blood vessel or tissue fluid can penetrate into the construct and provide 
the nutrient to the chondrocytes. 
To use the full-thickness defect for in vivo study in mouse models, the model needs to be 
modified. Pre-culturing the construct in vitro before placing in the subcutaneous of mice may 
let the chondrocytes become healthy enough to tolerate the low nutrient supply in the early 
stage of in vivo culture which was successfully studied by (342). Also, incorporating growth 
factors in the engineered tissue might help the development of cartilage matrix synthesis (346, 
347). In addition, the model may need a membrane, as in ACI protocol (348), to cover the 
alginate construct to keep the constructs in place in the osteochondral discs and prevent the 
mouse fibroblast invasion into the construct. However, the membrane should have structures 
that allow the fluid to flow in to the construct to provide the nutrient and oxygen to 
chondrocytes. 
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CHAPTER 8 : EFFECT OF SOLUBLE FACTORS SECRETED 
FROM OSTEOBLASTS ON CHONDROCYTES SUBPOPULATIONS 
UNDER COMPRESSION 
 
8.1 Introduction 
Osteoarthritis (OA) is a disorder commonly characterized by loss of articular cartilage. 
However, OA is recognized as a whole joint disease also affecting the subchondral bone 
(349). In the normal joint, the anabolic and catabolic activities of cartilage and other joint 
tissues are balanced, allowing maintenance of tissue properties and functions. A disturbance 
in the homeostatic balance clearly plays a role in the progression of OA. The exact 
mechanisms by which this balance is shifted towards catabolism are not known, but the 
communication between the subchondral bone and cartilage seems to play an important role 
in maintaining normal joint homeostasis and in the development of OA. 
Although the osteochondral interface was commonly thought to be a barrier to all 
communication, evidence to the contrary is mounting, suggesting that transport of signaling 
molecules between the subchondral bone and articular cartilage occurs. With progression of 
the disease, this transport increases due to the development of vascular channels, microcracks, 
etc., increasing the importance of the interactions between bone and cartilage. Direct 
interaction between chondrocytes and subchondral bone is likely minimal, given the large 
distances and density of the extracellular matrix. Thus, it is most likely that bone cells and 
chondrocytes communicate with each other through soluble factors such as growth factors 
and cytokines(350-353). These soluble factors bind to receptors in recipient cells and trigger 
specific signaling cascades in these cells. Previous study has shown that OA osteoblast 
conditioned medium induces hypertrophic changes in chondrocytes, and OA osteoblasts 
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suppress p38 phosphorylation and induce ERK-1/2 phosphorylation in co-cultured 
chondrocytes (354). There is also evidence that OA osteoblasts increase production of growth 
factors (TGF-β) and cytokines such as IL-6 and MMP-13(355, 356). 
In vitro studies indicate that secreted factors from osteoblasts have significant effects on 
chondrocyte function. Chondrocyte proliferation is enhanced by osteoblast-derived soluble 
factors, and chondrocyte differentiation is influenced by the differentiation level of the 
osteoblast (357). Factors from osteoblasts from sclerotic subchondral bone also increase 
chondrocyte production of MMPs and suppress chondrocyte production of aggrecan (358, 
359). Such osteoblasts also can shift the phenotype of normal chondrocytes towards an OA 
phenotype, including a shift in the activation of MAPK pathways (354).  
While the aforementioned studies provided detailed information on chondrocyte response to 
soluble signals, they did not take into account two relevant details of the normal and OA joint: 
the dynamic mechanical environment, and the differences between chondrocytes of the 
different depth zones. Changes in the cartilage with progressing OA are evident both near the 
articular surface (superficial zone) and near the subchondral bone (deep zone). The changes 
to the matrix result in changes in loading of the resident chondrocytes, which can affect their 
biosynthesis. There are clear differences between the subpopulations of chondrocytes in the 
different zones, in terms of production of specific molecules, such as proteoglycan 4 (PRG4) 
(13), rate of synthesis of major matrix components (360), and response to cytokines (361). 
Further, OA chondrocytes from different zones respond differently to mechanical stimulation 
with dynamic compression, including changes in mechanical properties of alginate constructs 
for S chondrocytes (253). Jeon, et al., demonstrated that cyclic compression promotes matrix 
synthesis in chondrocytes from OA patients in vitro. However, the effects of cyclic 
compression on chondrocytes in the OA environment with mechanical loading and 
osteoblast-derived factors still remain unknown. 
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We hypothesized that the soluble factors secreted from OA osteoblasts could reduce the 
matrix synthesis or induce matrix degradation of chondrocyte subpopulations and that cyclic 
compression can reverse the phenotype of OA chondrocytes by either inducing the matrix 
synthesis or reducing the matrix degradation related to chondrocytes cytokine production. 
The experiment aimed to determine the effect of osteoblast soluble factors on the 
subpopulation chondrocytes under the cyclic compression. 
8.2 Materials and methods 
8.2.1 Preparation of subchondral bone osteoblasts (SOBs) conditioned medium (CM) 
Normal and OA osteoblasts were isolated from human subchondral bone, as described 
previously (362), and cultured in expansion medium composed of HG-DMEM supplemented 
with 10% FBS, 50 U/mL, penicillin 50 μg/mL and streptomycin up to passage 2. Then, 2.5 x 
105 of normal and OA osteoblasts were changed to culture in HG-DMEM supplemented with 
50 U/mL, penicillin 50 µg/mL and streptomycin in 25 cm2 flasks for 2 days. The conditioned 
media were then collected and centrifuged at 500g for 15 min. The supernatants were kept at 
– 80°C for future co-culture experiment. 
8.2.2 Chondrocyte cultures 
Superficial and middle deep zone cartilage was harvested from the femoral condyle of 3 
patients undergoing knee replacement surgeries, as described previously (section 2.2). Cells 
were isolated and expanded in expansion medium for 2 passages (section 2.2). After 
trypsinization, S or MD chondrocytes were encapsulated in 2% alginate at a density of 107 
cells/mL to make the chondrocyte constructs (section 2.4). The constructs were cultured in 
serum-free chondrogenic medium supplemented with 10 ng/mL TGF-β3 (section 2.5) for 2 
weeks by changing the medium every 3-4 days. After 14 days, the constructs were divided 
into 3 groups. The first group was cultured in mixed equal volume of fresh chondrogenic 
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medium and fresh osteoblast medium as a control for 4 days (X). The second group was 
cultured in mixed equal volume of fresh chondrogenic medium and normal SOBs conditioned 
medium (N). The third group was cultured in mixed equal volume of fresh chondrogenic 
medium and OA SOBs conditioned medium (O). 
 
Figure 8.1: Overview of the experimental design for effect of soluble factors secreted from 
osteoblasts on chondrocytes subpopulations under compression. 
8.2.3 Cyclic compression application 
After 4 days of culture, cyclic compression at 1 Hz 50% strain for 3 h was applied to half of 
the constructs in a bioreactor (Tissue Growth Technologies, USA), whilst the other half 
remained in static culture. After 2 h rest, the constructs, were processed for RNA isolation for 
gene expression and the medium were processed for multiplex ELISA and GAG in the 
medium. The loading and sampling protocol was previously found to give the greatest 
response of OA chondrocytes in alginate to dynamic loading (43). The overall experimental 
design is shown in Fig 8.1. 
164 
 
8.2.4 Multiplex immunoassay 
Conditioned media were collected after compressive stimulation and were analyzed for the 
presence of various cytokines (IL-1β, IL-4, IL-6, IL-10, and TNF-α). Sample preparation and 
analysis was carried out according to the manufacturer’s protocol provided with the multiplex 
kits (cytokines: MPXHCYTO-60K, all from Millipore). Plates were read on a Bio-plex 200 
(Bio-Rad, USA) instrument. Cytokine concentrations in the media samples were quantified 
using serial dilutions of standards supplied by the manufacturer (Milliplex kit protocol, 
Millipore). 
8.2.5 GAG content 
The modified 1, 9-dimethylmethylene blue (DMMB, Sigma) colorimetric assay at pH 1.5 
was used to analyze the media samples for the amount of sulfated GAG (section 2.15) (265). 
8.2.6 Gene expression 
Gene expression levels were measured in chondrocytes embedded in alginate discs after 
culture in 3 different medium conditions with and without exposure to a single 3 h dynamic 
compression. RNA was extracted from constructs using TRIzol (Invitrogen) reagent 
according to the manufacturer’s protocol following homogenization. Chondrocyte constructs 
were homogenized in Eppendorf Safe-Lock tube. Chondrocyte constructs were placed in 
liquid nitrogen and a mixture of five 2 mm beads and 25 mg of 1 mm zirconium beads that 
were cooled in liquid nitrogen were added into the tube. Then, 500 µL of cold TRIzol reagent 
was added to the sample tube. The samples were then homogenized in a Bullet Blender (Next 
Advance, NY, USA) at speed level 10 for 5 min in a cold room. Then, the RNA solution was 
purified from the extract using the standard TRIzol protocol. After DNase treatment (DNase I, 
Invitrogen), cDNA was synthesized using DyNAmo™ cDNA Synthesis Kit (Finnzymes Oy., 
Vantaa, Finland). All cDNA were analyzed for gene expression level in triplicate using the 
SYBR Green PCR master mix (Applied Biosystems, CA, USA) and ABI 7900 Sequence 
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Detection System (Applied Biosystems, CA, USA). Chondrogenic (ACAN), superficial 
chondrocyte marker (PRG4), matrix degrading enzyme (MMP13, ADAMTS-5), and cytokine 
(IL-6) gene expression levels were measured. The cycle threshold (Ct) value of each gene 
was normalized to the housekeeping gene (ΔCt), 18SrRNA, using the comparative Ct method 
(2–ΔCt). 
Table 8.1: List of primer sequences used in the experiments for qRT-PCR. 
Gene Forward 5’-3’ Reverse 5’-3’ 
ACAN GCCTGCGCTCCAATGACT TAATGGAACACGATGCCTTTCA 
PRG4 GAGTACCCAATCAAGGCATTATCA TCCATCTACTGGCTTACCATTGC 
ADAMTS5 GGGCCAGATGGTCTGTCTGA CAGATTCTCCCCTTTCCACAAG 
MMP13 ACTTCACGATGGCATTGCTG CATAATTTGGCCCAGGAGGA 
IL6 AGGAGACTTGCCTGGTGAAA CAGGGGTGGTTATTGCATCT 
18S TTCGGAACTGAGGCCATGAT CGAACCTCCGACTTCGTTC 
 
8.2.7 Statistics 
SPSS (version 19.0) was used to perform the statistical analysis. Gene expression, cytokine 
level and GAG present in the medium data obtained from all groups are represented in bar 
graphs as mean + SD, showing the variations from 3-6 samples (3 patients). The statistical 
significance of the differences in each condition was tested using Univariate ANOVA with 
Tukey’s post hoc test. For all tests, p < 0.05 was considered significant. 
 
 
166 
 
8.3 Results 
8.3.1 Gene expression 
The gene expression of anabolic and catabolic factors by superficial and middle deep 
chondrocytes encapsulated in alginate hydrogels in response to 3 different medium conditions 
with and without cyclic compression was assessed. 
All changes in ACAN were not statistically significant. ACAN expression below the detection 
limit (Ct > 35) was mainly found in both S and MD chondrocytes in the control group 
without compression. 
PRG4 expression was significantly down-regulated in S chondrocytes when cultured with 
normal osteoblast (No compression 12.7 + 8.5 x 10-4, Compression 7.0 + 5.0 x 10-4) and OA 
osteoblast conditioned medium (No compression 20.6 + 15.8 x 10-4, Compression 19.0 + 6.2 
x 10-4) when compared to control medium (No compression 48.3 + 11.4 x 10-4, Compression 
39.7 + 12.4 x 10-4) (Fig 8.2 C, P < 0.05). However, there was no significant difference in 
PRG4 expression in MD chondrocytes between media types (Fig 8.2 D). PRG4 expression by 
S chondrocytes was not regulated by compression. However, PRG4 expression was 
significantly up-regulated in MD chondrocytes with compression (P < 0.05). 
MMP13 expression was not regulated by osteoblast conditioned media in either superficial or 
middle deep chondrocytes (Fig8.2 E, F). Cyclic compression was significantly down-
regulated MMP13 expression by S chondrocytes (Fig 8.2 E, P < 0.05). However, there was 
no significant difference in MMP13 expression by middle deep chondrocytes in the presence 
or absence of cyclic compression. 
ADAMTS5 expression was not regulated by osteoblasts conditioned media in either S or MD 
chondrocytes (Fig 8.2 G, H). All changes in ADAMTS5 were not statistically significant.  
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Figure 8.2: The gene expression of anabolic and catabolic factors by subpopulation 
chondrocytes encapsulated in alginate hydrogels in response to medium conditions with and 
without cyclic compression. 
The expression level of anabolic genes ACAN (A, B) and PRG4 (C, D), catabolic genes 
MMP-13 (E, F) and ADAMTS5 (G, H) gene expression in S chondrocytes (A, C, E, G) and 
MD chondrocytes (B, D, F, H) in control medium (X), normal osteoblast conditioned 
medium (N) and OA osteoblast conditioned medium (O) at day 4 without compression (No 
Comp) and with 3 h of dynamic compression (Comp). (* P < 0.05, # indicates data from one 
sample, + indicates data from 2 samples, and $ indicates undetermined data which the cycle 
threshold (Ct) value is greater than 35 for all 6 samples). 
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IL-6 expression by S chondrocytes was significantly down-regulated when cultured with OA 
osteoblast conditioned medium (No compression 7.1 + 8.2 x 10-3, Compression 4.4 + 2.4 x 
10-3), compared to culture with control medium (No compression 25.0 + 20.8 x 10-3, 
Compression 10.1 + 6.8 x 10-3) and normal osteoblast conditioned medium (No compression 
23.0 + 6.7 x 10-3, Compression 14.4 + 8.8 x 10-3) (Fig 8.3 A, P < 0.05). On the other hand, 
IL-6 gene expression by middle deep chondrocytes was not significantly different between 
media types (Fig 8.3 B). Cyclic compression was significantly down-regulated IL-6 
expression by S chondrocytes (P<0.05). Conversely, IL-6 expression by middle deep 
chondrocytes was significant up-regulated by compression (P < 0.05). 
 
Figure 8.3: Cytokine IL-6 gene expression factors by subpopulation chondrocytes 
encapsulated in alginate hydrogels in response to medium conditions with and without cyclic 
compression. 
The expression level of regulatory cytokine IL-6 gene expression in S chondrocytes (A) and 
MD chondrocytes (B) in control medium(X), normal osteoblast conditioned medium (N) and 
OA osteoblast conditioned medium (O) at day 4 with compression (Comp) and without 
compression (No Comp). P < 0.05 (*) was considered significant. 
8.3.2 Cytokines in media 
Conditioned media were tested for the presence of pro-inflammatory cytokines (IL-1β, TNF-
α), anti-inflammatory cytokines (IL-4, IL-10) and regulatory cytokines with both pro-
inflammatory and anti-inflammatory effects (IL-6) (363) through Multiplex ELISA (Fig 8.4). 
Superficial and middle deep zone chondrocyte cytokine levels showed the same general 
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trends when cultured with different media, but differences were only significant for S 
chondrocytes. There were no significant differences in either chondrocyte type with respect 
to compression. 
There were relatively low levels (<5 pg/mL) of pro-inflammatory cytokines, IL-1 and TNF-α, 
in the conditioned media from all sample groups. No significant effects of culture media or 
compression were found for either of these cytokines. 
IL-10, an anti-inflammatory cytokine, levels in conditioned media were significantly reduced 
when S chondrocytes were cultured with OA osteoblasts conditioned media (No compression 
2.7 + 1.2, Compression 1.4 + 1.0 pg/mL), compared to control media (No compression 5.2 + 
1.9, Compression 4.4 + 1.9 pg/mL) (Fig 8.4 E, P < 0.05). Middle deep chondrocytes showed 
the same trend, but there was no significant difference (Fig 8.4F). Compression resulted in a 
decreasing trend in IL-10 levels for both cell types, but these trends were not statistically 
significant. The other tested anti-inflammatory cytokine, IL-4, was below detection limits. 
IL-6, a regulatory cytokine, levels were the highest for all cytokines that we were studied, 
with several samples exceeding concentrations of 10 ng/mL. IL-6 levels above the detection 
limit values were found in 2 patients from all 3 patients (66%) and the majority is in no 
compression group and MD chondrocytes. To represent the trend of IL-6 level in condition 
media, the detection limit level of 1000 pg/mL were used as a minimal estimate of the IL-6 
level of samples exceeding the upper detection limit. In S chondrocytes, the Il-6 level in the 
culture with OA osteoblast conditioned medium (No compression 6.0 + 3.4, Compression 3.5 
+ 0.6 ng/mL) was lower than culture with normal osteoblast conditioned medium (No 
compression 9.1 + 1.9, Compression 9.5 + 0.6 ng/mL) (Fig 8.4 G, P < 0.05). The IL-6 level 
for middle deep chondrocytes had no statistical differences in any conditions. Compression 
did not affect IL-6 levels for superficial chondrocyte cultures. 
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Figure 8.4: Multiplex ELISA analysis of various cytokines in conditioned media. 
Multiplex ELISA analysis of IL-1β, TNF-α, IL-10 and IL-6 in superficial chondrocytes (S) 
and middle deep chondrocytes (MD) in alginate constructs cultured in media containing 
chondrogenic media plus X = fresh osteoblastic media, N = conditioned media from normal 
osteoblast culture, and O = conditioned media from OA osteoblast culture. Constructs were 
subjected to 3 h of cyclic compression (Comp), or maintained in static culture (No Comp). 
For IL-6, # indicates 2 samples over the detection limit (10000 pg/mL), and + indicates 1 
sample over the detection limit; these samples were assigned a value of 10000 pg/mL in these 
analyses as a minimal estimate. P < 0.05(*) was considered significant. 
8.3.3 GAG content 
 
Figure 8.5: GAG in media from constructs cultured in different media. 
Constructs were cultured in control medium (X), normal osteoblast conditioned medium (N) 
and OA osteoblast conditioned medium (O). GAG level of 3 conditioned media samples at 
day 0 and day 4, pooled from S chondrocytes and MD chondrocytes both groups with and 
without compression, as these factors did not affect GAG accumulation. P<0.05(*) was 
considered significant. 
8.4 Discussion 
There are many studies show that osteoblasts and chondrocytes influence each other during in 
vitro chondrogenesis in both healthy and OA conditions (354, 364). Our aim in this study was 
to evaluate the effect of soluble factors secreted from the osteoblasts (normal or OA) on gene 
expression and cytokine production in chondrocyte subpopulations under compressive 
loading. The chondrocytes were encapsulated in 2% alginate and pre-culture in chondrogenic 
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medium for 14 day to allow the chondrocytes to redifferentiate before study the effect of 
soluble factors and stimuli. The 4 days of co-culture with normal and OA conditioned media 
were chosen to maximize time for chondrocyte to secrete and accumulate the cytokine in the 
media, as this is typically the longest period between media changes. The cyclic compression 
conditions protocol using in this experiments has been shown the highest effect on the zonal 
chondrogenesis (43). 
Our results indicate that chondrocyte responses to osteoblast secreted soluble factors and 
compressive loading are zone-dependent. S chondrocytes appear more sensitive to soluble 
factors secreted from osteoblast conditioned media than MD chondrocytes, as shown by 
significant differences in PRG4 and IL-6 gene expression response to the soluble factors 
secreted from osteoblast only for S chondrocytes (Fig 8.2 C, 8.3 A). Further, the chondrocyte 
subpopulations responded to compression in a different pattern (Fig 8.2 C, E, 8.3 A). S 
chondrocytes exposed to normal or OA osteoblast-conditioned media significantly decreased 
PRG4 gene expression compared to those without the exposure whether the compression was 
applied or not (Fig 8.2 C). PRG4 gene is a well-known superficial zonal marker, which codes 
for lubricating proteins. Its expression levels have been known to increase in the presence of 
mechanical loading (365). In vivo, S chondrocytes are further removed from the subchondral 
bone compared to the MD chondrocytes. There is a possibility that S chondrocytes are 
influenced by the soluble factors secreted by the osteoblasts to behave more like the MD 
chondrocytes, which normally do not express PRG4, as shown by the significant difference 
of PRG4 gene expression of S chondrocytes  and MD chondrocytes without osteoblast 
soluble factors and without compression (Fig 8.3 C p = 0.00).  
Reports by Prasadam, et al., have shown decreased ACAN gene expression when 
chondrocytes were exposed to the conditioned media from the OA osteoblasts compared to 
those from the normal osteoblasts (354). However, our data show no difference in ACAN 
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gene expression whether they were exposed to OA-osteoblast media (O) or normal-osteoblast 
media (N). This is an interesting observation, and the differences between their result and 
ours may stem from utilizing different culture systems and chondrocyte sources. While we 
chose the alginate encapsulation culture, Prasadam, et al., used the pellet culture system, 
which exposes the chondrocytes in direct contact with the soluble factors in the medium and 
allows for direct cell-cell contact. Also, while we used S and MD zone chondrocytes 
separately, their chondrocytes were from the full-thickness cartilage. 
Gene expression levels of catabolic enzymes MMP-13 and ADAMTS-5 do not appear to be 
affected by the addition of osteoblast-conditioned media in both S and MD chondrocytes (Fig 
8.2 E-H). However, S chondrocytes in particular did show a significant decrease in MMP-13 
gene expression levels when exposed to compressive stimulation. MMP-13, a collagenase, 
cleaves collagen type II found in cartilage, and has an important role in the pathogenesis of 
osteoarthritis and cartilage degradation. Similar results have been reported in the past by (43), 
which shows that mechanical loading can help to decrease the gene expression levels of some 
catabolic enzymes such as MMP-13. Unlike MMP-13, ADAMTS-5 gene expression levels 
were similar in all conditions regardless of the media conditions, loading, and chondrocyte 
subpopulations. It is possible, however, that ADAMTS-5 gene expression changes have not 
been detected by the time points we have chosen, as different genes may peak at varying time 
points following compression or exposure to soluble factors.  
Gene expression levels of IL-6, a regulatory cytokine, were significantly down regulated in S 
chondrocytes cultured with OA osteoblast-conditioned medium compared to those cultured 
without, but this effect was not seen in MD chondrocytes. On the contrary, compressive 
loading had a significant influence on the IL-6 gene expression levels on both S and MD 
chondrocytes, and they had an opposite effect. Regardless of the media conditions, all S 
chondrocyte groups had a significant decrease in IL-6 gene expression while all MD groups 
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had an increase of IL-6 gene expression when exposed to compressive loading (Fig 8.3 C). 
Our results indicate that gene expression levels of certain catabolic enzymes and cytokines 
closely associated with OA progression are influenced greatly by osteoblast-secreted soluble 
factors and compressive loading simultaneously in a zone-dependent manner. 
When we analyzed the concentration levels pro-inflammatory cytokines (IL-1β, TNF-α), anti-
inflammatory cytokines (IL-4 and IL-10), and regulatory cytokine (IL-6) in the media, their 
levels varied mostly depending on whether they contained any osteoblast-condition media 
and not so much on the compressive loading. There were no significant differences in pro-
inflammatory cytokine (IL1 and TNF-α) levels in the media of S and MD chondrocytes in 
any groups (Fig 8.4 A-D). These cytokines, which are associated with cartilage destruction 
and inflammation, are produced by chondrocytes, mononuclear cells, osteoblast and synovial 
tissue. The levels of IL-1β and TNF-α in the condition medium were about 2.7 + 0.6 pg/mL 
and 0.9 + 0.6 pg/mL, while their level in the OA synovial fluid are about 150 pg/mL (366) 
and 2.0 pg/mL respectively (367). The low levels of IL-1β and TNF-α in the conditioned 
medium compared to the OA synovial fluid may stem from the absence of synovial cells, the 
presence of TGF-β3 in the media, and the limited time for cytokine accumulation between 
media changes. It is also possible that alginate gel may act as a barrier to trap some of the 
cytokine inside the alginate discs prior to being released into the conditioned medium. The 
low levels of IL-1β and TNF-α in the conditioned medium in our co-culture may indicate that 
the chondrocytes and osteoblast might not have a main role to produce IL-1β and TNF-α in 
OA joint. The low production of IL-1β and TNF-α by OA osteoblasts were previously 
reported by (355, 368).  
We also measured media concentration levels of IL-4 and IL-10, anti-inflammatory cytokines, 
but IL-4 levels were observed to be below the detection threshold (1 pg/mL). IL-10 was 
detectable, but it was also low in concentration (<10 pg/mL). We expected that the presence 
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of TGF-β3 in the media (10 ng/mL) was going to stimulate anti-inflammatory cytokine 
secretion by the chondrocytes, but just as the pro-inflammatory cytokines IL-1β and TNF-α 
were in low abundance, anti-inflammatory cytokines IL-4 and IL-10 were also scarce. IL-4 is 
normally present in relatively low concentration in OA synovial fluid (1.5 pg/mL) compared 
to the other types of cytokines (369). Also, our data indicate that the addition of OA 
osteoblast-conditioned media significantly lowers IL-10 concentrations in the chondrocyte 
culture (S chondrocytes only), which may have some in vivo implications. The decreased 
production of IL-10 which is a protective cytokine in the OA condition may increase the 
catalytic activity of chondrocytes and initiate the matrix degradation process. 
IL-6 levels found in the medium showed a similar trend with the IL-6 gene expression data 
(Fig 8.4 G, H). The concentration of IL-6 was relatively higher (> 100-fold) than other 
interleukins in all groups. IL-6 levels in the condition media were at least 3500 pg/mL and 
more, which are much higher than those found in the synovial fluid of OA patients (132 to 
2022 pg/mL) (370). IL-6 concentration levels in serum are reported to increase during the 
early stages of OA pathogenesis (371). The high level of IL-6 found in the medium may be 
due to our usage of chondrocytes obtained from the OA patients, although they were from the 
macroscopically normal areas of the joint. It is possible that even these chondrocytes 
resemble the early stages of OA, with an increased expression and production of IL-6, and 
perhaps these phenotypes still remain even after monolayer expansion in vitro. Interestingly, 
IL-6 level was significantly less when S chondrocytes were cultured in the presence of the 
OA osteoblast-conditioned media. Further studies may be needed in this aspect to clearly 
understand which components in the OA osteoblast-conditioned media brings about this 
change. The IL-6 synthesis from OA cells varied between donors. In our experiments found 
that chondrocytes mainly MD 2 from 3 patients produced high level of IL-6 cytokine which 
over the detection limit (10,000 pg/mL) in all media conditions. However, the IL-6 level from 
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one patient was lower than 5,000 pg/mL. The variation in IL-6 production by OA osteoblasts 
has been used previously to classify OA patients into groups with low (similar to normal 
osteoblasts) and high IL-6 level groups (355). 
In conclusion, our data suggests that there is a clear zonal difference in how chondrocytes 
respond to OA osteoblast-conditioned medium and compressive stimulation. We have shown 
that soluble factors from the OA osteoblast-conditioned media can significantly reduce the 
gene expression levels PRG4 and IL-6, while decreasing the media levels of IL-10 and IL-6 
in S chondrocytes, whereas MD chondrocytes are not significantly affected. Furthermore, we 
have shown in this experiment that subpopulation chondrocytes respond differently to the 
same loading protocol. Compressive loading significantly increased the gene expression 
levels of PRG4 and IL-6 in MD chondrocytes, while significantly decreasing the gene 
expression levels of MMP-13 and IL-6. Our findings support previous work that 
subpopulation chondrocytes respond differently to mechanical loading (372). The reduction 
of the protective inflammatory cytokine IL-10 and the regulatory cytokine IL-6 in S 
chondrocytes due to OA osteoblast conditioned media may be some of the early responses of 
chondrocytes to the soluble factors from the OA osteoblast. While the exposure to OA 
osteoblast media in our experiment did not incur any significant changes to the pro-
inflammatory cytokine levels in the media (IL-1β and TNF-α) or the gene expression levels 
of matrix-degrading enzymes (MMPs and ADAMTSs), it is possible that the time-frame of our 
experiment (4 days of culture time) was not long enough to induce significant changes. 
However, increasing trend of GAG release into the media with the addition of OA osteoblast-
conditioned media may suggest that other catabolic factors which we have not tested may be 
at work in degrading the newly-made matrix components. In future experiments, it would be 
important to look into other matrix degradation enzymes which may play a role in the early 
responses of chondrocytes to the OA environment in addition to MMP-13 and ADAMTS-5. 
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Our work mimics some components of the early OA environment, where chondrocytes from 
S and MD layers are simultaneously exposed to mechanical loading as well as the soluble 
factors secreted by the subchondral bone osteoblasts. Our results also have implications for 
those attempting to engineer cartilage tissues using OA chondrocytes which will be re-
implanted into the OA joint, where subchondral bone osteoblasts are also affected by OA. 
Our results highlight the importance of mechanical stimulation, and their role in decreasing 
the gene expression levels of catabolic enzymes such as MMP-13, and how soluble factors 
from the OA-osteoblasts can mediate the decrease in gene expression levels of lubricating 
molecules such as PRG4, which is necessary in preventing mechanically-induced surface 
fibrillation. Another important finding from our study is the fact that soluble factors from the 
OA-osteoblasts and mechanical loading can influence the levels of IL-6, which plays a 
critical role in OA pathogenesis. Further understanding into the role of mechanical loading 
the involvement of subchondral bone osteoblasts in OA progression may be an important 
stepping stone in finding a cure for the OA patients.  
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CHAPTER 9 : SUMMARY OF FINDINGS AND FUTURE 
DIRECTIONS 
 
9.1 Overview of thesis 
This chapter summarizes the important findings from my PhD project and discusses their 
relevance for cartilage tissue engineering research and future clinical applications. 
9.2 Finding potential cell sources for (zonal) cartilage tissue engineering 
There is a long-standing debate over the advantages and disadvantages of potential cells 
sources for cartilage tissue engineering. Mesenchymal progenitor cells and chondrocytes are 
two most popular cell types used in cartilage tissue engineering. However, there are both 
advantages and disadvantages in using these cells. Progenitor cells of mesenchymal origin 
have the potential to develop into cartilage, bone, and adipose tissues, and have the advantage 
of having a relatively less-invasive method of cell isolation. However, it is often difficult to 
ascertain their purity and also control their differentiation (e.g., prevent hypertrophy). 
Chondrocytes are the resident cells within the cartilage, and their help form and maintain the 
cartilage matrix. While they are ideal cell types for cartilage tissue engineering, they have the 
problem of invasive harvest procedures and it is difficult to prevent them from 
dedifferentiating in vitro once they are expanded in monolayer cultures. 
Human umbilical cord perivascular cells (HUCPVCs) are an attractive cell in potential usage 
in cartilage tissue engineering as they are easily isolated from umbilical cord which is a 
discarded tissues from labour processes and are known to express stem cell markers which 
may indicate their multipotent nature. As a result, we hypothesized that HUCPVCs may be 
differentiated into chondrocytes in vitro. When we investigated the chondrogenic potential of 
the HUCPVCs in vitro, however, we found that the HUCPVC had a high proliferative 
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capacity, but poorly differentiated into chondrocytes when they were expanded extensively in 
monolayer cultures (Chapter 3). HUCPVCs were purchased from a commercial source as 
passage 2 cells (Tissue Regeneration Therapeutics, Canada), and based on the number of 
cells needed to carry out the experiment, cells were further expanded to passage 5. This 
amounts to approximately 12-15 populations doubling (see proliferation result section 3.3) 
and at this level (passage 4-5), the differentiation capacity of HUCPVCs was lost. 
The loss of differentiation capacity over extended period of monolayer culture is also 
documented in chondrocytes as well as bone marrow-derived stem cells (BMSCs). The 
differentiation potential of BMSCs into 3 lineages (chondrogenic, osteogenic and adipogenic) 
is reported to be lost after about 20 population doublings (373), and for normal chondrocytes, 
this happens after about 9 population doublings (374). While we postulated that HUCPVCs 
may have progenitor cell-like capability similar to BMSCs, we observed that HUCPVCs lose 
their differentiation potential earlier than BMSCs, as we were not able to differentiate them in 
chondrogenic cultures after 14-15 doublings. Our results are in alignment with previous 
reports stating that stem cells from other tissues have lower chondrogenic differentiation 
potential compared to the BMSCs (375). 
While we could not show the differentiation potential for HUCPVCs at late passages (P5, 
P10), it is possible that at earlier passages (P1, P2), HUCPVCs may still be used for cartilage 
tissue engineering, and it remains to be tested. Others have shown that stem cells from 
umbilical cord matrix, Wharton's jelly, have chondrogenic differentiation potential and may 
potentially be used for zonal cartilage tissue engineering. If progenitor cells from cord tissues 
can be used for cartilage tissue engineering, it would be an interesting cell source as they do 
not cause donor site-related complications which may happen with autologous chondrocyte 
isolation techniques. 
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MSCs from adipose tissue, muscle, and synovial membrane have also shown potential for 
chondrogenic differentiation (150, 376, 377). However, inconsistencies of the proliferation 
and differentiation potential in published reports compromise their ability to be used in 
cartilage tissue engineering applications (378). The inconsistencies between studies using 
MSC may arise from the lack of exclusive markers to identify true stem cells. The 
Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular 
Therapy have proposed minimal criteria to use to identify and isolate MSCs. The procedure 
includes plastic- adherence, multilineage differentiation capacity, and the expression of stem-
cell related markers such as CD73, CD90, CD105 and the non-expression of CD14, CD34, 
CD45 or CD11b, CD79-α, CD19 and HLA-DR. While many studies do include plastic 
adherence and tri-lineage differentiation assays, they often use different markers to 
characterize their MSCs (379). Reports also suggest that only one third of MSCs have the 
capacity to differentiate into all three lineage and about two thirds display osteogenic and 
chondrogenic capacities (373). This might be another reason for inconsistency of the MSCs 
differentiation capacity. 
However, MSCs from bone marrow and other tissues are still being actively investigated for 
cartilage tissue engineering applications as millions of cells are likely to be required to 
successfully engineer a functional cartilage tissue, and their proliferative potential is highly 
desired. Therapeutics based on MSCs has already reached the commercial stages. Mesoblast, 
for example, commercializes adult-derived Mesenchymal Precursor Cells (MPCs) for the 
treatment of bone, cartilage and musculoskeletal conditions (380). Various products from this 
company are in clinical trials (381). 
In addition to MSCs and chondrocytes, embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) are the other cells types which have the potential for cartilage tissue 
engineering. 
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Embryonic stem cells (ESCs), which are derived from the inner cell mass of the blastocyst-
stage embryos, are considered as a promising cell source for cartilage tissue engineering. 
ESCs have the advantage of unlimited potential for self-renewal and pluripotency. These 
characteristics may allow the ESCs to be a potential source for an unlimited supply of 
chondrogenic cells (382). However, the potential issues with host immune response, 
differentiation challenges, and ethical concern are some of the major issues in utilizing ESCs 
for cartilage tissue engineering (383). 
Induced pluripotent stem cells (iPSCs), derived by genetically reprogramming somatic cells 
to an embryonic like-stem cell (384), may be a promising cell sources for cartilage 
regeneration in the future (385). iPSCs can be produced from the patient’s own cells, and 
therefore the immune response problem may not be a problem. They also may be derived 
from tissues which require less invasive procedures (eg. skin, hair follicles, and blood cells), 
making them a highly desirable source of cells for cartilage tissue engineering. However, 
differentiation challenges and safety concerns for clinical applications are some of the 
drawbacks of using iPSCs for cartilage tissue engineering. iPSCs, which are generally 
produced by viral transfection of stem cell-associated genes into somatic cells, have the 
potential to cause tumors (386). More recently, researchers succeeded in developing 
chemically-induced iPSCs without any genetic manipulation (387, 388). 
MSCs have been isolated from many tissues. As low chondrogenic differentiation potential of 
current defined MSCs, BMSCs and chondrocytes which are widely used for traditional 
cartilage tissue engineering seem to be a candidate for zonal cartilage tissue engineering. 
However, the matrix accumulation and the mechanical properties MSC-based engineered 
cartilage are inferior to those based on chondrocytes (389). Also, BMSCs always undergo to 
hypertrophy after culture in vitro (390).  
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While differentiating BMSCs to chondrocytes is fairly successful, their ability to mature into 
zone-specific chondrocytes is rarely shown in vitro. Coates, et al., reported that while S 
chondrocytes continue to express superficial zone-specific proteoglycan4 (PRG4), this is not 
seen in differentiating BMSCs in hydrogels made from alginate/hyaluronic acid 
(HA)/chondroitin sulfate (CS) (391). Huff, et al., also compared PRG4 expression in MSCs at 
27% and 3 % oxygen tension. The result show that hypoxic condition of 3% oxygen does not 
have a beneficial effect on the chondrogenesis of the MSCs and their expression of PRG4 
(392). Given the potential benefits of using MSCs for cartilage tissue engineering, it may be 
important to establish methods of differentiating the MSCs into zonal chondrocytes which can 
help create cartilage grafts that closely resemble the stratified nature of the articular cartilage. 
Ultimately from literature reviewed and our initial results, we switched the cell source for the 
majority of the studies to chondrocytes obtained from OA patients. 
While the work in this thesis will certainly not settle the debate over the best cell source for 
cartilage tissue engineering, it does bring to light some important considerations in zonal 
cartilage tissue engineering that are worthy of discussion.  
9.3 Importance of the microenvironment 
It is becoming increasingly clear that cells outside of their native microenvironment do not 
function as they do in the native microenvironment (393-395). Thus, the key to cartilage 
tissue engineering is not simply in finding the best cell type; the environment must also be 
engineered appropriately.  
9.3.1 Mechanical stimulation 
To maintain cell function and homeostasis in general, cells need to sense and respond to 
various extracellular signals and constituents such as extracellular matrix molecules, soluble 
growth factors, environmental stress (mechanical stimuli, oxygen tension, pH effect) and 
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intercellular interaction (Review in (396)). The extracellular signals can trigger downstream 
signaling eventually affecting how certain genes are transcribed. Up-regulation or down-
regulation of particular genes occurs through a complex network of signal transduction 
pathways to further modulate cell proliferation, migration and differentiation (396). 
Chondrocytes are exposed to varying levels and types of stresses throughout the depth of the 
articular cartilage. In this regard, we hypothesized that the manipulation of mechanical 
environment would promote the zone-specific changes in chondrocytes. 
It is widely accepted that mechanical stimuli have an effect on chondrocyte homeostasis both 
in vitro and in vivo, and that physiological stimuli promote matrix synthesis in chondrocytes. 
Previous work from our group shows that cyclic compression induces gene expression of 
chondrogenic (aggrecan and collagen type II) and S chondrocytes gene (PRG4) markers and 
significantly improves matrix accumulation in chondrocytes in a zone-dependent manner 
(253). In this project, we utilized the rocker plate to determine the effect of fluid shear stress 
on zonal chondrocyte differentiation. Some of the benefits in using the rocker plate to induce 
fluid shear stress are the possibility of using common laboratory tissue culture plastics, easy 
operation, and high throughput. Fluid-induced shear stress occurs in cartilage, mainly through 
the interstitial fluid movement during joint movement and may have a role in stimulating 
chondrocyte biosynthesis and zonal differentiation. Our hypothesis was that fluid shear stress 
produced by rocker plate bioreactors influence zonal chondrocyte differentiation. We 
therefore evaluated the effects of shear stress created by the movement of media in the simple 
rocker plate bioreactor to the zonal chondrocyte chondrogenesis after a high density seeding. 
Our results indicate that the loading protocol used in our study did not induce a positive effect 
on the zonal differentiation of the chondrocytes (Chapter 4). This suggests that further 
optimization in loading protocol may be necessary before we observe a beneficial effect of 
the loading. Based on our protocol, chondrocytes were subjected to fluid shear stress 
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following monolayer culture. Since it is well accepted that chondrocytes tend to de-
differentiate following monolayer expansion, it is possible that cells used in this study did not 
respond to shear stress as freshly-isolated cells would. In future studies, it may add further 
insight if analysis was done using cells that are pre-cultured in chondrogenic media prior to 
the exposure to the fluid shear stress. Following the chondrogenic differentiation culture, 
chondrocytes are likely to accumulate extracellular (ECM) and pericellular matrix (PCM) 
molecules, which may help sense the mechanical stimulation. Furthermore, there is indeed a 
limitation in trying to mimic the interstitial fluid movement through the rocker plate 
bioreactor, as the fluid movement that occurs in cartilage follows a more complex profile and 
occurs in combination of other stresses such as hydrostatic pressure. In conclusion, while our 
results show that rocker plates are an interesting model to apply fluid shear stress to 
chondrocytes in culture, additional optimization is required in order to enhance 
chondrogenesis using this culture method. 
9.3.2 Extracellular matrix 
In the second experimental chapter (Chapter 4), the results left us concerned about the effect 
of ECM, or lack-thereof, on chondrocyte mechanotransduction which is the process that cell 
changes the mechanical stimuli to biochemical signal to control cell functions. ECM, as well 
as PCM, may have a role in mechanotransduction in chondrocytes and they may influence 
chondrocyte responses to external stimuli. In cartilage, chondrocyte is embedded in ECM. 
When cartilage experiences mechanical signals in the form of compression, shear, or tensile 
load, those signals are transferred to the ECM and PCM before they reach the chondrocytes. 
While interaction between the chondrocytes and the surrounding matrix molecules are 
considered important, their effect on zonal chondrocyte differentiation is relatively unknown. 
Integrin-mediated cell interactions, which often involves amino acid sequences such as Arg–
Gly–Asp (RGD) on extracellular matrices (397), may have a role in how the chondrocytes 
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sense the external environment and respond accordingly. As integrins bind to extracellular 
matrices and trigger sequential clustering with adaptor proteins and several kinases, they can 
activate multiple signal transduction pathways inside the cell. Nuclear factor kappa B (NF-
κB), a nuclear transcription factor related to pro-inflammatory gene induction, is believed to 
be activated through receptor-mediated sensing of the extracellular stresses (398). As 
chondrocyte-ECM interactions have a role in cartilage function and homeostasis scaffolds 
which mimic cartilage composition and structure may aid in zonal cartilage tissue 
engineering. 
A few have attempted to engineer zonal cartilage constructs by using different combination 
of synthetic or natural biopolymers. For example, hydrogels combined with ECM molecules 
such as the chondroitin sulfate (CS), hyaluronic acid (HA), or collagen, have been used to 
generate stratified cartilage constructs. Reports also show that composite hydrogels 
containing poly ethylene glycol (PEG), collagen type I, and HA can induce chondrogenic 
gene expression of chondrocytes subpopulation in a zone-dependent manner (399). Similarly, 
Nguyen et al. have shown that incorporation of metalloproteinase-sensitive peptides (MMP-
pep) in the PEG/CS/HA hydrogels induced zonal phenotypes in BMSCs (251). However, the 
properties used to define zonal phenotypes in this work are not the level of zone-specific 
markers such as PRG4 for S chondrocytes but they only used the level of GAG, collagen II 
and compressive modulus. They further add that the addition of bioactive components in their 
hydrogel promoted the BMSC expression of collagen type II and aggrecan genes while 
allowing the construct to have depth-dependent compressive moduli comparable to the native 
cartilage. They also demonstrated that it may be possible to develop zonal architecture in 
cartilage tissue engineered grafts using hydrogel composites using PEG and ECM molecules 
(252). Although the zonal indicators they used in their work are collagen type II gene 
expression and GAG level, not zonal markers like PRG4, their results emphasize the potential 
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use of ECM molecules as additives to augment zonal differentiation in tissue engineered 
cartilage. The cartilage ECM is highly complex and interacts with chondrocytes in a number 
of ways; it is unlikely that the structure and complexity of this matrix can be directly 
engineered into a construct. Therefore, we decided to study bovine extracellular matrix as an 
environmental factor, in the form of decellularized bovine cartilage ECM pellet. 
When we cultured chondrocytes with their zone ECM in pellet form, we found that the 
expressions of chondrogenic genes were increased when superficial zone chondrocytes were 
mixed with superficial ECM environment (Chapter 5). These findings support the idea of 
using zonal cartilage tissue ECM to improve zonal differentiation of cartilage grafts. Whilst it 
would be difficult or impossible to harvest a sufficient amount of autologous zonal cartilage 
ECM from a patient for cartilage regeneration, the concept could be applied clinically using 
two alternative sources xenogeneic cartilage ECM, or allogeneic cartilage ECM. While there 
are some concerns of pathogens and immune rejection, these issues have largely been 
overcome through development of decellularization protocols. Xenogenic ECM from various 
tissues have a long history of successful clinical use (e.g., porcine small intestinal submucosa, 
foetal bovine skin, porcine skin (review in (400)). Allogeneic tissues including cartilage also 
have been used successfully for decades (401). Both of these sources could provide large 
amounts of zonal cartilage tissue that could also be characterized prior to surgical application. 
However, the use of zonal cartilage ECM needs more study to confirm their beneficial effects. 
If the benefit is confirmed, zonal cartilage ECM could be applied in several different ways to 
improve clinical outcomes. 
In the first method of application, the ECM could be used as a component in a hydrogel 
system, as in chapter 6, where we used decellularized bovine cartilage ECM as the additive in 
alginate hydrogels. Although the results in this thesis did not show a clear benefit of adding 
ECM in alginate constructs, this may be due to the specific design of the tissue-engineered 
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constructs. Different hydrogels may allow for more interaction between the chondrocytes and 
the cartilage ECM, and therefore give a greater response. Alternatively, a higher density of 
ECM may be needed. Further experiments are needed to test these hypotheses. 
A second method of ECM incorporation is through the use of porous scaffolds fabricated 
from ECM particles using the freeze-drying approach. Freeze-dried cartilage ECM scaffolds 
have been studied by others with promising results (194-196). However, these studies did not 
investigate the use of zonal ECMs but rather the full-thickness cartilage ECM to develop their 
scaffold. Therefore, we have attempted to prove the concept of making the freeze-dried ECM 
scaffolds with a zonal architecture. The zonal porous scaffold could be used for continuing 
study in zonal cartilage tissue engineering. The ECM powders were resuspended about 75% 
w/v in the PBS solution in separate middle deep ECM and superficial ECM. The middle deep 
ECM solution was added into a plastic mold about 75% of the depth and was snap frozen in 
liquid nitrogen, followed by layering a warmed superficial ECM solution. Constructs were 
freeze-dried and UV-stabilized for 12 h, resulting in a zonal ECM scaffold (Fig 9.1). The S 
chondrocytes can be seeded on the top (superficial) layer and the MD chondrocytes can be 
seeded in the bottom (middle deep) layer. This scaffold was seeded with zonal chondrocytes 
and cultured in vitro prior to the analysis. The major difficult of this study was to get an even 
cell distribution, and also keeping the scaffold intact during the in vitro culture. In future 
studies, it may be important to further cross-link the scaffold prior to cell culture to improve 
its stability in long term cultures. 
The final method of application is to simply mix the ECM powder with cells and media and 
form a pellet, as in Chapter 5, and implant this pellet directly to a chondral defect model. The 
cartilage powder is likely to provide stimulatory signals to the chondrocytes, increase the 
filling volume in the defect, and shorten the time required to heal the defect using clinically 
used surgical interventions such the ACI. Clearly, as with other ACI procedures, a membrane 
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would be needed to retain the cells and ECM. In addition, this ECM powder may also be used 
to mix with the cartilage crushed generated from the patient’s own cartilage biopsy (as a 
chondrocytes source) and placed back into the defect area to reduce the number of surgeries 
of ACI procedures from two to one. The concept of using crushed cartilage to reduce the 
secondary operation has been proven recently (402, 403). However, mixing freeze-dried 
cartilage ECM powder with the crushed cartilage from the patient needs further investigation. 
Although the outcomes from this study highlight the benefits of using the decellularized 
ECM, the safety of xenogeneic or allogeneic ECM remains a major concern. The sterilization 
and decellularization protocol needs to be improved to ensure that ECM does not retain any 
xenogeneic cells. Studies involving immunocompetent in vivo models may be needed to 
investigate the effect of the xenogenic ECM on host immune response.  
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Figure 9.1: Freeze-dried zonal cartilage ECM constructs. 
ECM constructs after UV cross-linking (A). SEM images of the ECM constructs are shown at 
low (B) and high magnification (C). 
9.3.3 Cartilage-bone interactions 
Osteoarthritis is now widely acknowledged as a whole joint disease. The same holds true for 
focal cartilage defects, in that damages to the cartilage usually also affect subchondral bone 
biology. Therefore, interactions between cells from different joint tissues must be 
investigated to gain better insight into cartilage degeneration and regeneration. In order to 
address this issue, we developed two model systems to study the interactions of chondrocytes 
and the subchondral bone. In the first model, we implanted the constructs in osteochondral 
explants from healthy bovine joints, with an experimentally created cartilage defect, and 
tested them in vitro (Chapter 6) and in vivo (Chapter 7). In the second approach, we used 
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conditioned media from normal and OA osteoblasts in tissue-engineered cartilage cultures 
(Chapter 8) and evaluated the effects of these interactions on zonal chondrocytes in the 
presence and absence of mechanical stimulation. 
As shown in chapter 6, while the full-thickness defect explants promoted GAG accumulation 
in the zonal alginate constructs in vitro, they did not promote PRG4 gene expression. To use 
this model with the aim of enhancing zonal differentiation, further development of the model 
may be required to incorporate other factors which may influence zone-dependent 
differentiation in chondrocytes.  
Unlike the in vitro outcomes, the full-thickness defect model did not improve the biosynthetic 
capacity of chondrocytes when implanted in SCID mice subcutaneously (Chapter 7). 
Applying the model to in vivo studies proved to be a challenge, and more work needs to be 
done to improve the model for this application. Our analysis of the histological images show 
that mouse cells have infiltrated into the defect sites which may have led to the low collagen 
type II and high collagen type I gene expression when compared with the in vitro culture. To 
use this defect model, constructs should be protected sufficiently from mouse cell invasion 
through the use of a sealant or a membrane, such as those used in the ACI protocol. Pre-
culturing cartilage constructs in vitro prior to the implantation may also help enhance 
chondrogenesis and help the chondrocytes to endure the low-nutrient environment prior to the 
development of the vasculature. 
The full-thickness defect model is a versatile system that can be used with different scaffold 
types. Other scaffolds or matrices that are able to support development of cartilaginous 
tissues may be used instead of the alginate. Additionally, the defect model can be used in 
vitro to test the effect of mechanical stimulation on defect tissue repair. Others have shown in 
that contact shear stresses induce PRG4 production (214, 215) and this may be used to 
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enhance zonal differentiation of the seeded chondrocytes. Recently, a bioreactor for contact 
shear stress stimulation of hydrogel constructs has been developed and studied in our group. 
Adaptation of this bioreactor to apply loads to full-thickness defect models will be another 
direction for future improvements to the model. 
Some of the limitations of the in vitro explant defect models are that it does not fully replicate 
the joint environment in OA patient. When tissue-engineered cartilage constructs are 
implanted in a clinical situation, they are exposed to a much harsher environment, and are 
affected by the mechanical and soluble factor signaling that can greatly influence the survival 
of the graft. Furthermore, in the case of joints with signs of OA, the presence of pro-
inflammatory cytokines or matrix metalloproteinase activity from the surrounding tissues 
may also play a role. In chapter 8, we evaluated the effect of soluble factors secreted from 
osteoblasts from both macroscopically normal bone and degenerative subchondral bone on 
chondrocyte biosynthesis when co-cultured with cartilage constructs. We also studied the 
compounding effects of the compressive stimuli on the chondrocytes biosynthesis during the 
co-culture. From this study, we found that soluble factors from osteoblasts affect chondrocyte 
gene expression, and the compressive stimuli can help to reduce the matrix degradation 
enzyme in vitro. This result provides further insight into the effects of mechanical and 
cytokine stimuli in the OA joints, and may also be used to study the development of tissue-
engineered cartilage implanted in cartilage defects that show signs of OA.  
9.4 Final conclusion 
The overall outcomes from this thesis indicate that the microenvironment is one modulator of 
chondrocyte differentiation. We have shown some benefit of the zonal ECM environment for 
chondrocyte subpopulations in zonal cartilage engineering. The sterile decellularized bovine 
ECM may be a feasible option for improving zonal tissue-engineered constructs, as we found 
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that superficial chondrocytes improve their chondrogenic gene expression when mixed with 
zone-specific ECMs derived from bovine cartilage. Nonetheless, much more work is needed 
before these findings can be applied in clinical settings. Using animal tissue in cartilage tissue 
engineering requires more research on many aspects, especially relating to safety. 
Additionally, further study is needed to optimize both the models and the designs of tissue-
engineered cartilage constructs. We also showed that chondrocytes from different zones 
respond to the soluble factors from normal and OA osteoblast conditioned media and 
mechanical stimuli in different ways in vitro. The findings highlight the importance of the 
zonal environment for the zonal cartilage tissue engineering. The ultimate goal of cartilage 
tissue engineering is to provide improved treatments for patients suffering from critical-sized 
cartilage defect or OA. Further investigation into enhancing cartilage grafts functionality and 
developing translational models for preclinical trials may help bring cutting edge cartilage 
tissue engineering concepts closer towards better patient care.  
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Appendix A: Proliferation data from 7 HUCPVC donors 
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Appendix Figure 1: Proliferation data of HUCPVCs from 7 patients in 4 different media. 
The missing values from 3 patients (patient number 108002, 108003 and 308001) are 
removed because of technical error in medium preparations.  
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Appendix B: Bovine osteochondral disc and full-thickness defect preparation 
Osteochondral tissues were harvested from bovine knees by a sterile saw and placed in a petri 
dish with sterile PBS containing 1% (P/S) (Invitrogen) (App. Fig. 3 A-C). An osteochondral 
fragment was fixed with a clamp and then 6 mm diameter osteochondral discs were cut by 
sterile trephine with a spray of cold sterile PBS containing 1% (P/S) (Invitrogen) to reduce 
heat damaging of cartilage and were placed in a tissue culture plate with sterile PBS 
containing 1% (P/S) (Invitrogen) (App. Fig. 3 D-E).Then, osteochondral discs were washed 
with cold sterile PBS containing 1% (P/S) before placing in tissue culture flasks and 
maintaining in culture medium LG-DMEM with 10% foetal bovine serum (BioWhittaker), as 
described in Section 2.2 for 3 days for sterility checks. After 3 days, the full-thickness defect 
was created in the osteochondral disc. A sterile 4 mm biopsy punch (KAI Medical) was used 
to mark the defect area on the osteochondral disc (App. Fig. 3 F). Then, the cartilage was 
removed from the osteochondral disc by 2 mm dental burr on the sterile area with spray of 
cold sterile PBS containing 1% (P/S) (Invitrogen) or in the petri dish contains cold sterile 
PBS containing 1% (P/S) (App. Fig. 3 G). The 6 mm osteochondral disc with 4 mm diameter 
full-thickness defect was shown in figure (App. Fig. 3 H, I) ready for full-thickness or zonal 
constructs assembly. 
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Appendix Figure 2: Images of full-thickness defect preparation. 
 
 
 
 
 
 
 
 
 
 
